NZ758795B2 - Atropine pharmaceutical compositions - Google Patents
Atropine pharmaceutical compositions Download PDFInfo
- Publication number
- NZ758795B2 NZ758795B2 NZ758555A NZ75855518A NZ758795B2 NZ 758795 B2 NZ758795 B2 NZ 758795B2 NZ 758555 A NZ758555 A NZ 758555A NZ 75855518 A NZ75855518 A NZ 75855518A NZ 758795 B2 NZ758795 B2 NZ 758795B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- substituted
- oxy
- compound
- alkyl
- compounds
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title description 59
- 229930006677 A03BA01 - Atropine Natural products 0.000 title 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N Atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 title 1
- 229960000396 Atropine Drugs 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract description 79
- 230000002401 inhibitory effect Effects 0.000 abstract description 17
- 238000000034 method Methods 0.000 abstract description 15
- 239000003112 inhibitor Substances 0.000 abstract description 6
- 239000000543 intermediate Substances 0.000 abstract description 4
- YPBKTZBXSBLTDK-UHFFFAOYSA-N 3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NONC1=C(N=O)NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 102000006639 indoleamine 2,3-dioxygenase family Human genes 0.000 abstract 1
- 108020004201 indoleamine 2,3-dioxygenase family Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 609
- 125000000217 alkyl group Chemical group 0.000 description 297
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 249
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 212
- 239000000203 mixture Substances 0.000 description 212
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 206
- -1 substituted Chemical class 0.000 description 196
- 125000000753 cycloalkyl group Chemical group 0.000 description 156
- 125000004404 heteroalkyl group Chemical group 0.000 description 131
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 125
- TVMXDCGIABBOFY-UHFFFAOYSA-N Octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 118
- 239000001257 hydrogen Substances 0.000 description 109
- 229910052739 hydrogen Inorganic materials 0.000 description 109
- 125000004432 carbon atoms Chemical group C* 0.000 description 101
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 98
- 229910052799 carbon Inorganic materials 0.000 description 96
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 88
- 239000000243 solution Substances 0.000 description 87
- 125000003710 aryl alkyl group Chemical group 0.000 description 85
- 125000003118 aryl group Chemical group 0.000 description 84
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 76
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 74
- 239000011780 sodium chloride Substances 0.000 description 72
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 71
- 235000002639 sodium chloride Nutrition 0.000 description 71
- 150000003839 salts Chemical class 0.000 description 69
- 125000001072 heteroaryl group Chemical group 0.000 description 67
- 125000001424 substituent group Chemical group 0.000 description 62
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 60
- 125000005842 heteroatoms Chemical group 0.000 description 59
- 239000003814 drug Substances 0.000 description 58
- 230000035492 administration Effects 0.000 description 53
- 239000000047 product Substances 0.000 description 47
- 235000019439 ethyl acetate Nutrition 0.000 description 44
- 229940079593 drugs Drugs 0.000 description 42
- 229910052760 oxygen Inorganic materials 0.000 description 42
- 230000015572 biosynthetic process Effects 0.000 description 40
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 40
- 108020004256 beta-Lactamases Proteins 0.000 description 37
- 102000006635 beta-Lactamases Human genes 0.000 description 37
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 37
- 238000003786 synthesis reaction Methods 0.000 description 37
- 230000002194 synthesizing Effects 0.000 description 37
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 36
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- 239000001301 oxygen Substances 0.000 description 34
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 34
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 32
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 32
- 206010060945 Bacterial infection Diseases 0.000 description 31
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 30
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 27
- 239000004480 active ingredient Substances 0.000 description 27
- 239000008079 hexane Substances 0.000 description 27
- 230000001225 therapeutic Effects 0.000 description 27
- 239000011541 reaction mixture Substances 0.000 description 26
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 26
- 239000002904 solvent Substances 0.000 description 26
- 238000004809 thin layer chromatography Methods 0.000 description 26
- 230000003115 biocidal Effects 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 25
- 239000003981 vehicle Substances 0.000 description 25
- 239000012298 atmosphere Substances 0.000 description 24
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 24
- 125000003545 alkoxy group Chemical group 0.000 description 23
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 23
- 239000003480 eluent Substances 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 239000007787 solid Substances 0.000 description 22
- 239000000725 suspension Substances 0.000 description 22
- 239000002552 dosage form Substances 0.000 description 21
- 239000000741 silica gel Substances 0.000 description 21
- 229910002027 silica gel Inorganic materials 0.000 description 21
- YBBRCQOCSYXUOC-UHFFFAOYSA-N Sulfuryl chloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 20
- 238000004440 column chromatography Methods 0.000 description 20
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 20
- 239000000651 prodrug Substances 0.000 description 20
- 229940002612 prodrugs Drugs 0.000 description 20
- 241000894006 Bacteria Species 0.000 description 18
- 239000003781 beta lactamase inhibitor Substances 0.000 description 18
- 125000004122 cyclic group Chemical group 0.000 description 18
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 18
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 17
- 239000002253 acid Substances 0.000 description 16
- 229910052786 argon Inorganic materials 0.000 description 16
- 125000000732 arylene group Chemical group 0.000 description 16
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 16
- 239000002132 β-lactam antibiotic Substances 0.000 description 16
- 239000012267 brine Substances 0.000 description 15
- 239000000839 emulsion Substances 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 15
- 239000000969 carrier Substances 0.000 description 14
- 229920001577 copolymer Polymers 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 14
- 239000006186 oral dosage form Substances 0.000 description 14
- 239000012453 solvate Substances 0.000 description 14
- 239000002775 capsule Substances 0.000 description 13
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 13
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 13
- 239000003921 oil Substances 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 13
- 210000004369 Blood Anatomy 0.000 description 12
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 12
- 239000003242 anti bacterial agent Substances 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 201000009910 diseases by infectious agent Diseases 0.000 description 12
- 125000004405 heteroalkoxy group Chemical group 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 12
- XTHPWXDJESJLNJ-UHFFFAOYSA-M Chlorosulfate Chemical compound [O-]S(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-M 0.000 description 11
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 230000000269 nucleophilic Effects 0.000 description 11
- 125000004043 oxo group Chemical group O=* 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 241000304886 Bacilli Species 0.000 description 10
- GUVUOGQBMYCBQP-UHFFFAOYSA-N DMPU Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 10
- 210000002381 Plasma Anatomy 0.000 description 10
- WRIKHQLVHPKCJU-UHFFFAOYSA-N Sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 10
- 229960002379 avibactam Drugs 0.000 description 10
- NDCUAPJVLWFHHB-UHNVWZDZSA-N avibactam Chemical compound C1N2[C@H](C(N)=O)CC[C@@]1([H])N(OS(O)(=O)=O)C2=O NDCUAPJVLWFHHB-UHNVWZDZSA-N 0.000 description 10
- 230000000875 corresponding Effects 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- NQRYJNQNLNOLGT-UHFFFAOYSA-O piperidinium(1+) Chemical compound C1CC[NH2+]CC1 NQRYJNQNLNOLGT-UHFFFAOYSA-O 0.000 description 10
- 229940040975 systemic penicillins Beta-lactamase inhibitors Drugs 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- MNFORVFSTILPAW-UHFFFAOYSA-N Β-Lactam Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 9
- GQSZUUPRBBBHRI-UHFFFAOYSA-N 2,2-dimethylbutane-1,4-diol Chemical compound OCC(C)(C)CCO GQSZUUPRBBBHRI-UHFFFAOYSA-N 0.000 description 8
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 230000035536 Oral bioavailability Effects 0.000 description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 8
- 230000002708 enhancing Effects 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 8
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 230000036220 oral bioavailability Effects 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 8
- 229910052717 sulfur Inorganic materials 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000004698 Polyethylene (PE) Substances 0.000 description 7
- 229950011310 Relebactam Drugs 0.000 description 7
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 7
- 229960004793 Sucrose Drugs 0.000 description 7
- SMOBCLHAZXOKDQ-ZJUUUORDSA-N [(2S,5R)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound O=C([C@H]1N2C[C@@](CC1)(N(C2=O)OS(O)(=O)=O)[H])NC1CCNCC1 SMOBCLHAZXOKDQ-ZJUUUORDSA-N 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 108010068385 carbapenemase Proteins 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 125000003709 fluoroalkyl group Chemical group 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 7
- 150000002367 halogens Chemical class 0.000 description 7
- 150000004677 hydrates Chemical class 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 7
- 125000003566 oxetanyl group Chemical group 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 229920000728 polyester Polymers 0.000 description 7
- 229920000573 polyethylene Polymers 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 239000006188 syrup Substances 0.000 description 7
- 235000020357 syrup Nutrition 0.000 description 7
- 230000000699 topical Effects 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- 150000003952 β-lactams Chemical class 0.000 description 7
- OKEPIEXJEOMDTL-UHFFFAOYSA-N ClS(=O)(=O)OCC(C(=O)OC(C)C)(C)C Chemical compound ClS(=O)(=O)OCC(C(=O)OC(C)C)(C)C OKEPIEXJEOMDTL-UHFFFAOYSA-N 0.000 description 6
- GGBKLHKNOVMGTE-UHFFFAOYSA-N ClS(=O)(=O)OCC(C(=O)OC)(C)C Chemical compound ClS(=O)(=O)OCC(C(=O)OC)(C)C GGBKLHKNOVMGTE-UHFFFAOYSA-N 0.000 description 6
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N Fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N Indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 125000002837 carbocyclic group Chemical group 0.000 description 6
- 150000001780 cephalosporins Chemical class 0.000 description 6
- 150000001781 cephams Chemical class 0.000 description 6
- 125000000000 cycloalkoxy group Chemical group 0.000 description 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 6
- JBDMHPJPFPMZLI-UHFFFAOYSA-N ethyl 3-hydroxy-2,2-dimethylpropanoate Chemical compound CCOC(=O)C(C)(C)CO JBDMHPJPFPMZLI-UHFFFAOYSA-N 0.000 description 6
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 229960005150 glycerol Drugs 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000008176 lyophilized powder Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000005022 packaging material Substances 0.000 description 6
- 238000007911 parenteral administration Methods 0.000 description 6
- 230000002335 preservative Effects 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 125000004434 sulfur atoms Chemical group 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 229940117958 vinyl acetate Drugs 0.000 description 6
- 239000000080 wetting agent Substances 0.000 description 6
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 5
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 5
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 5
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 5
- NLUFGAJTTKCPFQ-UHFFFAOYSA-N C(CC)(=O)OCCC(CO)(C)C Chemical compound C(CC)(=O)OCCC(CO)(C)C NLUFGAJTTKCPFQ-UHFFFAOYSA-N 0.000 description 5
- VFHDNXOLRHWZLI-UHFFFAOYSA-N C(CC)(=O)OCCC(COS(=O)(=O)Cl)(C)C Chemical compound C(CC)(=O)OCCC(COS(=O)(=O)Cl)(C)C VFHDNXOLRHWZLI-UHFFFAOYSA-N 0.000 description 5
- LLPPSZDUKQQMLS-UHFFFAOYSA-N C(CCCCC(=O)OC1=C(C(=C(C(=C1F)F)F)F)F)(=O)OCC1=CC=CC=C1 Chemical compound C(CCCCC(=O)OC1=C(C(=C(C(=C1F)F)F)F)F)(=O)OCC1=CC=CC=C1 LLPPSZDUKQQMLS-UHFFFAOYSA-N 0.000 description 5
- IZDXPEIMLFHYME-UHFFFAOYSA-N C(CCCCC(=O)OCCC(CO)(C)C)(=O)OCC1=CC=CC=C1 Chemical compound C(CCCCC(=O)OCCC(CO)(C)C)(=O)OCC1=CC=CC=C1 IZDXPEIMLFHYME-UHFFFAOYSA-N 0.000 description 5
- HUOJCOTWIQUMGL-UHFFFAOYSA-N C(CCCCC(=O)OCCC(COS(=O)(=O)Cl)(C)C)(=O)OCC1=CC=CC=C1 Chemical compound C(CCCCC(=O)OCCC(COS(=O)(=O)Cl)(C)C)(=O)OCC1=CC=CC=C1 HUOJCOTWIQUMGL-UHFFFAOYSA-N 0.000 description 5
- UDTUWSBTBPKKSP-UHFFFAOYSA-N ClS(=O)(=O)OCC(C(=O)OCCCCCC)(C)C Chemical compound ClS(=O)(=O)OCC(C(=O)OCCCCCC)(C)C UDTUWSBTBPKKSP-UHFFFAOYSA-N 0.000 description 5
- 241000588921 Enterobacteriaceae Species 0.000 description 5
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 5
- YBYIRNPNPLQARY-UHFFFAOYSA-N Indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 5
- 210000004379 Membranes Anatomy 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 239000004599 antimicrobial Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- TXWOGHSRPAYOML-UHFFFAOYSA-M cyclobutanecarboxylate Chemical compound [O-]C(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-M 0.000 description 5
- NZNMSOFKMUBTKW-UHFFFAOYSA-M cyclohexanecarboxylate Chemical compound [O-]C(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-M 0.000 description 5
- YMGUBTXCNDTFJI-UHFFFAOYSA-M cyclopropanecarboxylate Chemical compound [O-]C(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-M 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- AGZKZFGNNOGMLZ-UHFFFAOYSA-N hexyl 3-hydroxy-2,2-dimethylpropanoate Chemical compound CCCCCCOC(=O)C(C)(C)CO AGZKZFGNNOGMLZ-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 229940079866 intestinal antibiotics Drugs 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 5
- 150000002959 penams Chemical class 0.000 description 5
- NQFOGDIWKQWFMN-UHFFFAOYSA-N phenalene Chemical compound C1=CC([CH]C=C2)=C3C2=CC=CC3=C1 NQFOGDIWKQWFMN-UHFFFAOYSA-N 0.000 description 5
- CTYRPMDGLDAWRQ-UHFFFAOYSA-N phenyl hydrogen sulfate Chemical compound OS(=O)(=O)OC1=CC=CC=C1 CTYRPMDGLDAWRQ-UHFFFAOYSA-N 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- QWYHNBGEJNPGDW-UHFFFAOYSA-N propan-2-yl 3-hydroxy-2,2-dimethylpropanoate Chemical compound CC(C)OC(=O)C(C)(C)CO QWYHNBGEJNPGDW-UHFFFAOYSA-N 0.000 description 5
- 239000006215 rectal suppository Substances 0.000 description 5
- 230000001603 reducing Effects 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- YEJRWHAVMIAJKC-UHFFFAOYSA-N γ-lactone 4-hydroxy-butyric acid Chemical group O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 5
- OZJPLYNZGCXSJM-UHFFFAOYSA-N δ-Valerolactone Chemical group O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 description 5
- GSDXFZZDKAQJSD-UHFFFAOYSA-N (4-hydroxy-3,3-dimethylbutyl) benzoate Chemical compound OCC(C)(C)CCOC(=O)C1=CC=CC=C1 GSDXFZZDKAQJSD-UHFFFAOYSA-N 0.000 description 4
- FOMUQBCOZUHIAR-UHFFFAOYSA-N 1-chlorosulfonyloxy-2,2-dimethylpropane Chemical compound CC(C)(C)COS(Cl)(=O)=O FOMUQBCOZUHIAR-UHFFFAOYSA-N 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- JTXMVXSTHSMVQF-UHFFFAOYSA-N 2-acetyloxyethyl acetate Chemical compound CC(=O)OCCOC(C)=O JTXMVXSTHSMVQF-UHFFFAOYSA-N 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 239000010752 BS 2869 Class D Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- MLKQWHOBBVAYIW-UHFFFAOYSA-N C(C1=CC=CC=C1)(=O)OCC(COS(=O)(=O)Cl)(C)C Chemical compound C(C1=CC=CC=C1)(=O)OCC(COS(=O)(=O)Cl)(C)C MLKQWHOBBVAYIW-UHFFFAOYSA-N 0.000 description 4
- FLQCZBVUDWRPOI-UHFFFAOYSA-N C(C1=CC=CC=C1)(=O)OCCC(COS(=O)(=O)Cl)(C)C Chemical compound C(C1=CC=CC=C1)(=O)OCCC(COS(=O)(=O)Cl)(C)C FLQCZBVUDWRPOI-UHFFFAOYSA-N 0.000 description 4
- UJOBWOGCFQCDNV-UHFFFAOYSA-N Carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 4
- DMJPMGIRCNBTLR-UHFFFAOYSA-N ClS(=O)(=O)OCC(C(=O)OCC)(C)C Chemical compound ClS(=O)(=O)OCC(C(=O)OCC)(C)C DMJPMGIRCNBTLR-UHFFFAOYSA-N 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 239000005977 Ethylene Substances 0.000 description 4
- 229940015001 Glycerin Drugs 0.000 description 4
- KPSSIOMAKSHJJG-UHFFFAOYSA-N Neopentyl alcohol Chemical compound CC(C)(C)CO KPSSIOMAKSHJJG-UHFFFAOYSA-N 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- IVBHGBMCVLDMKU-GXNBUGAJSA-N Piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- LYLDIIUFTYRPPK-UHFFFAOYSA-M [O-]S(=O)(=O)c1ncc[nH]1 Chemical compound [O-]S(=O)(=O)c1ncc[nH]1 LYLDIIUFTYRPPK-UHFFFAOYSA-M 0.000 description 4
- 150000001241 acetals Chemical class 0.000 description 4
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 4
- 229960003022 amoxicillin Drugs 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000001580 bacterial Effects 0.000 description 4
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 230000001665 lethal Effects 0.000 description 4
- 231100000518 lethal Toxicity 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 235000019371 penicillin G benzathine Nutrition 0.000 description 4
- 150000002960 penicillins Chemical class 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 229920000139 polyethylene terephthalate Polymers 0.000 description 4
- 239000005020 polyethylene terephthalate Substances 0.000 description 4
- 229920000915 polyvinyl chloride Polymers 0.000 description 4
- 239000004800 polyvinyl chloride Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 229920002379 silicone rubber Polymers 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 238000007910 systemic administration Methods 0.000 description 4
- 230000001839 systemic circulation Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000002588 toxic Effects 0.000 description 4
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 4
- XTXRWKRVRITETP-UHFFFAOYSA-N vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 4
- ORFOPKXBNMVMKC-DWVKKRMSSA-O (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-O 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 3
- HXXOPVULXOEHTK-UHFFFAOYSA-N 4-methyl-1,3-dioxol-2-one Chemical compound CC1=COC(=O)O1 HXXOPVULXOEHTK-UHFFFAOYSA-N 0.000 description 3
- MWPLVEDNUUSJAV-UHFFFAOYSA-N Anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- CUFNKYGDVFVPHO-UHFFFAOYSA-N Azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 3
- BVGLIYRKPOITBQ-ANPZCEIESA-N Benzathine benzylpenicillin Chemical compound C=1C=CC=CC=1C[NH2+]CC[NH2+]CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 BVGLIYRKPOITBQ-ANPZCEIESA-N 0.000 description 3
- 230000036912 Bioavailability Effects 0.000 description 3
- 229940041011 Carbapenems Drugs 0.000 description 3
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N Cefalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 3
- 229960001139 Cefazolin Drugs 0.000 description 3
- MLYYVTUWGNIJIB-BXKDBHETSA-N Cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 3
- 229960000484 Ceftazidime Drugs 0.000 description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 3
- 229940106164 Cephalexin Drugs 0.000 description 3
- VZWXIQHBIQLMPN-UHFFFAOYSA-N Chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 3
- WDECIBYCCFPHNR-UHFFFAOYSA-N Chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 3
- 241000588923 Citrobacter Species 0.000 description 3
- VPUGDVKSAQVFFS-UHFFFAOYSA-N Coronene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3)C4=C4C3=CC=C(C=C3)C4=C2C3=C1 VPUGDVKSAQVFFS-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- YFAGHNZHGGCZAX-JKIFEVAISA-N Dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 3
- AVAACINZEOAHHE-VFZPANTDSA-N Doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- GVEPBJHOBDJJJI-UHFFFAOYSA-N Fluoranthene Chemical compound C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 3
- 229940093915 Gynecological Organic acids Drugs 0.000 description 3
- 229940047650 Haemophilus influenzae Drugs 0.000 description 3
- 241000606768 Haemophilus influenzae Species 0.000 description 3
- QSQIGGCOCHABAP-UHFFFAOYSA-N Hexacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC6=CC=CC=C6C=C5C=C4C=C3C=C21 QSQIGGCOCHABAP-UHFFFAOYSA-N 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N Hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 description 3
- 229940045505 Klebsiella pneumoniae Drugs 0.000 description 3
- 241000588747 Klebsiella pneumoniae Species 0.000 description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 3
- 229940067606 Lecithin Drugs 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 229940041033 Macrolides Drugs 0.000 description 3
- DMJNNHOOLUXYBV-PQTSNVLCSA-N Meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 3
- 230000035633 Metabolized Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000588655 Moraxella catarrhalis Species 0.000 description 3
- OKDQKPLMQBXTNH-UHFFFAOYSA-N N,N-dimethyl-2H-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 3
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N Nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 3
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 3
- 241000588650 Neisseria meningitidis Species 0.000 description 3
- LSQODMMMSXHVCN-UHFFFAOYSA-N Ovalene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3C5=C6C(C=C3)=CC=C3C6=C6C(C=C3)=C3)C4=C5C6=C2C3=C1 LSQODMMMSXHVCN-UHFFFAOYSA-N 0.000 description 3
- UWYHMGVUTGAWSP-JKIFEVAISA-N Oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 3
- SLIUAWYAILUBJU-UHFFFAOYSA-N Pentacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC=CC=C5C=C4C=C3C=C21 SLIUAWYAILUBJU-UHFFFAOYSA-N 0.000 description 3
- GUVXZFRDPCKWEM-UHFFFAOYSA-N Pentalene Chemical compound C1=CC2=CC=CC2=C1 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 description 3
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 3
- GBROPGWFBFCKAG-UHFFFAOYSA-N Picene Chemical compound C1=CC2=C3C=CC=CC3=CC=C2C2=C1C1=CC=CC=C1C=C2 GBROPGWFBFCKAG-UHFFFAOYSA-N 0.000 description 3
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- BBEAQIROQSPTKN-UHFFFAOYSA-N Pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 3
- 229940076185 Staphylococcus aureus Drugs 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229940032147 Starch Drugs 0.000 description 3
- 210000002784 Stomach Anatomy 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- OHKOGUYZJXTSFX-KZFFXBSXSA-N Ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 3
- 229960004659 Ticarcillin Drugs 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- GJCOSYZMQJWQCA-UHFFFAOYSA-N Xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 3
- QVXFGVVYTKZLJN-KHPPLWFESA-N [(Z)-hexadec-7-enyl] acetate Chemical compound CCCCCCCC\C=C/CCCCCCOC(C)=O QVXFGVVYTKZLJN-KHPPLWFESA-N 0.000 description 3
- 230000035507 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- JDPAVWAQGBGGHD-UHFFFAOYSA-N aceanthrylene Chemical group C1=CC=C2C(C=CC3=CC=C4)=C3C4=CC2=C1 JDPAVWAQGBGGHD-UHFFFAOYSA-N 0.000 description 3
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 3
- SQFPKRNUGBRTAR-UHFFFAOYSA-N acephenanthrylene Chemical group C1=CC(C=C2)=C3C2=CC2=CC=CC=C2C3=C1 SQFPKRNUGBRTAR-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating Effects 0.000 description 3
- 239000011149 active material Substances 0.000 description 3
- 230000002730 additional Effects 0.000 description 3
- 230000000111 anti-oxidant Effects 0.000 description 3
- BVUSIQTYUVWOSX-UHFFFAOYSA-N arsindole Chemical compound C1=CC=C2[As]C=CC2=C1 BVUSIQTYUVWOSX-UHFFFAOYSA-N 0.000 description 3
- KNNXFYIMEYKHBZ-UHFFFAOYSA-N as-indacene Chemical compound C1=CC2=CC=CC2=C2C=CC=C21 KNNXFYIMEYKHBZ-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229960000626 benzylpenicillin Drugs 0.000 description 3
- 125000003460 beta-lactamyl group Chemical group 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 230000035514 bioavailability Effects 0.000 description 3
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 3
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 229960003525 cefalexin Drugs 0.000 description 3
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000005712 crystallization Effects 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 230000004059 degradation Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 229960001585 dicloxacillin Drugs 0.000 description 3
- 229960000895 doripenem Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000002702 enteric coating Substances 0.000 description 3
- 229960002770 ertapenem Drugs 0.000 description 3
- 239000007888 film coating Substances 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- PKIFBGYEEVFWTJ-UHFFFAOYSA-N hexaphene Chemical compound C1=CC=C2C=C3C4=CC5=CC6=CC=CC=C6C=C5C=C4C=CC3=CC2=C1 PKIFBGYEEVFWTJ-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 230000000670 limiting Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000003120 macrolide antibiotic agent Substances 0.000 description 3
- 229960002260 meropenem Drugs 0.000 description 3
- 230000002503 metabolic Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- RSBPYSTVZQAADE-RQJHMYQMSA-N nacubactam Chemical compound C1N2[C@H](C(=O)NOCCN)CC[C@@]1([H])N(OS(O)(=O)=O)C2=O RSBPYSTVZQAADE-RQJHMYQMSA-N 0.000 description 3
- 229950005001 nacubactam Drugs 0.000 description 3
- 229960000515 nafcillin Drugs 0.000 description 3
- 230000003000 nontoxic Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- PFTXKXWAXWAZBP-UHFFFAOYSA-N octacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC6=CC7=CC8=CC=CC=C8C=C7C=C6C=C5C=C4C=C3C=C21 PFTXKXWAXWAZBP-UHFFFAOYSA-N 0.000 description 3
- OVPVGJFDFSJUIG-UHFFFAOYSA-N octalene Chemical compound C1=CC=CC=C2C=CC=CC=CC2=C1 OVPVGJFDFSJUIG-UHFFFAOYSA-N 0.000 description 3
- WTFQBTLMPISHTA-UHFFFAOYSA-N octaphene Chemical compound C1=CC=C2C=C(C=C3C4=CC5=CC6=CC7=CC=CC=C7C=C6C=C5C=C4C=CC3=C3)C3=CC2=C1 WTFQBTLMPISHTA-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 229960001019 oxacillin Drugs 0.000 description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
- 230000001717 pathogenic Effects 0.000 description 3
- 244000052769 pathogens Species 0.000 description 3
- JQQSUOJIMKJQHS-UHFFFAOYSA-N pentaphene Chemical compound C1=CC=C2C=C3C4=CC5=CC=CC=C5C=C4C=CC3=CC2=C1 JQQSUOJIMKJQHS-UHFFFAOYSA-N 0.000 description 3
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- DIJNSQQKNIVDPV-UHFFFAOYSA-N pleiadene Chemical compound C1=C2[CH]C=CC=C2C=C2C=CC=C3[C]2C1=CC=C3 DIJNSQQKNIVDPV-UHFFFAOYSA-N 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 230000003405 preventing Effects 0.000 description 3
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 3
- LNKHTYQPVMAJSF-UHFFFAOYSA-N pyranthrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC3=C(C=CC=C4)C4=CC4=CC=C1C2=C34 LNKHTYQPVMAJSF-UHFFFAOYSA-N 0.000 description 3
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- FMKFBRKHHLWKDB-UHFFFAOYSA-N rubicene Chemical compound C12=CC=CC=C2C2=CC=CC3=C2C1=C1C=CC=C2C4=CC=CC=C4C3=C21 FMKFBRKHHLWKDB-UHFFFAOYSA-N 0.000 description 3
- WEMQMWWWCBYPOV-UHFFFAOYSA-N s-indacene Chemical compound C=1C2=CC=CC2=CC2=CC=CC2=1 WEMQMWWWCBYPOV-UHFFFAOYSA-N 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000002459 sustained Effects 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 125000005580 triphenylene group Chemical group 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- VEZXCJBBBCKRPI-UHFFFAOYSA-N β-Propiolactone Chemical group O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 3
- GSDSWSVVBLHKDQ-JTQLQIEISA-N (2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic acid Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 2
- DKZFIPFKXAGEBP-UHFFFAOYSA-N (3-hydroxy-2,2-dimethylpropyl) benzoate Chemical compound OCC(C)(C)COC(=O)C1=CC=CC=C1 DKZFIPFKXAGEBP-UHFFFAOYSA-N 0.000 description 2
- PUOAETJYKQITMO-FYJGNVAPSA-N (3E)-1-[1-(4-fluorophenyl)ethyl]-3-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]piperidin-2-one Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1\C=C(C1=O)/CCCN1C(C)C1=CC=C(F)C=C1 PUOAETJYKQITMO-FYJGNVAPSA-N 0.000 description 2
- JFPVXVDWJQMJEE-IZRZKJBUSA-N (6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-Tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
- LGXVIGDEPROXKC-UHFFFAOYSA-N 1,1-Dichloroethene Chemical compound ClC(Cl)=C LGXVIGDEPROXKC-UHFFFAOYSA-N 0.000 description 2
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 2
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- MFJCPDOGFAYSTF-UHFFFAOYSA-N 1H-isochromene Chemical compound C1=CC=C2COC=CC2=C1 MFJCPDOGFAYSTF-UHFFFAOYSA-N 0.000 description 2
- AAQTWLBJPNLKHT-UHFFFAOYSA-N 1H-perimidine Chemical compound N1C=NC2=CC=CC3=CC=CC1=C32 AAQTWLBJPNLKHT-UHFFFAOYSA-N 0.000 description 2
- ODMMNALOCMNQJZ-UHFFFAOYSA-N 1H-pyrrolizine Chemical compound C1=CC=C2CC=CN21 ODMMNALOCMNQJZ-UHFFFAOYSA-N 0.000 description 2
- WGIMXKDCVCTHGW-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCCO WGIMXKDCVCTHGW-UHFFFAOYSA-N 0.000 description 2
- IOOWNWLVCOUUEX-WPRPVWTQSA-N 2-[(3R,6S)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid Chemical compound OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC1=CC=CS1 IOOWNWLVCOUUEX-WPRPVWTQSA-N 0.000 description 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 2
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-hydroxypropyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 2
- VHOQXEIFYTTXJU-UHFFFAOYSA-N 2-methylbuta-1,3-diene;2-methylprop-1-ene Chemical compound CC(C)=C.CC(=C)C=C VHOQXEIFYTTXJU-UHFFFAOYSA-N 0.000 description 2
- KUDUQBURMYMBIJ-UHFFFAOYSA-N 2-prop-2-enoyloxyethyl prop-2-enoate Chemical compound C=CC(=O)OCCOC(=O)C=C KUDUQBURMYMBIJ-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 2
- RDFQSFOGKVZWKF-UHFFFAOYSA-N 3-hydroxy-2,2-dimethylpropanoic acid Chemical compound OCC(C)(C)C(O)=O RDFQSFOGKVZWKF-UHFFFAOYSA-N 0.000 description 2
- QYIOFABFKUOIBV-UHFFFAOYSA-N 4,5-dimethyl-1,3-dioxol-2-one Chemical compound CC=1OC(=O)OC=1C QYIOFABFKUOIBV-UHFFFAOYSA-N 0.000 description 2
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 2
- 206010056519 Abdominal infection Diseases 0.000 description 2
- 241000589291 Acinetobacter Species 0.000 description 2
- 241000607528 Aeromonas hydrophila Species 0.000 description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N Amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N Azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
- WZPBZJONDBGPKJ-VEHQQRBSSA-N Aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 2
- 229960003644 Aztreonam Drugs 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- 241000606124 Bacteroides fragilis Species 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N Benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N Benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- 210000001124 Body Fluids Anatomy 0.000 description 2
- 229940095259 Butylated Hydroxytoluene Drugs 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- FPPNZSSZRUTDAP-UWFZAAFLSA-N Carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 2
- 229960003669 Carbenicillin Drugs 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 229960005361 Cefaclor Drugs 0.000 description 2
- NBFNMSULHIODTC-CYJZLJNKSA-N Cefadroxil Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 2
- 229960004841 Cefadroxil Drugs 0.000 description 2
- GPRBEKHLDVQUJE-VINNURBNSA-N Cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 2
- 229960004261 Cefotaxime Drugs 0.000 description 2
- SRZNHPXWXCNNDU-RHBCBLIFSA-N Cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 2
- 229960005495 Cefotetan Drugs 0.000 description 2
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N Cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 2
- 229960002682 Cefoxitin Drugs 0.000 description 2
- WYUSVOMTXWRGEK-HBWVYFAYSA-N Cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 2
- 229960004755 Ceftriaxone Drugs 0.000 description 2
- 229960001668 Cefuroxime Drugs 0.000 description 2
- 108010020487 Cephalosporinase Proteins 0.000 description 2
- 239000004709 Chlorinated polyethylene Substances 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- WCZVZNOTHYJIEI-UHFFFAOYSA-N Cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N Ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- HZZVJAQRINQKSD-PBFISZAISA-N Clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N Clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 241000193155 Clostridium botulinum Species 0.000 description 2
- 241000193468 Clostridium perfringens Species 0.000 description 2
- 241000193449 Clostridium tetani Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- 241000589566 Elizabethkingia meningoseptica Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229940092559 Enterobacter aerogenes Drugs 0.000 description 2
- 229940088598 Enzyme Drugs 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 229940023064 Escherichia coli Drugs 0.000 description 2
- OBNCKNCVKJNDBV-UHFFFAOYSA-N Ethyl butyrate Chemical compound CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 2
- ZVGNESXIJDCBKN-UUEYKCAUSA-N Fidaxomicin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@H]([C@H]1O)OC)OCC\1=C/C=C/C[C@H](O)/C(C)=C/[C@@H]([C@H](/C(C)=C/C(/C)=C/C[C@H](OC/1=O)[C@@H](C)O)O[C@H]1[C@H]([C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O1)O)CC)C(=O)C1=C(O)C(Cl)=C(O)C(Cl)=C1CC ZVGNESXIJDCBKN-UUEYKCAUSA-N 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 241000605909 Fusobacterium Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- ZRCVYEYHRGVLOC-HYARGMPZSA-N Gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 229940093912 Gynecological Sulfonamides Drugs 0.000 description 2
- 241000606790 Haemophilus Species 0.000 description 2
- 229940037467 Helicobacter pylori Drugs 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 240000008528 Hevea brasiliensis Species 0.000 description 2
- 229960002182 IMIPENEM Drugs 0.000 description 2
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N IMIPENEM Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 2
- HOBCFUWDNJPFHB-UHFFFAOYSA-N Indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 2
- UXGVMFHEKMGWMA-UHFFFAOYSA-N Isobenzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 2
- GWVMLCQWXVFZCN-UHFFFAOYSA-N Isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N Isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N Isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 241000588915 Klebsiella aerogenes Species 0.000 description 2
- 241000589901 Leptospiraceae Species 0.000 description 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N Levofloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 2
- 229960005015 Local anesthetics Drugs 0.000 description 2
- 229940083877 Local anesthetics for treatment of hemorrhoids and anal fissures for topical use Drugs 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- 230000036740 Metabolism Effects 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N Methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 229940041009 Monobactams Drugs 0.000 description 2
- 241000588771 Morganella <proteobacterium> Species 0.000 description 2
- 229940076266 Morganella morganii Drugs 0.000 description 2
- 241000588772 Morganella morganii Species 0.000 description 2
- FABPRXSRWADJSP-MEDUHNTESA-N Moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 2
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 229960001180 Norfloxacin Drugs 0.000 description 2
- OGJPXUAPXNRGGI-UHFFFAOYSA-N Norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 229960001699 Ofloxacin Drugs 0.000 description 2
- 229940051027 Pasteurella multocida Drugs 0.000 description 2
- 241000606856 Pasteurella multocida Species 0.000 description 2
- 229940049954 Penicillin Drugs 0.000 description 2
- 239000004186 Penicillin G benzathine Substances 0.000 description 2
- 108010087702 Penicillinase Proteins 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N Phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical compound C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- LFSXCDWNBUNEEM-UHFFFAOYSA-N Phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 2
- 241000606999 Plesiomonas shigelloides Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 239000005062 Polybutadiene Substances 0.000 description 2
- 229920002367 Polyisobutene Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 241000605861 Prevotella Species 0.000 description 2
- RUOJZAUFBMNUDX-UHFFFAOYSA-N Propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 2
- 241000588777 Providencia rettgeri Species 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- CPNGPNLZQNNVQM-UHFFFAOYSA-N Pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- MGADZUXDNSDTHW-UHFFFAOYSA-N Pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N Pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N Quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N Quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 Saccharin Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- 206010039447 Salmonellosis Diseases 0.000 description 2
- 229940098362 Serratia marcescens Drugs 0.000 description 2
- 241000607715 Serratia marcescens Species 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- 241000605008 Spirillum Species 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 2
- 229940030998 Streptococcus agalactiae Drugs 0.000 description 2
- 241000193985 Streptococcus agalactiae Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229940032484 Sulfisoxazole Drugs 0.000 description 2
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfizole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 2
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N Tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 description 2
- LJVAJPDWBABPEJ-PNUFFHFMSA-N Telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 description 2
- 229940040944 Tetracyclines Drugs 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N Tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N Thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 2
- 229960000707 Tobramycin Drugs 0.000 description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N Tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 2
- 229940116362 Tragacanth Drugs 0.000 description 2
- 241000589884 Treponema pallidum Species 0.000 description 2
- 229940117013 Triethanolamine oleate Drugs 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 2
- 206010046577 Urinary tract infection Diseases 0.000 description 2
- 229940118696 Vibrio cholerae Drugs 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- 229940098232 Yersinia enterocolitica Drugs 0.000 description 2
- 241000607447 Yersinia enterocolitica Species 0.000 description 2
- NWGKJDSIEKMTRX-HSACVWGTSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (E)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-HSACVWGTSA-N 0.000 description 2
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 231100000494 adverse effect Toxicity 0.000 description 2
- 241001148470 aerobic bacillus Species 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229960004821 amikacin Drugs 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 230000001458 anti-acid Effects 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 239000008122 artificial sweetener Substances 0.000 description 2
- 229960004099 azithromycin Drugs 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N benzohydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- WHRVRSCEWKLAHX-LQDWTQKMSA-N benzylpenicillin procaine Chemical compound [H+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 WHRVRSCEWKLAHX-LQDWTQKMSA-N 0.000 description 2
- 108010034752 beta-lactamase NDM-1 Proteins 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229920005549 butyl rubber Polymers 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000003197 catalytic Effects 0.000 description 2
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 2
- 229960005090 cefpodoxime Drugs 0.000 description 2
- 229940036735 ceftaroline Drugs 0.000 description 2
- RGFBRLNVZCCMSV-BIRGHMBHSA-N ceftaroline Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OCC)C=2N=C(N)SN=2)CC=1SC(SC=1)=NC=1C1=CC=[N+](C)C=C1 RGFBRLNVZCCMSV-BIRGHMBHSA-N 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 2
- 229960002626 clarithromycin Drugs 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- 229960005188 collagen Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 2
- KLYCPFXDDDMZNQ-UHFFFAOYSA-N dehydrobenzene Chemical group C1=CC#CC=C1 KLYCPFXDDDMZNQ-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- 239000008355 dextrose injection Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- 229920005558 epichlorohydrin rubber Polymers 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- IMROMDMJAWUWLK-UHFFFAOYSA-N ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229960000628 fidaxomicin Drugs 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960003170 gemifloxacin Drugs 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical group OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001965 increased Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940079867 intestinal antiinfectives Sulfonamides Drugs 0.000 description 2
- 229920000554 ionomer Polymers 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229960003376 levofloxacin Drugs 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229940064003 local anesthetic throat preparations Drugs 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 229940099690 malic acid Drugs 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035786 metabolism Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 102000030974 metallo-beta-lactamase family Human genes 0.000 description 2
- 108060004734 metallo-beta-lactamase family Proteins 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- ZIYVHBGGAOATLY-UHFFFAOYSA-L methylmalonate(2-) Chemical compound [O-]C(=O)C(C)C([O-])=O ZIYVHBGGAOATLY-UHFFFAOYSA-L 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229960003702 moxifloxacin Drugs 0.000 description 2
- 229920001194 natural rubber Polymers 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940005938 ophthalmologic antiinfectives Sulfonamides Drugs 0.000 description 2
- 230000003204 osmotic Effects 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- WYNCHZVNFNFDNH-UHFFFAOYSA-N oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 2
- 239000006179 pH buffering agent Substances 0.000 description 2
- 229940056365 penicillin G benzathine Drugs 0.000 description 2
- 230000036231 pharmacokinetics Effects 0.000 description 2
- PUXKSJCSTXMIKR-UHFFFAOYSA-N phenyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OC1=CC=CC=C1 PUXKSJCSTXMIKR-UHFFFAOYSA-N 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-M phenylacetate Chemical compound [O-]C(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-M 0.000 description 2
- 229940049953 phenylacetate Drugs 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229960002292 piperacillin Drugs 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 2
- 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 description 2
- 229920001084 poly(chloroprene) Polymers 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920002857 polybutadiene Polymers 0.000 description 2
- 229920001195 polyisoprene Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000000069 prophylaxis Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 229940093625 propylene glycol monostearate Drugs 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008117 stearic acid Chemical group 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229960000654 sulfafurazole Drugs 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- HIFJUMGIHIZEPX-UHFFFAOYSA-N sulfuric acid;sulfur trioxide Chemical compound O=S(=O)=O.OS(O)(=O)=O HIFJUMGIHIZEPX-UHFFFAOYSA-N 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- 229960003865 tazobactam Drugs 0.000 description 2
- 229960003250 telithromycin Drugs 0.000 description 2
- 229920001897 terpolymer Polymers 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 229940026752 topical Sulfonamides Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- NJGIRBISCGPRPF-KXQOOQHDSA-N (2-aminoethoxy)[(2R)-2-(icosanoyloxy)-3-(pentadecanoyloxy)propoxy]phosphinic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP(O)(=O)OCCN)COC(=O)CCCCCCCCCCCCCC NJGIRBISCGPRPF-KXQOOQHDSA-N 0.000 description 1
- KWMLJOLKUYYJFJ-AIECOIEWSA-N (2R,3R,4R,5S,6R)-2,3,4,5,6,7-hexahydroxyheptanoic acid Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-AIECOIEWSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- DKOQGJHPHLTOJR-PUIFZAHNSA-N (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(6,7-dihydro-5H-cyclopenta[b]pyridin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-PUIFZAHNSA-N 0.000 description 1
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6R,7R)-7-[[(2R)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(E)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-Heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N 1,1-Diethoxyethane Chemical compound CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- YLPCXVWMHNNQGI-UHFFFAOYSA-N 1,2-diazabicyclo[3.2.1]octane Chemical group C1C2CCN1NCC2 YLPCXVWMHNNQGI-UHFFFAOYSA-N 0.000 description 1
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N 1-Hexanol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N 1-ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
- SLCVBVWXLSEKPL-UHFFFAOYSA-N 2,2-dimethylpropane-1,3-diol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 1
- OZARAEFTGONNJV-UHFFFAOYSA-M 2,2-dimethylpropane-1-sulfonate Chemical class CC(C)(C)CS([O-])(=O)=O OZARAEFTGONNJV-UHFFFAOYSA-M 0.000 description 1
- GOHPTLYPQCTZSE-UHFFFAOYSA-N 2,2-dimethylsuccinic acid Chemical compound OC(=O)C(C)(C)CC(O)=O GOHPTLYPQCTZSE-UHFFFAOYSA-N 0.000 description 1
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 1
- VAMSVIZLXJOLHZ-QWFSEIHXSA-N 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(3S)-2,2-dimethyl-4-oxo-1-sulfooxyazetidin-3-yl]amino]-2-oxoethylidene]amino]oxyacetic acid Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1 VAMSVIZLXJOLHZ-QWFSEIHXSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-H 2-hydroxypropane-1,2,3-tricarboxylate;phosphate Chemical compound [O-]P([O-])([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O GHCZTIFQWKKGSB-UHFFFAOYSA-H 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N 2-methyl-2-propenoic acid methyl ester Chemical class COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- MJKVTPMWOKAVMS-UHFFFAOYSA-N 3 Hydroxycoumarin Chemical class C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- ALEVUYMOJKJJSA-UHFFFAOYSA-N 4-hydroxy-2-propylbenzoic acid Chemical class CCCC1=CC(O)=CC=C1C(O)=O ALEVUYMOJKJJSA-UHFFFAOYSA-N 0.000 description 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 1
- WHJKCPTVEYZNOG-UHFFFAOYSA-N 6-(hydroxymethyl)-5-methoxy-2-[4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane-3,4-diol Chemical group COCC1OC(OC)C(OC)C(OC)C1OC1C(O)C(O)C(OC)C(CO)O1 WHJKCPTVEYZNOG-UHFFFAOYSA-N 0.000 description 1
- CQSWISNVQPOAEM-UHFFFAOYSA-N 6-oxo-6-phenylmethoxyhexanoic acid Chemical compound OC(=O)CCCCC(=O)OCC1=CC=CC=C1 CQSWISNVQPOAEM-UHFFFAOYSA-N 0.000 description 1
- BPMFPOGUJAAYHL-UHFFFAOYSA-N 9H-pyrido[2,3-b]indole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=N1 BPMFPOGUJAAYHL-UHFFFAOYSA-N 0.000 description 1
- 229940069428 ANTACIDS Drugs 0.000 description 1
- 229940074728 ANTIINFECTIVE OPHTHALMOLOGICS Drugs 0.000 description 1
- 101700027113 AREA Proteins 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N Acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 241000605281 Anaplasma phagocytophilum Species 0.000 description 1
- 229940021383 Antiinfective irrigating solutions Drugs 0.000 description 1
- 229960005475 Antiinfectives Drugs 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- JTWOMNBEOCYFNV-NFFDBFGFSA-N Azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
- 229960003623 Azlocillin Drugs 0.000 description 1
- 229940065181 Bacillus anthracis Drugs 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 229940092528 Bartonella bacilliformis Drugs 0.000 description 1
- 241000606685 Bartonella bacilliformis Species 0.000 description 1
- 241001518086 Bartonella henselae Species 0.000 description 1
- 241000606108 Bartonella quintana Species 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229960001950 Benzethonium Chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M Benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N Benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N Benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- 230000035639 Blood Levels Effects 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 229940097269 Borrelia burgdorferi Drugs 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241000589539 Brevundimonas diminuta Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- 241000589513 Burkholderia cepacia Species 0.000 description 1
- 241000020730 Burkholderia cepacia complex Species 0.000 description 1
- 229940105657 CATALASE Drugs 0.000 description 1
- 229960002129 CEFIXIME Drugs 0.000 description 1
- 229960000466 CEFPIROME Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N Camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 229940015062 Campylobacter jejuni Drugs 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N Cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N Cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N Cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N Ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 description 1
- HOKIDJSKDBPKTQ-GLXFQSAKSA-N Cephalosporin C Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H](N)C(O)=O)[C@@H]12 HOKIDJSKDBPKTQ-GLXFQSAKSA-N 0.000 description 1
- 229940106195 Cephalothin Drugs 0.000 description 1
- 229940112822 Chewing Gum Drugs 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- 229940038705 Chlamydia trachomatis Drugs 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 241000606069 Chlamydiaceae Species 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 Chlorobutanol Drugs 0.000 description 1
- 241000588879 Chromobacterium violaceum Species 0.000 description 1
- 229940095223 Cilastatin / Imipenem Drugs 0.000 description 1
- VDUWPHTZYNWKRN-UHFFFAOYSA-N Cinoxacin Chemical compound C1=C2N(CC)N=C(C(O)=O)C(=O)C2=CC2=C1OCO2 VDUWPHTZYNWKRN-UHFFFAOYSA-N 0.000 description 1
- 229960004621 Cinoxacin Drugs 0.000 description 1
- 241000588919 Citrobacter freundii Species 0.000 description 1
- 241000588917 Citrobacter koseri Species 0.000 description 1
- VRZYKULPKHQCHS-UHFFFAOYSA-N ClS(=O)(=O)OCC(C(=O)OCC1=CC=CC=C1)(C)C Chemical compound ClS(=O)(=O)OCC(C(=O)OCC1=CC=CC=C1)(C)C VRZYKULPKHQCHS-UHFFFAOYSA-N 0.000 description 1
- 229940090805 Clavulanate Drugs 0.000 description 1
- 229960003324 Clavulanic Acid Drugs 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193464 Clostridium sp. Species 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N Cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 241000223203 Coccidioides Species 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001517041 Corynebacterium jeikeium Species 0.000 description 1
- 229940118765 Coxiella burnetii Drugs 0.000 description 1
- 241000606678 Coxiella burnetii Species 0.000 description 1
- 241000246077 Coxiellaceae Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 229940097362 Cyclodextrins Drugs 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N Cypionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N DAPTOMYCIN Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- 229940030606 DIURETICS Drugs 0.000 description 1
- 229960005484 Daptomycin Drugs 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N Diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- MUZIZEZCKKMZRT-UHFFFAOYSA-N Dithiolane Chemical compound C1CSSC1 MUZIZEZCKKMZRT-UHFFFAOYSA-N 0.000 description 1
- 229960003722 Doxycycline Drugs 0.000 description 1
- 208000006922 Drug-Related Side Effects and Adverse Reaction Diseases 0.000 description 1
- 102000016938 EC 1.11.1.6 Human genes 0.000 description 1
- 108010053835 EC 1.11.1.6 Proteins 0.000 description 1
- 241000605310 Ehrlichia chaffeensis Species 0.000 description 1
- 241000588878 Eikenella corrodens Species 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 229940119563 Enterobacter cloacae Drugs 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 229940032049 Enterococcus faecalis Drugs 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N Ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- 230000036081 Excretion rate Effects 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N FOSFOMYCIN Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- HGGAKXAHAYOLDJ-FHZUQPTBSA-N Faropenem Chemical compound S([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1[C@H]1CCCO1 HGGAKXAHAYOLDJ-FHZUQPTBSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229960004273 Floxacillin Drugs 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 229960001731 GLUCEPTATE Drugs 0.000 description 1
- 241000207201 Gardnerella vaginalis Species 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- XUBOMFCQGDBHNK-UHFFFAOYSA-N Gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCNC(C)C1 XUBOMFCQGDBHNK-UHFFFAOYSA-N 0.000 description 1
- 241001147749 Gemella morbillorum Species 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 241000606766 Haemophilus parainfluenzae Species 0.000 description 1
- 206010020429 Human ehrlichiosis Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 230000035809 INACTIVATION RATE Effects 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N Isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 241000588749 Klebsiella oxytoca Species 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N Lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N Lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N Linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N Lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 241000195947 Lycopodium Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 240000006217 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 229960000282 Metronidazole Drugs 0.000 description 1
- 229960004023 Minocycline Drugs 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 210000004400 Mucous Membrane Anatomy 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241001502334 Mycobacterium avium complex bacterium Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 229940010383 Mycobacterium tuberculosis Drugs 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241001302239 Mycobacterium tuberculosis complex Species 0.000 description 1
- 229940013390 Mycoplasma pneumoniae Drugs 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229960000210 Nalidixic Acid Drugs 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 229940052778 Neisseria meningitidis Drugs 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229960000564 Nitrofurantoin Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N Nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 241000606693 Orientia tsutsugamushi Species 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 241000520272 Pantoea Species 0.000 description 1
- 241000588912 Pantoea agglomerans Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229940056360 Penicillin G Drugs 0.000 description 1
- 239000004185 Penicillin G procaine Substances 0.000 description 1
- 229940090663 Penicillin V Potassium Drugs 0.000 description 1
- 229950009506 Penicillinase Drugs 0.000 description 1
- 241000206590 Peptococcus niger Species 0.000 description 1
- 241000192033 Peptostreptococcus sp. Species 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N Phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N Phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N Phenylpropanoic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- UNJJBGNPUUVVFQ-ZJUUUORDSA-N Phosphatidylserine Chemical compound CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O UNJJBGNPUUVVFQ-ZJUUUORDSA-N 0.000 description 1
- 229960004838 Phosphoric acid Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 241000607000 Plesiomonas Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- 241000605894 Porphyromonas Species 0.000 description 1
- 229940069328 Povidone Drugs 0.000 description 1
- 241001135223 Prevotella melaninogenica Species 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 229960001309 Procaine hydrochloride Drugs 0.000 description 1
- 229940075579 Propyl Gallate Drugs 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 229940055033 Proteus mirabilis Drugs 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000334216 Proteus sp. Species 0.000 description 1
- 229940007042 Proteus vulgaris Drugs 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000588768 Providencia Species 0.000 description 1
- 241000168225 Pseudomonas alcaligenes Species 0.000 description 1
- 241000589540 Pseudomonas fluorescens Species 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 241000589614 Pseudomonas stutzeri Species 0.000 description 1
- 229940107700 Pyruvic Acid Drugs 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N Quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- WTHRRGMBUAHGNI-LCYNINFDSA-N Quinupristin Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O WTHRRGMBUAHGNI-LCYNINFDSA-N 0.000 description 1
- 229950000381 RAZUPENEM Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N RIFAMPICIN Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- XFGOMLIRJYURLQ-GOKYHWASSA-N Razupenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)SC(SC=1)=NC=1C1=C[C@H](C)NC1 XFGOMLIRJYURLQ-GOKYHWASSA-N 0.000 description 1
- 229940100618 Rectal Suppository Drugs 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- 229940046939 Rickettsia prowazekii Drugs 0.000 description 1
- 241000606697 Rickettsia prowazekii Species 0.000 description 1
- 241000606695 Rickettsia rickettsii Species 0.000 description 1
- 241000606726 Rickettsia typhi Species 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- 229940081190 Rifampin Drugs 0.000 description 1
- WDZCUPBHRAEYDL-GZAUEHORSA-N Rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 description 1
- 229940100996 SODIUM BISULFATE Drugs 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 241000607356 Salmonella enterica subsp. arizonae Species 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 230000037165 Serum Concentration Effects 0.000 description 1
- 206010040490 Sexually transmitted disease Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010040550 Shigella infection Diseases 0.000 description 1
- 241000607758 Shigella sp. Species 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 229960004249 Sodium Acetate Drugs 0.000 description 1
- 229960003885 Sodium Benzoate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M Sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- DZZWHBIBMUVIIW-DTORHVGOSA-N Sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000122971 Stenotrophomonas Species 0.000 description 1
- 241001478878 Streptobacillus Species 0.000 description 1
- 241001478880 Streptobacillus moniliformis Species 0.000 description 1
- 241000194008 Streptococcus anginosus Species 0.000 description 1
- 241000911872 Streptococcus anginosus group Species 0.000 description 1
- 241001291896 Streptococcus constellatus Species 0.000 description 1
- 241000194049 Streptococcus equinus Species 0.000 description 1
- 241001464947 Streptococcus milleri Species 0.000 description 1
- 241001134658 Streptococcus mitis Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000194024 Streptococcus salivarius Species 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 229960005256 Sulbactam Drugs 0.000 description 1
- FKENQMMABCRJMK-RITPCOANSA-N Sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 1
- VACCAVUAMIDAGB-UHFFFAOYSA-N Sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 1
- 229940035528 Sulfamethoxazole / Trimethoprim Drugs 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- BSUXZTMOMIFYBF-FFWSUHOLSA-N Tabtoxinine β-lactam Chemical compound OC(=O)[C@@H](N)CC[C@]1(O)CNC1=O BSUXZTMOMIFYBF-FFWSUHOLSA-N 0.000 description 1
- SNUDIPVBUUXCDG-QHSBEEBCSA-N Tebipenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(=O)OCOC(=O)C(C)(C)C)=O)[C@H](O)C)SC(C1)CN1C1=NCCS1 SNUDIPVBUUXCDG-QHSBEEBCSA-N 0.000 description 1
- XFALPSLJIHVRKE-GFCCVEGCSA-N Tedizolid Chemical compound CN1N=NC(C=2N=CC(=CC=2)C=2C(=CC(=CC=2)N2C(O[C@@H](CO)C2)=O)F)=N1 XFALPSLJIHVRKE-GFCCVEGCSA-N 0.000 description 1
- 229960005240 Telavancin Drugs 0.000 description 1
- ONUMZHGUFYIKPM-MXNFEBESSA-N Telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 description 1
- BVCKFLJARNKCSS-DWPRYXJFSA-N Temocillin Chemical compound N([C@]1(OC)C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C=1C=CSC=1 BVCKFLJARNKCSS-DWPRYXJFSA-N 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 229960002180 Tetracycline Drugs 0.000 description 1
- ZUHZGEOKBKGPSW-UHFFFAOYSA-N Tetraethylene glycol dimethyl ether Chemical compound COCCOCCOCCOCCOC ZUHZGEOKBKGPSW-UHFFFAOYSA-N 0.000 description 1
- 235000002423 Theobroma angustifolium Nutrition 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 235000002425 Theobroma bicolor Nutrition 0.000 description 1
- 235000002424 Theobroma grandiflorum Nutrition 0.000 description 1
- 235000002323 Theobroma simiarum Nutrition 0.000 description 1
- WKDDRNSBRWANNC-ATRFCDNQSA-N Thienamycin Chemical compound C1C(SCCN)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 WKDDRNSBRWANNC-ATRFCDNQSA-N 0.000 description 1
- 229940033663 Thimerosal Drugs 0.000 description 1
- ODJQKYXPKWQWNK-UHFFFAOYSA-N Thiodipropionic acid Chemical compound OC(=O)CCSCCC(O)=O ODJQKYXPKWQWNK-UHFFFAOYSA-N 0.000 description 1
- 239000003490 Thiodipropionic acid Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- FPZLLRFZJZRHSY-HJYUBDRYSA-N Tigecycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- YFNKIDBQEZZDLK-UHFFFAOYSA-N Triethylene glycol dimethyl ether Chemical compound COCCOCCOCCOC YFNKIDBQEZZDLK-UHFFFAOYSA-N 0.000 description 1
- 229960001082 Trimethoprim Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N Trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical class [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N Trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N VANCOMYCIN Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229950007158 Vaborbactam Drugs 0.000 description 1
- 229960003165 Vancomycin Drugs 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241001331543 Veillonella sp. Species 0.000 description 1
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 1
- 241000607265 Vibrio vulnificus Species 0.000 description 1
- 229940046009 Vitamin E Drugs 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 Xylitol Drugs 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 241000209149 Zea Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical class CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000006241 alcohol protecting group Chemical group 0.000 description 1
- 230000001476 alcoholic Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- YVKMMZAFUFUAAX-UHFFFAOYSA-N aluminum;tetrahydrate Chemical compound O.O.O.O.[Al] YVKMMZAFUFUAAX-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated Effects 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
- 230000001396 anti-anti-diuretic Effects 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 230000000843 anti-fungal Effects 0.000 description 1
- 230000002924 anti-infective Effects 0.000 description 1
- 230000000845 anti-microbial Effects 0.000 description 1
- 230000000244 anti-pseudomonad Effects 0.000 description 1
- 230000003078 antioxidant Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000005018 aryl alkenyl group Chemical group 0.000 description 1
- 125000005015 aryl alkynyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 150000001542 azirines Chemical class 0.000 description 1
- 230000003385 bacteriostatic Effects 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- MRMBZHPJVKCOMA-YJFSRANCSA-N biapenem Chemical compound C1N2C=NC=[N+]2CC1SC([C@@H]1C)=C(C([O-])=O)N2[C@H]1[C@@H]([C@H](O)C)C2=O MRMBZHPJVKCOMA-YJFSRANCSA-N 0.000 description 1
- 229960003169 biapenem Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 238000011087 biopharmaceutical technology Methods 0.000 description 1
- 101700008150 blaP Proteins 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- 229960002580 cefprozil Drugs 0.000 description 1
- 229960004086 ceftibuten Drugs 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- XDJYMJULXQKGMM-RVYUQJQSSA-N colistin A Chemical compound CC[C@@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O XDJYMJULXQKGMM-RVYUQJQSSA-N 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 description 1
- 125000005357 cycloalkylalkynyl group Chemical group 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229960002488 dalbavancin Drugs 0.000 description 1
- KGPGQDLTDHGEGT-SZUNQUCBSA-N dalbavancin Chemical compound C=1C([C@@H]2C(=O)N[C@H](C(N[C@@H](C3=CC(O)=C4)C(=O)NCCCN(C)C)=O)[C@H](O)C5=CC=C(C(=C5)Cl)OC=5C=C6C=C(C=5O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@H](O5)C(O)=O)NC(=O)CCCCCCCCC(C)C)OC5=CC=C(C=C5)C[C@@H]5C(=O)N[C@H](C(N[C@H]6C(=O)N2)=O)C=2C(Cl)=C(O)C=C(C=2)OC=2C(O)=CC=C(C=2)[C@H](C(N5)=O)NC)=CC=C(O)C=1C3=C4O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O KGPGQDLTDHGEGT-SZUNQUCBSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000008380 degradant Substances 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035510 distribution Effects 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 150000004659 dithiocarbamates Chemical class 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical group CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- JBIWCJUYHHGXTC-AKNGSSGZSA-N doxycycline Chemical compound O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O JBIWCJUYHHGXTC-AKNGSSGZSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 230000000534 elicitor Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 230000001586 eradicative Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960000379 faropenem Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960005394 flucloxacillin Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000001408 fungistatic Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000000174 gluconic acid Chemical group 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000004220 glutamic acid Chemical group 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000002373 hemiacetals Chemical class 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 239000007946 hypodermic tablet Substances 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000002427 irreversible Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminium hydride Substances [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 1
- OCZDCIYGECBNKL-UHFFFAOYSA-N lithium;alumanuide Chemical compound [Li+].[AlH4-] OCZDCIYGECBNKL-UHFFFAOYSA-N 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- KJRFTNVYOAGTHK-UHFFFAOYSA-N methyl 3-hydroxy-2,2-dimethylpropanoate Chemical compound COC(=O)C(C)(C)CO KJRFTNVYOAGTHK-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000198 mezlocillin Drugs 0.000 description 1
- GTGQRSIMEUWHPA-ZBJAFUORSA-M mezlocillin sodium Chemical compound [Na+].N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O GTGQRSIMEUWHPA-ZBJAFUORSA-M 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 230000000116 mitigating Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 125000005483 neopentyl alcohol group Chemical group 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 229910001317 nickel manganese cobalt oxide (NMC) Inorganic materials 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 1
- CTNZOGJNVIFEBA-UPSUJEDGSA-N nocardicin A Chemical compound C1=CC(OCC[C@@H](N)C(O)=O)=CC=C1C(=N\O)\C(=O)N[C@@H]1C(=O)N([C@@H](C(O)=O)C=2C=CC(O)=CC=2)C1 CTNZOGJNVIFEBA-UPSUJEDGSA-N 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960001607 oritavancin Drugs 0.000 description 1
- VHFGEBVPHAGQPI-LXKZPTCJSA-N oritavancin Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(NCC=4C=CC(=CC=4)C=4C=CC(Cl)=CC=4)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 VHFGEBVPHAGQPI-LXKZPTCJSA-N 0.000 description 1
- 108010006945 oritavancin Proteins 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 108010071437 oxacillinase Proteins 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000003071 parasitic Effects 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- 238000010951 particle size reduction Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 150000002961 penems Chemical class 0.000 description 1
- 229940056362 penicillin G procaine Drugs 0.000 description 1
- 235000019370 penicillin G procaine Nutrition 0.000 description 1
- PMJHHCWVYXUKFD-UHFFFAOYSA-N penta-1,3-diene Chemical compound CC=CC=C PMJHHCWVYXUKFD-UHFFFAOYSA-N 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 235000006678 peppermint Nutrition 0.000 description 1
- 235000015132 peppermint Nutrition 0.000 description 1
- 235000007735 peppermint Nutrition 0.000 description 1
- 229940021222 peritoneal dialysis Isotonic solutions Drugs 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960004331 phenoxymethylpenicillin Drugs 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003449 preventive Effects 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- ZTHYODDOHIVTJV-UHFFFAOYSA-N propyl 3,4,5-trihydroxybenzoate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 229960005442 quinupristin Drugs 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229960002599 rifapentine Drugs 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003335 secondary amines Chemical group 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 235000019613 sensory perceptions of taste Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000001509 sodium citrate Chemical class 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- DCQXTYAFFMSNNH-UHFFFAOYSA-M sodium;2-[bis(2-hydroxyethyl)amino]ethanol;acetate Chemical compound [Na+].CC([O-])=O.OCCN(CCO)CCO DCQXTYAFFMSNNH-UHFFFAOYSA-M 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 230000003381 solubilizing Effects 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 229960004954 sparfloxacin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 229960005158 sulfamethizole Drugs 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N sulfonic acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000035917 taste Effects 0.000 description 1
- 230000035923 taste sensation Effects 0.000 description 1
- 229960003879 tedizolid Drugs 0.000 description 1
- 108010089019 telavancin Proteins 0.000 description 1
- 229960001114 temocillin Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical group 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003553 thiiranes Chemical class 0.000 description 1
- 235000019303 thiodipropionic acid Nutrition 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- 229950010206 tigemonam Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 229940029612 triethanolamine Drugs 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 239000011778 trisodium citrate Chemical class 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960000497 trovafloxacin Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000008136 water-miscible vehicle Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/08—Mydriatics or cycloplegics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Abstract
The present application is directed to processes and intermediates for making 4-({2-[(aminosulfonyl)amino]ethyl}amino)-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide, which is an inhibitor of indoleamine 2,3-dioxygenase, useful in the treatment of cancer and other disorders. .
Description
BETA-LACTAMASE INHIBITORS AND USES THEREOF
FIELD
The present disclosure relates to β-lactamase inhibitors and pharmaceutical compositions
thereof and the use of the β-lactamase inhibitors to treat bacterial infections.
BACKGROUND
Overuse, incorrect use, and agricultural use of antibiotics has led to the emergence of resistant
bacteria that are refractory to eradication by conventional anti-infective agents, such as those based on
β-lactams or fluoroquinolone architectures. Alarmingly, many of these resistant bacteria are
responsible for common infections including, for example, pneumonia, sepsis, etc.
Development of resistance to commonly used β-lactam anti-infectives is related to expression
of β-lactamases by the targeted bacteria. β-Lactamases typically hydrolyze the β-lactam ring, thus
rendering the antibiotic ineffective against bacteria. Accordingly, inhibition of β-lactamases by a
suitable substrate can prevent degradation of the β-lactam antibiotic, thereby increasing the
effectiveness of the administered antibiotic and mitigating the emergence of resistance.
Avibactam is a known β-lactamase inhibitor that is currently marketed in combination with
ceftazidime to treat gram negative bacterial infections. Avibactam must be administered
intravenously, which limits use to expensive clinical settings.
SUMMARY
According to the present invention, compounds have the structure of Formula (1):
or a pharmaceutically acceptable salt thereof, wherein,
each R is independently selected from C alkyl, or each R and the geminal carbon atom to
which they are bonded forms a C cycloalkyl ring, a C heterocycloalkyl ring, a substituted C
3-6 3-6 3-6
cycloalkyl ring, or a substituted C heterocycloalkyl ring;
R is selected from a single bond, C alkanediyl, C heteroalkanediyl, C cycloalkanediyl,
1-6 1-6 5-6
C heterocycloalkanediyl, C arenediyl, C heteroarenediyl, substituted C alkanediyl, substituted
-6 6 5-6 1-6
C heteroalkanediyl, substituted C cycloalkanediyl, substituted C heterocycloalkanediyl,
1-6 5-6 5-6
substituted C arenediyl, and substituted C heteroarenediyl;
6 5-6
3 4 4 4 4
R is selected from C alkyl, –O–C(O)–R , –S–C(O)–R , –NH–C(O)–R , –O–C(O)–O–R , –
4 4 4 4 4 4
S–C(O)–O–R , –NH–C(O)–O–R , –C(O)–O–R , –C(O)–S–R , –C(O)–NH–R , –O–C(O)–O–R , –O–
4 4 4 4 4 4
C(O)–S–R , –O–C(O)–NH–R , –S–S–R , –S–R , –NH–R , –CH(–NH )(–R ), C heterocycloalkyl,
2 5-6
C heteroaryl, substituted C cycloalkyl, substituted C heterocycloalkyl, substituted C aryl,
-6 5-6 5-6 5-6
substituted C heteroaryl, and –CH=C(R ) ; wherein,
-6 2
R is selected from hydrogen, C alkyl, C heteroalkyl, C cycloalkyl, C
1-8 1-8 5-8 5-8
heterocycloalkyl, C cycloalkylalkyl, C heterocycloalkylalkyl, C aryl, C heteroaryl,
-10 5-10 6-8 5-8
C arylalkyl, C heteroarylalkyl, substituted C alkyl, substituted C heteroalkyl,
7-10 5-10 1-8 1-8
substituted C cycloalkyl, substituted C heterocycloalkyl, substituted C cycloalkylalkyl,
-8 5-8 5-10
substituted C heterocycloalkylalkyl, substituted C aryl, substituted C heteroaryl,
-10 6-8 5-8
substituted C arylalkyl, and substituted C heteroarylalkyl;
7-10 5-10
R is selected from hydrogen, C alkyl, C cycloalkyl, C cycloalkylalkyl, C
1-6 5-8 6-12 2-6
heteroalkyl, C heterocycloalkyl, C heterocycloalkylalkyl, substituted C alkyl, substituted C
-8 6-12 1-6 5-8
cycloalkyl, substituted C cycloalkylalkyl, substituted C heteroalkyl, substituted C
6-12 2-6 5-8
heterocycloalkyl, and substituted C heterocycloalkylalkyl;
6-12
R is selected from hydrogen, C alkyl, C cycloalkyl, C cycloalkylalkyl, C
1-6 5-8 6-12 2-6
heteroalkyl, C heterocycloalkyl, C heterocycloalkylalkyl, substituted C alkyl, substituted C
-8 6-12 1-6 5-8
cycloalkyl, substituted C cycloalkylalkyl, substituted C heteroalkyl, substituted C
6-12 2-6 5-8
heterocycloalkyl, and substituted C heterocycloalkylalkyl; and
6-12
A is a single bond (–) and R is hydrogen, or A is a double bond (=) and R is C alkyl.
According to the present invention, pharmaceutical compositions comprise the compound
according to the present invention and a pharmaceutically acceptable vehicle.
According to the present invention, methods of treating a bacterial infection in a patient
comprise administering to a patient in need of such treatment a therapeutically effective amount of the
compound according to the present invention.
According to the present invention, methods of treating a bacterial infection in a patient
comprise administering to a patient in need of such treatment a therapeutically effective amount of the
pharmaceutical composition according to the present invention.
According to the present invention, methods of inhibiting a β-lactamase in a patient comprise
administering to the patient an effective amount of the compound according to the present invention.
According to the present invention, methods of inhibiting a β-lactamase in a patient comprise
administering to the patient an effective amount of the pharmaceutical composition according to the
present invention.
Reference is now made to certain compounds and methods. The disclosed embodiments are
not intended to be limiting of the claims. To the contrary, the claims are intended to cover all
alternatives, modifications, and equivalents.
DETAILED DESCRIPTION
A dash (“–”) that is not between two letters or symbols is used to indicate a point of
attachment for a moiety or substituent. For example, –CONH is attached through the carbon atom.
“Alkyl” refers to a saturated or unsaturated, branched, or straight-chain, monovalent
hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a
parent alkane, alkene, or alkyne. Examples of alkyl groups include methyl; ethyls such as ethanyl,
ethenyl, and ethynyl; propyls such as propanyl, propanyl, propenyl, propenyl,
propenyl (allyl), propynyl, propynyl, etc.; butyls such as butanyl, butanyl,
2-methyl-propanyl, 2-methyl-propanyl, butenyl, butenyl, 2-methyl-propenyl,
butenyl, butenyl, buta-1,3-dienyl, buta-1,3-dienyl, butynyl, butynyl,
butynyl, etc.; and the like. The term “alkyl” is specifically intended to include groups having
any degree or level of saturation, i.e., groups having exclusively carbon-carbon single bonds, groups
having one or more carbon-carbon double bonds, groups having one or more carbon-carbon triple
bonds, and groups having combinations of carbon-carbon single, double, and triple bonds. Where a
specific level of saturation is intended, the terms alkanyl, alkenyl, and alkynyl are used. An alkyl
group can be C alkyl, C alkyl, C alkyl, C alkyl, ethyl or methyl.
1-6 1-5 1-4 1-3
“Alkoxy” refers to a radical –OR where R is alkyl as defined herein. Examples of alkoxy
groups include methoxy, ethoxy, propoxy, and butoxy. An alkoxy group can be C alkoxy, C
1-6 1-5
alkoxy, C alkoxy, C alkoxy, ethoxy, or methoxy.
1-4 1-3
“Aryl” by itself or as part of another substituent refers to a monovalent aromatic hydrocarbon
radical derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic
ring system. Aryl encompasses 5- and 6-membered carbocyclic aromatic rings, for example, benzene;
bicyclic ring systems wherein at least one ring is carbocyclic and aromatic, for example, naphthalene,
indane, and tetralin; and tricyclic ring systems wherein at least one ring is carbocyclic and aromatic,
for example, fluorene. Aryl encompasses multiple ring systems having at least one carbocyclic
aromatic ring fused to at least one carbocyclic aromatic ring, cycloalkyl ring, or heterocycloalkyl ring.
For example, aryl includes a phenyl ring fused to a 5- to 7-membered heterocycloalkyl ring containing
one or more heteroatoms selected from N, O, and S. For such fused, bicyclic ring systems wherein
only one of the rings is a carbocyclic aromatic ring, the radical carbon atom may be at the carbocyclic
aromatic ring or at the heterocycloalkyl ring. Examples of aryl groups include groups derived from
aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene,
fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene,
naphthalene, octacene, octaphene, octalene, ovalene, pentacene, pentalene, pentaphene, perylene,
phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene,
trinaphthalene, and the like. An aryl group can be C aryl, C aryl, C aryl, or phenyl. Aryl,
6-10 6-9 6-8
however, does not encompass or overlap in any way with heteroaryl, separately defined herein.
“Arylalkyl” refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a
carbon atom is replaced with an aryl group. Examples of arylalkyl groups include benzyl,
2-phenylethanyl, 2-phenylethenyl, naphthylmethyl, 2-naphthylethanyl, 2-naphthylethenyl,
naphthobenzyl, and 2-naphthophenylethanyl. Where specific alkyl moieties are intended, the
nomenclature arylalkanyl, arylalkenyl, or arylalkynyl is used. An arylalkyl group can be C
7-16
arylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is C and the aryl moiety
is C An arylalkyl group can be C arylalkyl, such as the alkanyl, alkenyl or alkynyl moiety of
6-10. 7-16
the arylalkyl group is C and the aryl moiety is C . An arylalkyl group can be C arylalkyl,
1-6 6-10 7-9
wherein the alkyl moiety is C alkyl and the aryl moiety is phenyl. An arylalkyl group can be C
1-3 7-16
arylalkyl, C arylalkyl, C arylalkyl, C arylalkyl, C arylalkyl, or benzyl.
7-14 7-12 7-10 7-8
“Bioavailability” refers to the rate and amount of a drug that reaches the systemic circulation
of a patient following administration of the drug or prodrug thereof to the patient and can be
determined by evaluating, for example, the plasma or blood concentration-versus-time profile for a
drug. Parameters useful in characterizing a plasma or blood concentration-versus-time curve include
the area under the curve (AUC), the time to maximum concentration (T ), and the maximum drug
concentration (C ), where C is the maximum concentration of a drug in the plasma or blood of a
max max
patient following administration of a dose of the drug or form of drug to the patient, and T is the
time to the maximum concentration (C ) of a drug in the plasma or blood of a patient following
administration of a dose of the drug or form of drug to the patient.
“Oral bioavailability” (F%) refers to the fraction of an oral administered drug that reaches
systemic circulation. Oral bioavailability is a product of the fraction absorbed, the fraction escaping
gut-wall elimination, and the fraction escaping hepatic elimination; and the factors that influence
bioavailability can be divided into physiological, physicochemical, and biopharmaceutical factors.
“Compounds” and moieties disclosed herein include any specific compounds within these
formulae. Compounds may be identified either by their chemical structure and/or chemical name.
Compounds are named using the ChemBioDraw Ultra Version 14.0.0.117 (CambridgeSoft,
Cambridge, MA) nomenclature/structure program. When the chemical structure and chemical name
conflict, the chemical structure is determinative of the identity of the compound. The compounds
described herein may comprise one or more stereogenic centers and/or double bonds and therefore
may exist as stereoisomers such as double-bond isomers (i.e., geometric isomers), enantiomers,
diastereomers, or atropisomers. Accordingly, any chemical structures within the scope of the
specification depicted, in whole or in part, with a relative configuration encompass all possible
enantiomers and stereoisomers of the illustrated compounds including the stereoisomerically pure
form (e.g., geometrically pure, enantiomerically pure, or diastereomerically pure) and enantiomeric
and stereoisomeric mixtures. Enantiomeric and stereoisomeric mixtures may be resolved into their
component enantiomers or stereoisomers using separation techniques or chiral synthesis techniques
well known to the skilled artisan.
Compounds and moieties disclosed herein include optical isomers of compounds and
moieties, racemates thereof, and other mixtures thereof. In such embodiments, the single enantiomers
or diastereomers may be obtained by asymmetric synthesis or by resolution of the racemates.
Resolution of the racemates may be accomplished, for example, by conventional methods such as
crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral
high-pressure liquid chromatography (HPLC) column with chiral stationary phases. In addition,
compounds include (Z)- and (E)-forms (or cis- and trans-forms) of compounds with double bonds
either as single geometric isomers or mixtures thereof.
Compounds and moieties may also exist in several tautomeric forms including the enol form,
the keto form, and mixtures thereof. Accordingly, the chemical structures depicted herein encompass
all possible tautomeric forms of the illustrated compounds. Compounds may exist in unsolvated
forms as well as solvated forms, including hydrated forms. Certain compounds may exist in multiple
crystalline, co-crystalline, or amorphous forms. Compounds include pharmaceutically acceptable
salts thereof, or pharmaceutically acceptable solvates of the free acid form of any of the foregoing, as
well as crystalline forms of any of the foregoing
“Cycloalkyl” refers to a saturated or partially unsaturated cyclic alkyl radical. A cycloalkyl
group can beC cycloalkyl, C cycloalkyl, C cycloalkyl, cyclopropyl, cyclopentyl, or cyclohexyl.
3-6 3-5 5-6
A cycloalkyl can be selected from cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
“Cycloalkylalkyl” refers to an acyclic alkyl radical in which one of the hydrogen atoms
bonded to a carbon atom is replaced with a cycloalkyl group as defined herein. Where specific alkyl
moieties are intended, the nomenclature cycloalkylalkyl, cycloalkylalkenyl, or cycloalkylalkynyl is
used. A cycloalkylalkyl group can be C cycloalkylalkyl, for example, the alkanyl, alkenyl, or
4-30
alkynyl moiety of the cycloalkylalkyl group is C and the cycloalkyl moiety of the cycloalkylalkyl
1-10
moiety is C . A cycloalkylalkyl group can be C cycloalkylalkylfor example, the alkanyl, alkenyl,
3-20 4-20
or alkynyl moiety of the cycloalkylalkyl group is C and the cycloalkyl moiety of the cycloalkylalkyl
group is C . A cycloalkylalkyl can be C cycloalkylalkyl, wherein the alkyl moiety of the
3-12 4-9
cycloalkylalkyl group is C alkyl, and the cycloalkyl moiety of the cycloalkylalkyl group is C
1-3 3-6
cycloalkyl. A cycloalkylalkyl group can be C cycloalkylalkyl, C cycloalkylalkyl, C
4-12 4-10 4-8
cycloalkylalkyl, and C cycloalkylalkyl. A cycloalkylalkyl group can be cyclopropylmethyl (–CH –
4-6 2
cyclo-C H ), cyclopentylmethyl (–CH –cyclo-C H ), or cyclohexylmethyl (–CH –cyclo-C H ). A
3 5 2 5 9 2 6 11
cycloalkylalkyl group can be cyclopropylethenyl (–CH=CH–cyclo-C H ), or cyclopentylethynyl (–
C ≡C–cyclo-C H ).
“Cycloalkylheteroalkyl” by itself or as part of another substituent refers to a heteroalkyl group
in which one or more of the carbon atoms (and certain associated hydrogen atoms) of an alkyl group
are independently replaced with the same or different heteroatomic group or groups and in which one
of the hydrogen atoms bonded to a carbon atom is replaced with a cycloalkyl group. Where specific
alkyl moieties are intended, the nomenclature cycloalkylheteroalkanyl, cycloalkylheteroalkenyl, and
cycloalkylheteroalkynyl is used. In a cycloalkylheteroalkyl, the heteroatomic group can be selected
from –O–, –S–, –NH–, –N(–CH )–, –SO–, and –SO –, or the heteroatomic group can be selected from
–O–and –NH–, or the heteroatomic group is –O– or –NH–.
“Cycloalkyloxy” refers to a radical –OR where R is cycloalkyl as defined herein. Examples
of cycloalkyloxy groups include cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, and cyclohexyloxy.
A cycloalkyloxy group can be C cycloalkyloxy, C cycloalkyloxy, C cycloalkyloxy,
3-6 3-5 5-6
cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, or cyclohexyloxy.
“Disease” refers to a disease, disorder, condition, or symptom of any of the foregoing.
“Fluoroalkyl” refers to an alkyl group as defined herein in which one or more of the hydrogen
atoms is replaced with a fluoro. A fluoroalkyl group can be C fluoroalkyl, C fluoroalkyl, C
1-6 1-5 1-4
fluoroalkyl, or C fluoroalkyl. A fluoroalkyl group can be pentafluoroethyl (–CF CF ), or
1-3 2 3
trifluoromethyl (–CF ).
“Fluoroalkoxy” refers to an alkoxy group as defined herein in which one or more of the
hydrogen atoms is replaced with a fluoro. A fluoroalkoxy group can be C fluoroalkoxy, C
1-6 1-5
fluoroalkoxy, C fluoroalkoxy C , fluoroalkoxy, –OCF CF or –OCF .
1-4 1-3 2 3 3
“Halogen” refers to a fluoro, chloro, bromo, or iodo group.
“Heteroalkoxy” refers to an alkoxy group in which one or more of the carbon atoms are
replaced with a heteroatom. A heteroalkoxy group can be C heteroalkoxy, C heteroalkoxy, C
1-6 1-5 1-4
heteroalkoxy, or C heteroalkoxy. In a heteroalkoxy, the heteroatomic group can be selected from –
O–, –S–, –NH–, –NR–, –SO –, and –SO –, or the heteroatomic group can be selected from –O– and –
NH–, or the heteroatomic group is –O– and –NH–. A heteroalkoxy group can be C heteroalkoxy,
C heteroalkoxy, C heteroalkoxy, or C heteroalkoxy.
1-5 1-4 1-3
“Heteroalkyl” by itself or as part of another substituent refer to an alkyl group in which one or
more of the carbon atoms (and certain associated hydrogen atoms) are independently replaced with
the same or different heteroatomic group or groups. Examples of heteroatomic groups include –O–, –
S–, –NH–, –NR–, –O–O–, –S–S–, =N–N=, –N=N–, –N=N–NR–, –PR–, –P(O)OR–, –P(O)R–, –POR–
, –SO–, –SO –, –Sn(R) –, and the like, where each R is independently selected from hydrogen, C
2 2 1-6
alkyl, substituted C alkyl, C aryl, substituted C aryl, C arylalkyl substituted C arylalkyl,
1-6 6-12 6-12 7-18 , 7-18
C cycloalkyl, substituted C cycloalkyl C heterocycloalkyl, substituted C heterocycloalkyl, C
3-7 3-7 , 3-7 3-7 1-
heteroalkyl, substituted C heteroalkyl, C heteroaryl, substituted C heteroaryl, C
6 1-6 6-12 6-12 7-18
heteroarylalkyl, and substituted C heteroarylalkyl. Each R can be independently selected from
7-18
hydrogen and C alkyl. Reference to, for example, a C heteroalkyl, means a C alkyl group in
1-3 1-6 1-6
which at least one of the carbon atoms (and certain associated hydrogen atoms) is replaced with a
heteroatom. For example, C heteroalkyl includes groups having five carbon atoms and one
heteroatom, groups having four carbon atoms and two heteroatoms, etc. In a heteroalkyl, the
heteroatomic group can be selected from –O–, –S–, –NH–, –N(–CH )–, –SO–, and –SO –, or the
heteroatomic group can be selected from –O– and –NH–, or the heteroatomic group can be –O– or –
NH–. A heteroalkyl group can be C heteroalkyl, C heteroalkyl, or C heteroalkyl, or C
1-6 1-5 1-4 1-3
heteroalkyl.
“Heteroaryl” by itself or as part of another substituent refers to a monovalent heteroaromatic
radical derived by the removal of one hydrogen atom from a single atom of a parent heteroaromatic
ring system. Heteroaryl encompasses multiple ring systems having at least one heteroaromatic ring
fused to at least one other ring, which may be aromatic or non-aromatic. For example, heteroaryl
encompasses bicyclic rings in which one ring is heteroaromatic and the second ring is a
heterocycloalkyl ring. For such fused, bicyclic heteroaryl ring systems wherein only one of the rings
contains one or more heteroatoms, the radical carbon may be at the aromatic ring or at the
heterocycloalkyl ring. When the total number of N, S, and O atoms in the heteroaryl group exceeds
one, the heteroatoms may or may not be adjacent to one another. The total number of heteroatoms in
the heteroaryl group is not more than two. In a heteroaryl, the heteroatomic group can be selected
from –O–, –S–, –NH–, –N(–CH )–, –S(O)–, and –SO –, or the heteroatomic group can be selected
from –O– and –NH–, or the heteroatomic group can be –O– or –NH–. A heteroaryl group can be
selected from C heteroaryl, C heteroaryl, C heteroaryl, C heteroaryl, C heteroaryl, C
-10 5-9 5-8 5-7 5-6 5
heteroaryl or C heteroaryl.
Examples of suitable heteroaryl groups include groups derived from acridine, arsindole,
carbazole, α-carboline, chromane, chromene, cinnoline, furan, imidazole, indazole, indole, indoline,
indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole,
naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine,
phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole,
pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole,
thiophene, triazole, xanthene, thiazolidine, oxazolidine, and the like. A heteroaryl group can be
derived from thiophene, pyrrole, benzothiophene, benzofuran, indole, pyridine, quinoline, imidazole,
oxazole, or pyrazine. For example, a heteroaryl can be C heteroaryl and can be selected from furyl,
thienyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, or isoxazolyl. A heteroaryl can be C heteroaryl,
and can be selected from pyridinyl, pyrazinyl, pyrimidinyl, and pyridazinyl.
“Heteroarylalkyl” refers to an arylalkyl group in which one of the carbon atoms (and certain
associated hydrogen atoms) is replaced with a heteroatom. A heteroarylalkyl group can be C
6-16
heteroarylalkyl, C heteroarylalkyl, C heteroarylalkyl, C heteroarylalkyl, C heteroarylalkyl,
6-14 6-12 6-10 6-8
or C heteroarylalkyl, or C heteroarylalkyl. In a heteroarylalkyl, the heteroatomic group can be
selected from –O–, –S–, –NH–, –N(–CH )–, –SO–, and –SO –, or the heteroatomic group can be
selected from –O–and –NH–, or the heteroatomic group can be –O– or –NH–.
“Heterocycloalkyl” by itself or as part of another substituent refers to a saturated or
unsaturated cyclic alkyl radical in which one or more carbon atoms (and certain associated hydrogen
atoms) are independently replaced with the same or different heteroatom; or to a parent aromatic ring
system in which one or more carbon atoms (and certain associated hydrogen atoms) are independently
replaced with the same or different heteroatom such that the ring system violates the Hückel-rule.
Examples of heteroatoms to replace the carbon atom(s) include N, P, O, S, and Si. Examples of
heterocycloalkyl groups include groups derived from epoxides, azirines, thiiranes, imidazolidine,
morpholine, piperazine, piperidine, pyrazolidine, pyrrolidine, and quinuclidine. A heterocycloalkyl
can be C heterocycloalkyl and is selected from pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl,
imidazolidinyl, oxazolidinyl, thiazolidinyl, doxolanyl, and dithiolanyl. A heterocycloalkyl can be C
heterocycloalkyl and can be selected from piperidinyl, tetrahydropyranyl, piperizinyl, oxazinyl,
dithianyl, and dioxanyl. A heterocycloalkyl group can be C heterocycloalkyl, C heterocycloalkyl,
3-6 3-5
C heterocycloalkyl, C heterocycloalkyl or C heterocycloalkyl. In a heterocycloalkyl, the
-6 5 6
heteroatomic group can be selected from –O–, –S–, –NH–, –N(–CH )–, –SO–, and –SO –, or the
heteroatomic group can be selected from –O– and –NH–, or the heteroatomic group can be –O– or –
NH–.
“Heterocycloalkylalkyl” refers to a cycloalkylalkyl group in which one or more carbon atoms
(and certain associated hydrogen atoms) of the cycloalkyl ring are independently replaced with the
same or different heteroatom. A heterocycloalkylalkyl can be C heterocycloalkylalkyl, C
4-12 4-10
heterocycloalkylalkyl, C heterocycloalkylalkyl, C heterocycloalkylalkyl, C
4-8 4-6 6-7
heterocycloalkylalkyl, or C heterocycloalkylalkyl or C heterocycloalkylalkyl. In a
heterocycloalkylalkyl, the heteroatomic group can be selected from –O–, –S–, –NH–, –N(–CH )–, –
SO–, and –SO –, or the heteroatomic group can be selected from –O– and –NH–, or the heteroatomic
group can be –O– or –NH–.
“Parent aromatic ring system” refers to an unsaturated cyclic or polycyclic ring system having
a cyclic conjugated (pi) electron system with 4n+2 electrons (Hückel rule). Included within the
definition of “parent aromatic ring system” are fused ring systems in which one or more of the rings
are aromatic and one or more of the rings are saturated or unsaturated, such as, for example, fluorene,
indane, indene, phenalene, etc. Examples of parent aromatic ring systems include aceanthrylene,
acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene,
fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene,
octacene, octaphene, octalene, ovalene, pentacene, pentalene, pentaphene, perylene, phenalene,
phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene, and the
like.
“Hydrates” refers to incorporation of water into to the crystal lattice of a compound described
herein, in stoichiometric proportions, resulting in the formation of an adduct. Methods of making
hydrates include, but are not limited to, storage in an atmosphere containing water vapor, dosage
forms that include water, or routine pharmaceutical processing steps such as, for example,
crystallization (i.e., from water or mixed aqueous solvents), lyophilization, wet granulation, aqueous
film coating, or spray drying. Hydrates may also be formed, under certain circumstances, from
crystalline solvates upon exposure to water vapor, or upon suspension of the anhydrous material in
water. Hydrates may also crystallize in more than one form resulting in hydrate polymorphism.
“Metabolic intermediate” refers to a compound that is formed in vivo by metabolism of a
parent compound and that further undergoes reaction in vivo to release an active agent. Compounds
of Formula (1) are protected sulfonate nucleophile prodrugs of non- β-lactam β-lactamase inhibitors
that are metabolized in vivo to provide the corresponding metabolic intermediates such as avibactam
([2S,5R]carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl hydrogen sulfate). Metabolic
intermediates undergo nucleophilic cyclization to release a non- β-lactam β-lactamase inhibitor such as
avibactam and one or more reaction products. It is desirable that the reaction products or metabolites
thereof not be toxic.
“"Neopentyl” refers to a radical in which a methylene carbon is bonded to a carbon atom,
which is bonded to three non-hydrogen substituents. Examples of non-hydrogen substituents include
carbon, oxygen, nitrogen, and sulfur. Each of the three non-hydrogen substituents can be carbon.
Two of the three non-hydrogen substituents can be carbon, and the third non-hydrogen substituent can
be selected from oxygen and nitrogen. A neopentyl group can have the structure:
where each R is defined as for Formula (1).
“Parent Aromatic Ring System” refers to an unsaturated cyclic or polycyclic ring system
having a conjugated electron system. Specifically included within the definition of “parent aromatic
ring system” are fused ring systems in which one or more of the rings are aromatic and one or more of
the rings are saturated or unsaturated, such as, for example, fluorene, indane, indene, phenalene, etc.
Examples of parent aromatic ring systems include aceanthrylene, acenaphthylene, acephenanthrylene,
anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene,
hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene,
ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene,
picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, and trinaphthalene.
“Parent heteroaromatic ring system” refers to an aromatic ring system in which one or more
carbon atoms (and any associated hydrogen atoms) are independently replaced with the same or
different heteroatom in such a way as to maintain the continuous -electron system characteristic of
aromatic systems and a number of -electrons corresponding to the Hückel rule (4n +2). Examples of
heteroatoms to replace the carbon atoms include N, P, O, S, and Si, etc. Specifically included within
the definition of “parent heteroaromatic ring systems” are fused ring systems in which one or more of
the rings are aromatic and one or more of the rings are saturated or unsaturated, such as, for example,
arsindole, benzodioxan, benzofuran, chromane, chromene, indole, indoline, and xanthene. Examples
of parent heteroaromatic ring systems include arsindole, carbazole, -carboline, chromane, chromene,
cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene,
isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole,
perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran,
pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline,
quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, thiazolidine,
and oxazolidine.
“Patient” refers to a mammal, for example, a human. The term “patient” is used
interchangeably with “subject.”
“Pharmaceutically acceptable” refers to approved or approvable by a regulatory agency of the
Federal or a state government or listed in the U.S. Pharmacopoeia or other generally recognized
pharmacopoeia for use in animals, and more particularly in humans.
“Pharmaceutically acceptable salt” refers to a salt of a compound, which possesses the desired
pharmacological activity of the parent compound. Such salts include acid addition salts, formed with
inorganic acids and one or more protonable functional groups such as primary, secondary, or tertiary
amines within the parent compound. Examples of inorganic acids include hydrochloric acid,
hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. A salt can be formed with
organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic
acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid,
tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic
acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic
acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid,
4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-octenecarboxylic acid,
glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl
sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid,
muconic acid, and the like. A salt can be formed when one or more acidic protons present in the
parent compound are replaced by a metal ion, such as an alkali metal ion, an alkaline earth ion, or an
aluminum ion, or combinations thereof; or coordinates with an organic base such as ethanolamine,
diethanolamine, triethanolamine, and N-methylglucamine. A pharmaceutically acceptable salt can be
the hydrochloride salt. A pharmaceutically acceptable salt can be the sodium salt. In compounds
having two or more ionizable groups, a pharmaceutically acceptable salt can comprise one or more
counterions, such as a bi-salt, for example, a dihydrochloride salt.
The term “pharmaceutically acceptable salt” includes hydrates and other solvates, as well as
salts in crystalline or non-crystalline form. Where a particular pharmaceutically acceptable salt is
disclosed, it is understood that the particular salt such as a hydrochloride salt, is an example of a salt,
and that other salts may be formed using techniques known to one of skill in the art. Additionally,
one of skill in the art would be able to convert the pharmaceutically acceptable salt to the
corresponding compound, free base and/or free acid, using techniques generally known in the art.
“Pharmaceutically acceptable vehicle” refers to a pharmaceutically acceptable diluent, a
pharmaceutically acceptable adjuvant, a pharmaceutically acceptable excipient, a pharmaceutically
acceptable carrier, or a combination of any of the foregoing with which a compound provided by the
present disclosure may be administered to a patient and which does not destroy the pharmacological
activity thereof and which is non-toxic when administered in doses sufficient to provide a
therapeutically effective amount of the compound.
“Pharmaceutical composition” refers to a compound of Formula (1) or a pharmaceutically
acceptable salt thereof and at least one pharmaceutically acceptable vehicle, with which the compound
of Formula (1) or a pharmaceutically acceptable salt thereof is administered to a patient.
Pharmaceutically acceptable vehicles are known in the art.
“Preventing” or “prevention” refers to a reduction in risk of acquiring a disease or disorder
(i.e., causing at least one of the clinical symptoms of the disease not to develop in a patient that may
be exposed to or predisposed to the disease but does not yet experience or display symptoms of the
disease). In some embodiments, “preventing” or “prevention” refers to reducing symptoms of the
disease by taking the compound in a preventative fashion. The application of a therapeutic for
preventing or prevention of a disease of disorder is known as prophylaxis. Compounds provided by
the present disclosure can provide superior prophylaxis because of lower long-term side effects over
long time periods.
“Prodrug” refers to a derivative of a drug molecule that requires a transformation within the
body to release the active drug. Prodrugs are frequently, although not necessarily, pharmacologically
inactive until converted to the parent drug.
“Promoiety” refers to a group bonded to a drug, typically to a functional group of the drug,
via bond(s) that are cleavable under specified conditions of use. The bond(s) between the drug and
promoiety may be cleaved by enzymatic or non-enzymatic means. Under the conditions of use, for
example following administration to a patient, the bond(s) between the drug and promoiety may be
cleaved to release the parent drug. The cleavage of the promoiety may proceed spontaneously, such
as via a hydrolysis reaction, or it may be catalyzed or induced by another agent, such as by an
enzyme, by light, by acid, or by a change of or exposure to a physical or environmental parameter,
such as a change of temperature, pH, etc. The agent may be endogenous to the conditions of use, such
as an enzyme present in the systemic circulation of a patient to which the prodrug is administered or
the acidic conditions of the stomach or the agent may be supplied exogenously. For example, for a
compound of Formula (1), the promoiety can have the structure:
1 2 3
where R , R , and R are defined as for Formula (1).
“Single bond” as in the expression “R is selected from a single bond” refers to a moiety in
2 1 2 3 2
which R is a single bond. For example, in a moiety having the structure –C(R ) –R –R , where R is
2 1 3
a single bond, –R – corresponds to a single bond, “–", and the moiety has the structure –C(R ) –R .
Solvate” refers to a molecular complex of a compound with one or more solvent molecules in
a stoichiometric or non-stoichiometric amount. Such solvent molecules are those commonly used in
the pharmaceutical arts, which are known to be innocuous to a patient, such as water, ethanol, and the
like. A molecular complex of a compound or moiety of a compound and a solvent can be stabilized
by non-covalent intra-molecular forces such as, for example, electrostatic forces, van der Waals
forces, or hydrogen bonds. The term “hydrate” refers to a solvate in which the one or more solvent
molecules is water.
“Solvates” refers to incorporation of solvents into to the crystal lattice of a compound
described herein, in stoichiometric proportions, resulting in the formation of an adduct. Methods of
making solvates include, but are not limited to, storage in an atmosphere containing a solvent, dosage
forms that include the solvent, or routine pharmaceutical processing steps such as, for example,
crystallization (i.e., from solvent or mixed solvents) vapor diffusion. Solvates may also be formed,
under certain circumstances, from other crystalline solvates or hydrates upon exposure to the solvent
or upon suspension material in solvent. Solvates may crystallize in more than one form resulting in
solvate polymorphism.
“Substituted” refers to a group in which one or more hydrogen atoms are independently
replaced with the same or different substituent(s). Each substituent can be independently selected
from deuterio, halogen, –OH, –CN, –CF , –OCF , =O, –NO , C alkoxy, C alkyl, –COOR, –NR ,
3 3 2 1-6 1-6 2
and –CONR ; wherein each R is independently selected from hydrogen and C alkyl. Each
2 1-6
substituent can be independently selected from deuterio, halogen, –NH , –OH, C alkoxy, and C
2 1-3 1-3
alkyl, trifluoromethoxy, and trifluoromethyl. Each substituent can be independently selected from
deuterio, –OH, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, and trifluoromethoxy. Each
substituent can be selected from deuterio, C alkyl, =O, C alkyl, C alkoxy, and phenyl. Each
1-3 1-3 1-3
substituent can be selected from deuterio, –OH, –NH , C alkyl, and C alkoxy.
2 1-3 1-3
“Treating” or “treatment” of a disease refers to arresting or ameliorating a disease or at least
one of the clinical symptoms of a disease or disorder, reducing the risk of acquiring a disease or at
least one of the clinical symptoms of a disease, reducing the development of a disease or at least one
of the clinical symptoms of the disease or reducing the risk of developing a disease or at least one of
the clinical symptoms of a disease. “Treating” or “treatment” also refers to inhibiting the disease,
either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of
a physical parameter), or both, and to inhibiting at least one physical parameter or manifestation that
may or may not be discernible to the patient. “Treating” or “treatment” also refers to delaying the
onset of the disease or at least one or more symptoms thereof in a patient who may be exposed to or
predisposed to a disease or disorder even though that patient does not yet experience or display
symptoms of the disease.
“Therapeutically effective amount” refers to the amount of a compound that, when
administered to a subject for treating a disease, or at least one of the clinical symptoms of a disease, is
sufficient to affect such treatment of the disease or symptom thereof. The “therapeutically
effective amount” may vary depending, for example, on the compound, the disease and/or symptoms
of the disease, severity of the disease and/or symptoms of the disease or disorder, the age, weight,
and/or health of the patient to be treated, and the judgment of the prescribing physician. An
appropriate amount in any given instance may be ascertained by those skilled in the art or capable of
determination by routine experimentation.
“Therapeutically effective dose” refers to a dose that provides effective treatment of a disease
or disorder in a patient. A therapeutically effective dose may vary from compound to compound, and
from patient to patient, and may depend upon factors such as the condition of the patient and the route
of delivery. A therapeutically effective dose may be determined in accordance with routine
pharmacological procedures known to those skilled in the art.
“Therapeutically effective amount” means the amount of a compound that, when administered
to a patient for treating a disease, is sufficient to affect such treatment for the disease. The
“therapeutically effective amount” will vary depending, for example, on the compound, the disease
and its severity and the age, weight, adsorption, distribution, metabolism and excretion, of the patient
to be treated.
“Vehicle” refers to a diluent, excipient or carrier with which a compound is administered to a
subject. In some embodiments, the vehicle is pharmaceutically acceptable.
Reference is now made in detail to certain embodiments of compounds, compositions, and
methods. The disclosed embodiments are not intended to be limiting of the claims. To the contrary,
the claims are intended to cover all alternatives, modifications, and equivalents.
Compounds provided by the present disclosure are sulfonate ester prodrugs of non- β-lactam
β-lactamase inhibitors. In the non- β-lactam β-lactamase inhibitor prodrugs a nucleophilic moiety is
positioned proximate to the hydrogen sulfate group. In vivo, the nucleophilic moiety reacts to release
the non- β-lactam β-lactamase inhibitor. Examples of non- β-lactam β-lactamase inhibitors include
avibactam ([2S,5R]carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl hydrogen sulfate),
relebactam ((1R,2S,5R)oxo(piperidinylcarbamoyl)-1,6-diazabicyclo[3.2.1]octanyl
hydrogen sulfate), and nacubactam (1R,2S,5R)((2-aminoethoxy)carbamoyl)oxo-1,6-
diazabicyclo[3.2.1]octanyl hydrogen sulfate, and derivatives and analogs of any of the foregoing.
These compounds are inhibitors of class A, class C, and certain Class D β-lactamases and are useful in
the treatment of bacterial infections when used in conjunction with β-lactam antibiotics.
Compounds provided by the present disclosure include compounds of Formula (1):
or a pharmaceutically acceptable salt thereof, wherein,
each R is independently selected from C alkyl, or each R and the geminal carbon atom to
which they are bonded forms a C cycloalkyl ring, a C heterocycloalkyl ring, a substituted C
3-6 3-6 3-6
cycloalkyl ring, or a substituted C heterocycloalkyl ring;
R is selected from a single bond, C alkanediyl, C heteroalkanediyl, C cycloalkanediyl,
1-6 1-6 5-6
C heterocycloalkanediyl, C arenediyl, C heteroarenediyl, substituted C alkanediyl, substituted
-6 6 5-6 1-6
C heteroalkanediyl, substituted C cycloalkanediyl, substituted C heterocycloalkanediyl,
1-6 5-6 5-6
substituted C arenediyl, and substituted C heteroarenediyl;
6 5-6
3 4 4 4 4
R is selected from C alkyl, –O–C(O)–R , –S–C(O)–R , –NH–C(O)–R , –O–C(O)–O–R , –
4 4 4 4 4 4
S–C(O)–O–R , –NH–C(O)–O–R , –C(O)–O–R , –C(O)–S–R , –C(O)–NH–R , –O–C(O)–O–R , –O–
4 4 4 4 4 4
C(O)–S–R , –O–C(O)–NH–R , –S–S–R , –S–R , –NH–R , –CH(–NH )(–R ), C heterocycloalkyl,
2 5-6
C heteroaryl, substituted C cycloalkyl, substituted C heterocycloalkyl, substituted C aryl,
-6 5-6 5-6 5-6
substituted C heteroaryl, and –CH=C(R ) , wherein,
-6 2
R is selected from hydrogen, C alkyl, C heteroalkyl, C cycloalkyl, C
1-8 1-8 5-8 5-8
heterocycloalkyl, C cycloalkylalkyl, C heterocycloalkylalkyl, C aryl, C heteroaryl,
-10 5-10 6-8 5-8
C arylalkyl, C heteroarylalkyl, substituted C alkyl, substituted C heteroalkyl,
7-10 5-10 1-8 1-8
substituted C cycloalkyl, substituted C heterocycloalkyl, substituted C cycloalkylalkyl,
-8 5-8 5-10
substituted C heterocycloalkylalkyl, substituted C aryl, substituted C heteroaryl,
-10 6-8 5-8
substituted C arylalkyl, and substituted C heteroarylalkyl;
7-10 5-10
R is selected from hydrogen, C alkyl, C cycloalkyl, C cycloalkylalkyl, C
1-6 5-8 6-12 2-6
heteroalkyl, C heterocycloalkyl, C - heterocycloalkylalkyl, substituted C alkyl, substituted C
-8 6 12 1-6 5-8
cycloalkyl, substituted C cycloalkylalkyl, substituted C heteroalkyl, substituted C
6-12 2-6 5-8
heterocycloalkyl, and substituted C heterocycloalkylalkyl;
6-12
R is selected from hydrogen, C alkyl, C cycloalkyl, C cycloalkylalkyl, C
1-6 5-8 6-12 2-6
heteroalkyl, C heterocycloalkyl, C heterocycloalkylalkyl, substituted C alkyl, substituted C
-8 6-12 1-6 5-8
cycloalkyl, substituted C cycloalkylalkyl, substituted C heteroalkyl, substituted C
6-12 2-6 5-8
heterocycloalkyl, and substituted C heterocycloalkylalkyl; and
6-12
A is a single bond (–) and R is hydrogen, or A is a double bond (=) and R is C alkyl.
In compounds of Formula (1), each substituent can be independently selected from deuterio, –
OH, –CN, –CF , –OCF , =O, –NO , C alkoxy, C alkyl, –COOR, –NR , and –CONR ; wherein
3 3 2 1-6 1-6 2 2
each R is independently selected from hydrogen and C alkyl, such has methyl, ethyl, n-propyl,
isopropyl, n-butyl, tert-butyl, or iso-butyl.
In compounds of Formula (1), a substituent group can be a nucleophilic group. Nucleophilic
groups are functional group having a reactive pair of electrons and having the ability of forming a
chemical bond by donating electrons. Examples of suitable nucleophilic groups include esters,
carboxylates, sulfonates, substituted or unsubstituted amines, alcohols (hydroxyl), thiols, sulfides,
hydroxylamines, and imines. Other examples of suitable nucleophilic groups include –OH, –CF , –
4 4 4 4 4
O–CF , –NO , –O–C(O)–R , –S–C(O)–R , –NH–C(O)–R , –O–C(O)–O–R , –S–C(O)–O–R , –NH–
4 4 4 4 4 4
C(O)–O–R , –C(O)–O–R , –C(O)–S–R , –C(O)–NH–R , –O–C(O)–O–R , –O–C(O)–S–R , –O–
4 4 4 4 4 4
C(O)–NH–R , –S–S–R , –S–R , –NH–R , –CH(–NH )(–R ), where each R is independently selected
from hydrogen, C alkyl, C heteroalkyl, C cycloalkyl, C heterocycloalkyl, C
1-6 1-6 5-8 5-8 5-10
cycloalkylalkyl, C heterocycloalkylalkyl, C aryl, C heteroaryl, C arylalkyl, C
-10 6-8 6-8 5-10 5-10
heteroarylalkyl, substituted C alkyl, substituted C heteroalkyl, substituted C cycloalkyl,
1-6 1-6 5-8
substituted C heterocycloalkyl, substituted C cycloalkylalkyl, substituted C
-8 5-10 5-10
heterocycloalkylalkyl, substituted C aryl, substituted C heteroaryl, substituted C arylalkyl, and
6-8 6-8 5-10
substituted C heteroarylalkyl.
-10
In compounds of Formula (1), each substituent can independently be selected from –OH, –
4 4 4 4 4
CF , –O–CF , –NO ,–O–C(O)–R , –S–C(O)–R , –NH–C(O)–R , –O–C(O)–O–R , –S–C(O)–O–R , –
3 3 2
4 4 4 4 4 4
NH–C(O)–O–R , –C(O)–O–R , –C(O)–S–R , –C(O)–NH–R , –O–C(O)–O–R , –O–C(O)–S–R , –O–
4 4 4 4 4 4
C(O)–NH–R , –S–S–R , –S–R , –NH–R , –CH(–NH )(–R ), wherein each R is selected from
hydrogen, C alkyl, and C heteroalkyl.
1-8 1-8
In compounds of Formula (1), A can be a single bond (–) and R can be hydrogen.
In compounds of Formula (1), A can be a double bond (=) and R can be C alkyl, such as
methyl, ethyl, n-propyl, or iso-propyl.
In compounds of Formula (1), each of R and R can be hydrogen.
In compounds of Formula (1), A can be a single bond (–); R can be hydrogen; and R can be
hydrogen.
In compounds of Formula (1), A can be a double bond (=) and R can be C alkyl, such as
methyl, ethyl, n-propyl, or iso-propyl; and each of R and R can be hydrogen.
In compounds of Formula (1), the compound can have the structure of Formula (2):
In compounds of Formula (1), the compound can have the structure of Formula (2a):
(2a)
In compounds of Formula (1), the compound can have the structure of Formula (3):
In compounds of Formula (1), the compound can have the structure of Formula (3a):
(3a)
In compounds of Formula (1), the compound can have the structure of Formula (4):
In compounds of Formula (1), the compound can have the structure of Formula (5):
In compounds of Formula (1), R can be C heteroalkyl comprising a terminal amine group,
and R can be hydrogen. For example, R can be –O–(CH ) –NH , –CH –O–CH –NH ,–(CH ) –O–
2 2 2 2 2 2 2 2
CH –NH , or –CH –O–(CH ) –NH .
2 2 2 2 2 2
In compounds of Formula (1), A can be a single bond (–) and R can be hydrogen, R can be –
O–(CH ) –NH , and R can be hydrogen.
2 2 2
In compounds of Formula (1), R can be C heterocycloalkyl comprising at least one –NH–
moiety, and R can be hydrogen. For example, R can be 2-yl-piperidine, 3-yl-piperidine, or 4-yl-
piperidine.
In compounds of Formula (1), A can be a single bond (–) and R can be hydrogen, R can be
4-yl-piperidine, and R can be hydrogen.
In compounds of Formula (1)-(5), each R can independently be C alkyl.
In compounds of Formula (1)-(5), each R can independently be methyl, ethyl, or n-propyl.
In compounds of Formula (1)-(5), each R can be same and is methyl, ethyl, or n-propyl.
In compounds of Formula (1)-(5), each R is methyl.
In compounds of Formula (1)-(5), each R together with the geminal carbon atom to which
they are bonded can form a C cycloalkyl ring or a substituted C cycloalkyl ring.
3-6 3-6
In compounds of Formula (1)-(5), each R together with the geminal carbon atom to which
they are bonded can form a C cycloalkyl ring. For example, each R together with the geminal
carbon atom to which they are bonded can form a cyclopropyl ring, a cyclobutyl ring, a cyclopentyl
ring, or a cyclohexyl ring.
compounds of Formula (1)-(5), each R each R together with the geminal carbon atom to
which they are bonded can form a C heterocycloalkyl ring or a substituted C heterocycloalkyl
3-6 3-6
ring.
In compounds of Formula (1)-(5), R can be selected from a single bond, C alkanediyl, and
substituted C alkanediyl.
In compounds of Formula (1)-(5), R can be a single bond.
In compounds of Formula (1)-(5), R can be a single bond; and R can be C alkyl.
In compounds of Formula (1)-(5), R can be selected from C alkanediyl and substituted C
1-2 1-2
alkanediyl.
In compounds of Formula (1)-(5), R can be methanediyl, ethanediyl, substituted
methanediyl, or substituted ethanediyl.
In compounds of Formula (1)-(5), R can be substituted C alkanediyl where the substituted
group can be selected from –OH, –CN, –CF , –OCF , =O, –NO , C alkoxy, C alkyl, –COOR, –
3 3 2 1-6 1-6
NR , and –CONR ; wherein each R is independently selected from hydrogen and C alkyl.
2 2 1-6
In compounds of Formula (1)-(5), R can be substituted C alkanediyl where the substituent
group can be a nucleophilic group. For example, R can be substituted C alkanediyl where the
substituent group can be selected from –OH, –CF , –O–CF , –NO ,–O–C(O)–R , –S–C(O)–R , –NH–
3 3 2
4 4 4 4 4 4
C(O)–R , –O–C(O)–O–R , –S–C(O)–O–R , –NH–C(O)–O–R , –C(O)–O–R , –C(O)–S–R , –C(O)–
4 4 4 4 4 4 4
NH–R , –O–C(O)–O–R , –O–C(O)–S–R , –O–C(O)–NH–R , –S–S–R , –S–R , –NH–R , –CH(–
4 4 4
NH )(–R ), where each R is defined as for Formula (1), or each R is selected from hydrogen and C
2 1-8
alkyl.
In compounds of Formula (1)-(5), R can be substituted C alkanediyl where the substituent
4 4 4 4 4
group is selected from –OH, –O–C(O)–R , –S–C(O)–R , –NH–C(O)–R ,–C(O)–O–R , –C(O)–S–R ,
4 4 4 4 4 4
–C(O)–NH–R ,–S–S–R , –S–R , –NH–R , –CH(–NH )(–R ), substituted C aryl, –NHR , –CH(–
2 5-6
4 4 4
NH )(–R ); and R is defined as for Formula (1), or each R is selected from hydrogen and C alkyl.
2 1-8
In compounds of Formula (1)-(5), where R is substituted C alkanediyl, substituted C
1-6 1-6
heteroalkanediyl, or substituted C arenediyl, the stereochemistry of the carbon atom to which the
substituent group is bonded can be of the (S) configuration.
In compounds of Formula (1)-(5), where R is substituted C alkanediyl, substituted C
1-6 1-6
heteroalkanediyl, or substituted C arenediyl, the stereochemistry of the carbon atom to which the
substituent group is bonded can be of the (R) configuration.
In compounds of Formula (1)-(5), R is selected from C cycloalkanediyl, C
-6 5-6
heterocycloalkanediyl, C arenediyl, and C heterocycloalkanediyl.
-6 5-6
In compounds of Formula (1)-(5), R can be cyclopenta-1,3-diene-diyl, substituted
cyclopenta-1,3-diene-diyl, benzene-diyl or substituted benzene-diyl. For example, R can be 1,2-
benzene-diyl or substituted 1,2-benzene-diyl.
3 4 4
In compounds of Formula (1)-(5), R can be selected from –O–C(O)–R , –S–C(O)–R , –NH–
4 4 4 4 4 4
C(O)–R , –O–C(O)–O–R , –S–C(O)–O–R , –NH–C(O)–O–R , –C(O)–O–R , –C(O)–S–R , –C(O)–
4 4 4 4 4 4 4
NH–R , –O–C(O)–O–R , –O–C(O)–S–R , –O–C(O)–NH–R , –S–S–R , –S–R , –NH–R , –CH(–
4 4 4
NH )(–R ); where R is defined as for Formula (1), or each R is selected from hydrogen and C
2 1-8
alkyl.
3 4 4
In compounds of Formula (1)-(5), R can be selected from –O–C(O)–R , –C(O)–O–R , –S–
4 4 4 4 4 4
C(O)–R , –C(O)–S–R , –S–S–R , –NH–R , and –CH(–NH )(–R ); where R is defined as for Formula
(1), or each R is selected from hydrogen and C alkyl.
3 4 4
In compounds of Formula (1)-(5), R is –C(O)–O–R ); where R is defined as for Formula (1),
or each R is selected from hydrogen and C alkyl.
In compounds of Formula (1)-(5), R can be selected from hydrogen, C alkyl, C
1-3 5-6
cycloalkyl, C heterocycloalkyl, C aryl, substituted C alkyl, substituted C cycloalkyl,
-6 5-6 1-3 5-6
substituted C heterocycloalkyl, and substituted C aryl.
-6 5-6
In compounds of Formula (1)-(5), R can be selected from methyl, ethyl, phenyl, and benzyl.
In compounds of Formula (1)-(5), R can be selected from hydrogen and C alkyl.
In compounds of Formula (1)-(5), R can be selected from C alkyl, C heteroalkyl, C
1-8 1-8 7-9
arylalkyl, C heterocycloalkyl, substituted C alkyl, substituted C heteroalkyl, substituted C
-7 1-8 1-8 7-9
arylalkyl, and substituted C heterocycloalkyl.
In compounds of Formula (1)-(5), R can be selected from C alkyl, C heteroalkyl, C
1-8 1-8 7-9
arylalkyl, and C heterocycloalkyl.
In compounds of Formula (1)-(5), R can be selected from methyl, ethyl, n-propyl, isopropyl,
n-butyl, sec-butyl isobutyl, tert-butyl, 2-methoxyethyl, methylbenzene, oxetaneoxy-yl, cyclopentyl,
cyclohexyl, and 2-pyrrolidinyl.
3 4 4
In compounds of Formula (1)-(5), R can be –C(O)–O–R ; and R can be selected from C
alkyl, C heteroalkyl, C cycloalkyl, C heterocycloalkyl, C aryl, C arylalkyl, substituted C
1-8 5-7 5-7 6 7-9 1-8
alkyl, substituted C heteroalkyl, substituted C cycloalkyl, substituted C heterocycloalkyl,
1-8 5-6 5-6
substituted C aryl, and C arylalkyl,
6 7-9
3 4 4
In compounds of Formula (1)-(5), R can be –C(O)–O–R ; and R can be selected from C
alkyl, C heteroalkyl, C arylalkyl, C heterocycloalkyl, substituted C alkyl, substituted C
1-8 7-9 5-7 1-8 1-8
heteroalkyl, substituted C arylalkyl, and substituted C heterocycloalkyl.
7-9 5-7
3 4 4
In compounds of Formula (1)-(5), R can be –C(O)–O–R ; and R can be selected from C
alkyl, C heteroalkyl, C arylalkyl, and C heterocycloalkyl.
1-8 7-9 5-7
In compounds of Formula (1)-(5), R can be selected from –O–C(O)–CH , –O–C(O)–CH –
CH , –O–C(O)–phenyl, –O–C(O)–CH –phenyl, –S–C(O)–CH , –S–C(O)–CH –CH , –S–C(O)–
3 2 3 2 3
phenyl, –S–C(O)–CH –phenyl, –NH–C(O)–CH , –NH–C(O)–CH –CH , –NH–C(O)–phenyl, –NH–
2 3 2 3
C(O)–CH –phenyl, –O–C(O)–O–CH , –O–C(O)–O–CH –CH , –O–C(O)–O–phenyl, –O–C(O)–O–
2 3 2 3
CH –phenyl, –S–C(O)–O–CH , –S–C(O)–O–CH –CH , –S–C(O)–O–phenyl, –S–C(O)–O–CH –
2 3 2 3 2
phenyl, –NH–C(O)–O–CH , –NH–C(O)–O–CH –CH , –NH–C(O)–O–phenyl, –NH–C(O)–O–CH –
3 2 3 2
phenyl, –C(O)–O–CH ,–C(O)–O–CH –CH , –C(O)–O–phenyl, –C(O)–O–CH –phenyl, –C(O)–S–
3 2 3 2
CH ,–C(O)–S–CH –CH , –C(O)–S–phenyl, –C(O)–S–CH –phenyl, –C(O)–NH–CH , –C(O)–NH–
3 2 3 2 3
CH –CH , –C(O)–NH–phenyl, –C(O)–NH–CH –phenyl, –O–C(O)–O–CH , –O–C(O)–O–CH –CH ,
2 3 2 3 2 3
–O–C(O)–O–phenyl, –O–C(O)–O–CH –phenyl, –O–C(O)–S–CH , –O–C(O)–S–CH –CH , –O–
2 3 2 3
C(O)–S–phenyl, –O–C(O)–S–CH –phenyl, –O–C(O)–NH–CH , –O–C(O)–NH–CH –CH , –O–C(O)–
2 3 2 3
NH–phenyl, –O–C(O)–NH–CH –phenyl, –S–SH, –S–S–CH , –S–S–CH –CH , –S–S–phenyl, –S–S–
2 3 2 3
CH –phenyl, –SH, –S–CH , –S–CH –CH , –S–phenyl, –S–CH –phenyl, –NH , –NH–CH , –NH–
2 3 2 3 2 2 3
CH –CH , –NH–phenyl, –NH–CH –phenyl, –CH(–NH )(–CH ), –CH(–NH )(–CH –CH ), –CH(–
2 3 2 2 3 2 2 3
NH )(–phenyl), and –CH(–NH )(–CH –phenyl).
2 2 2
In compounds of Formula (1)-(5), R can be selected from C cycloalkyl, C
-6 5-6
heterocycloalkyl, C aryl, C heteroaryl, substituted C cycloalkyl, substituted C
-6 5-6 5-6 5-6
heterocycloalkyl, substituted C aryl, and substituted C heteroaryl, comprising at least one
-6 5-6
nucleophilic group. For example, R can have the structure of Formula (4a) or Formula (4b):
(4a) (4b)
In compounds of Formula (1)-(5), R can be selected from C alkyl, C cycloalkyl, C
1-3 5-6 5-6
heterocycloalkyl, C aryl, substituted C alkyl, substituted C cycloalkyl, substituted C
-6 1-3 5-6 5-6
heterocycloalkyl, and substituted C aryl.
In compounds of Formula (1)-(5), each R together with the carbon atom to which they are
bonded form a C heterocycloalkyl ring comprising two adjacent S atoms or a substituted C
4-6 4-6
heterocycloalkyl ring comprising at least one heteroatom selected from O and S, and a carbonyl (=O)
substituent group bonded to a carbon atom adjacent the at least one heteroatom.
2 3 1
In compounds of Formula (1)-(5), R can be a bond; R can be C alkyl; and each R together
with the carbon atom to which they are bonded form a C heterocycloalkyl ring comprising two
adjacent S atoms or a substituted C heterocycloalkyl ring comprising at least one heteroatom
selected from O and S, and a =O substituent group bonded to a carbon atom adjacent the heteroatom.
1 3 4
In compounds of Formula (1)-(5), the promoiety –CH –C(R ) –R –R can have any of the
following structures, where R can be C alkyl, such as C alkyl, such as methyl or ethyl:
1-6 1-4
2 3 1
In compounds of Formula (1)-(5), R can be a single bond; R can be C alkyl; and each R
together with the carbon atom to which they are bonded can form a C heterocycloalkyl ring or a
substituted C heterocycloalkyl ring.
2 3 1
In compounds of Formula (1)-(5), R can be a single bond; R can be C alkyl; and each R
together with the carbon atom to which they are bonded can form a C heterocycloalkyl ring
comprising two adjacent S atoms or a substituted C heterocycloalkyl ring comprising at least one
heteroatom selected from O and S, and a carbonyl (=O) substituent group bonded to a carbon atom
adjacent the heteroatom.
2 3 1
In compounds of Formula (1)-(5), R can be a single bond; R can be C alkyl; and each R
together with the carbon atom to which they are bonded can form a 1,2-dithiolane, 1,2-dithane ring,
thietanone ring, dihydrothiophen-2(3H)-one ring, tetrahydro-2H-thipyranone ring, oxetanone
ring dihydrofuran-2(3H)-one ring, or tetrahydro-2H-pyranone ring.
In compounds of Formula (1)-(5),
each R can be methyl;
R can be selected from a single bond, methanediyl, ethanediyl, –CH(–OH)–, –CH(–O–C(O)–
CH CH )–, and 1,2-benzene-diyl; and
3 4 4 4 4 4
R can be selected from –O–C(O)–R , –C(O)–O–R , –S–C(O)–R , –C(O)–S–R , –S–S–R , –
4 4 4
NHR , and –CH(–NH )(–R ), where R can be selected from hydrogen, methyl, ethyl, cyclopentyl,
cyclohexyl, phenyl, benzyl, and 2-pyrrolidinyl.
In compounds of Formula (1)-(5),
each R and the geminal carbon to which they are bonded can form a C cycloalkyl ring;
R can be selected from a bond, methanediyl, ethanediyl, –CH(–OH)–, –CH(–O–C(O)–
CH CH )–, and 1,2-benzene-diyl; and
3 4 4 4 4 4
R can be selected from –O–C(O)–R , –C(O)–O–R , –S–C(O)–R , –C(O)–S–R , –S–S–R , –
4 4 4
NHR , and –CH(–NH )(–R ), where R can be selected from hydrogen, methyl, ethyl, cyclopentyl,
cyclohexyl, phenyl, benzyl, and 2-pyrrolidinyl.
In compounds of Formula (1)-(5),
R can be a bond;
R be C alkyl; and
each R together with the carbon atom to which they are bonded can form a 1,2-dithiolante,
1,2-dithane ring, thietanone ring, dihydrothiophen-2(3H)-one ring, tetrahydro-2H-thipyranone
ring, oxetanone ring dihydrofuran-2(3H)-one ring, or tetrahydro-2H-pyranone ring.
In compounds of Formula (1)-(5), each R can be methyl;
R can be selected from a single bond, methanediyl, ethanediyl, –CH(–OH)–, –CH(–O–C(O)–
CH CH )–, and 1,2-benzene-diyl; and
3 4 4 4 4 4
R can be selected from –O–C(O)–R , –C(O)–O–R , –S–C(O)–R , –C(O)–S–R , –S–S–R , –
NHR , and –CH(–NH )(–R );
wherein R can be selected from C alkyl, C heteroalkyl, C arylalkyl, and C
1-8 1-8 7-9 5-7
heterocycloalkyl.
In compounds of Formula (1)-(5),
each R can be methyl;
R can be selected from a single bond, methanediyl, ethanediyl, –CH(–OH)–, –CH(–O–C(O)–
CH CH )–, and 1,2-benzene-diyl; and
R can be–C(O)–O–R ;
wherein R can be selected from C alkyl, C heteroalkyl, C arylalkyl, and C
1-8 1-8 7-9 5-7
heterocycloalkyl.
In compounds of Formula (1)-(5),
each R can be methyl;
R can be selected from a single bond, methanediyl, ethanediyl, –CH(–OH)–, –CH(–O–C(O)–
CH CH )–, and 1,2-benzene-diyl; and
3 4 4 4 4 4
R can be selected from –O–C(O)–R , –C(O)–O–R , –S–C(O)–R , –C(O)–S–R , –S–S–R , –
NHR , and –CH(–NH )(–R );
wherein R can be selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl
isobutyl, tert-butyl, 2-methoxyethyl, methylbenzene, oxetaneoxy-yl, cyclopentyl, cyclohexyl, and
2-pyrrolidinyl.
In compounds of Formula (1)-(5),
each R can be methyl;
R can be selected from a single bond, methanediyl, ethanediyl, –CH(–OH)–, –CH(–O–C(O)–
CH CH )–, and 1,2-benzene-diyl; and
R can be–C(O)–O–R ;
wherein R can be selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl
isobutyl, tert-butyl, 2-methoxyethyl, methylbenzene, oxetaneoxy-yl, cyclopentyl, cyclohexyl, and
2-pyrrolidinyl.
In compounds of Formula (1)-(5),
each R can be methyl;
R can be a single bond; and
R can be–C(O)–O–R ;
wherein R can be selected from C alkyl, C heteroalkyl, C alkylarene, and C
1-10 1-10 7-10 5-10
heteroalkylcycloalkyl.
In compounds of Formula (1)-(5),
each R can be methyl;
R can be a single bond;
R can be–C(O)–O–R ;
wherein R can be selected from C alkyl, C heteroalkyl, C alkylarene, and C
1-10 1-10 7-10 5-10
heteroalkylcycloalkyl;
6 7
each of R , R , and R can be hydrogen; and
A is a single bond.
6 7
In compounds of Formula (1)-(5), A can be a single bond, and each of R , R , and R can be
hydrogen.
In compounds of Formula (1)-(5), A can be a single bond; each R can be independently C
2 5 6 7
alkyl; each R can be a single bond; and each of R , R , and R can be hydrogen;
In compounds of Formula (1), the compound can be selected from:
3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2-dimethylpropyl benzoate (2);
ethyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (3);
benzyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (4);
4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
3,3-dimethylbutyl benzoate (6);
4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
3,3-dimethylbutyl propionate (7);
benzyl (4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-3,3-dimethylbutyl) adipate (8);
6-(4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
3,3-dimethylbutoxy)oxohexanoic acid (9);
methyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (10);
isopropyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (11);
hexyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (12);
heptyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (13);
tert-butyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (14);
2-methoxyethyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (15);
oxetanyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (16);
ethyl 1-((((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)cyclohexanecarboxylate (17);
ethyl 1-((((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)cyclopropanecarboxylate (18);
ethyl 1-((((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)cyclobutanecarboxylate (19);
(1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl 1H-imidazolesulfonate
(34);
ethyl 5-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-4,4-dimethylpentanoate (35);
hexyl 5-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-4,4-dimethylpentanoate (36);
heptyl 5-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-4,4-dimethylpentanoate (37);
2-methoxyethyl 5-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-4,4-dimethylpentanoate (38);
-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2,4,4-tetramethylpentyl propionate (39);
-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2,4,4-tetramethylpentyl benzoate (40);
-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2,4,4-tetramethylpentyl 2,6-dimethylbenzoate (41);
(1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl ((3-methyl
oxotetrahydrofuranyl)methyl) sulfate (42);
3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2-dimethylpropyl pivalate (43);
3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2-dimethylpropyl 3-chloro-2,6-dimethoxybenzoate (44);
4-(((((1R,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2,3,3-tetramethylbutyl 2,6-dimethylbenzoate (45);
4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2,3,3-tetramethylbutyl benzoate (46);
4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2,3,3-tetramethylbutyl propionate (47);
(1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl ((3-methyl
oxotetrahydro-2H-pyranyl)methyl) sulfate (48);
2-(3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2-dimethylpropyl)phenyl acetate (49);
2-(3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2-dimethylpropyl)phenyl pivalate (50);
S-(4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
3,3-dimethylbutyl) ethanethioate (51);
S-(5-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
4,4-dimethylpentyl) ethanethioate (52);
S-(3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2-dimethylpropyl) ethanethioate (53);
3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2-dimethylpropyl 2,6-dimethylbenzoate (54);
3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2-dimethylpropyl adamantanecarboxylate (55);
diethyl 2-((((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)methylmalonate (56);
propyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (57);
butyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (58);
(5-methyloxo-1,3-dioxolyl)methyl 3-(((((,2S,5R)carbamoyloxo-1,6-
diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (59);
4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
3,3-dimethylbutyl pivalate (60);
ethyl 2-((((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)ethylbutanoate (61);
4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
3,3-dimethylbutyl 2,6-dimethylbenzoate (62);
4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
3,3-dimethylbutyl adamantanecarboxylate (63);
4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
3,3-dimethylbutyl 2,6-dimethoxybenzoate (64);
-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
4,4-dimethylpentyl benzoate (65);
-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
4,4-dimethylpentyl 2,6-dimethoxybenzoate (66);
-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
4,4-dimethylpentyl 2,6-dimethylbenzoate (67);
-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
4,4-dimethylpentyl 2-methylbenzoate (68);
4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2,3,3-tetramethylbutyl 3-chloro-2,6-dimethoxybenzoate (69);
2-((((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)methylpropane-1,3-diyl dibenzoate (70);
2-((((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)methylpropane-1,3-diyl diacetate (71);
-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2,4,4-tetramethylpentyl 2,6-dimethoxybenzoate (72);
ethyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylbutanoate (73);
(1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl ((3,5,5-trimethyl
oxotetrahydrofuranyl)methyl) sulfate (74);
a pharmaceutically acceptable salt of any of the foregoing; and
a combination of any of the foregoing.
In compounds of Formula (1), the compound can be selected from:
ethyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (3);
benzyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (4);
methyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (10);
isopropyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (11);
hexyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (12);
heptyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (13);
tert-butyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (14);
2-methoxyethyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (15);
oxetanyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (16);
ethyl 1-((((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)cyclohexanecarboxylate (17);
ethyl 1-((((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)cyclopropanecarboxylate (18);
ethyl 1-((((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)cyclobutanecarboxylate (19);
hexyl 5-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-4,4-dimethylpentanoate (36);
heptyl 5-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-4,4-dimethylpentanoate (37);
(1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl ((3-methyl
oxotetrahydrofuranyl)methyl) sulfate (42);
S-(3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2-dimethylpropyl) ethanethioate (53);
propyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (57);
butyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (58);
(5-methyloxo-1,3-dioxolyl)methyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-
diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (59);
a pharmaceutically acceptable salt of any of the foregoing; and
a combination of any of the foregoing.
In compounds of Formula (1), the compound can be selected from:
ethyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (3);
benzyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (4);
methyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (10);
isopropyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (11);
hexyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (12);
heptyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (13);
tert-butyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (14);
2-methoxyethyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (15);
oxetanyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (16);
ethyl 1-((((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)cyclohexanecarboxylate (17);
ethyl 1-((((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)cyclopropanecarboxylate (18);
ethyl 1-((((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)cyclobutanecarboxylate (19);
a pharmaceutically acceptable salt of any of the foregoing; and
a combination of any of the foregoing.
In compounds of Formula (1), the compound can be selected from:
hexyl 5-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-4,4-dimethylpentanoate (36);
heptyl 5-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-4,4-dimethylpentanoate (37);
(1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl ((3-methyl
oxotetrahydrofuranyl)methyl) sulfate (42);
S-(3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2-dimethylpropyl) ethanethioate (53);
propyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (57);
butyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (58);
(5-methyloxo-1,3-dioxolyl)methyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-
diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (59);
a pharmaceutically acceptable salt of any of the foregoing; and
a combination of any of the foregoing.
In a compound of Formula (2a),
each R can be independently selected from C alkyl, or each R together with the geminal
carbon atom to which they are bonded form a C cycloalkyl ring, a substituted C cycloalkyl ring, a
3-6 3-6
C heterocycloalkyl ring, or a substituted C heterocycloalkyl ring;
3-6 3-6
R can be a single bond;
R can be –C(O)–O–R ; and
R can be selected from C alkyl, C heteroalkyl, C arylalkyl, C heterocycloalkyl,
1-8 1-8 7-9 5-7
substituted C alkyl, substituted C heteroalkyl, substituted C arylalkyl, and substituted C
1-8 1-8 7-9 5-7
heterocycloalkyl.
In a compound of Formula (2a),
each R can be independently selected from C alkyl, or each R together with the carbon
atom to which they are bonded form a C cycloalkyl ring;
R can be selected from single bond, methane-diyl, and ethane-diyl; and
3 4 4 4
R can be selected from –C(O)–O–R and –S–C(O)–R , wherein R can be selected from C
1-10
alkyl, C heteroalkyl, C arylalkyl, C heterocycloalkyl, and substituted C
1-10 5-10 3-6 4-10
heterocycloalkylalkyl.
In a compound of Formula (2a),
each R can be independently selected from C alkyl, or each R together with the carbon
atom to which they are bonded form a C cycloalkyl ring;
R can be a single bond; and
3 4 4
R can be –C(O)–O–R , where R can be selected from C alkyl, C heteroalkyl, C
1-10 1-10 5-10
arylalkyl, C heterocycloalkyl, and substituted C heterocycloalkylalkyl.
3-6 4-10
In a compound of Formula (2a),
each R can be independently selected from C alkyl, or each R together with the carbon
atom to which they are bonded form a C cycloalkyl ring;
R can be –(CH ) –; and
3 4 4
R can be –C(O)–O–R wherein R can be selected from C alkyl, C heteroalkyl, C
1-10 1-10 5-10
arylalkyl, C heterocycloalkyl, and substituted C heterocycloalkylalkyl.
3-6 4-10
In a compound of Formula (2a),
each R can be selected from C alkyl, or each R together with the carbon atom to which
they are bonded form a C cycloalkyl ring;
R can be –CH –; and
3 4 4
R can be –S–C(O)–R , wherein R can be selected from C alkyl, C heteroalkyl, C
1-10 1-10 5-10
arylalkyl, C heterocycloalkyl, substituted C heterocycloalkylalkyl.
3-6 4-10
In a compound of Formula (2a),
each R together with the carbon atom to which they are bonded form a C cycloalkyl ring, a
C heterocycloalkyl ring, a C cycloalkyl ring, or a C heterocycloalkyl ring;
3-6 3-6 3-6
R can be a single bond; and
R can be C alkyl.
In a compound of Formula (2a),
each R can be independently selected from C alkyl;
R can be selected from a single bond and methanediyl; and
3 4 4 4
R can be selected from –O–C(O)–R and –C(O)–O–R , wherein R can be selected from C
1-10
alkyl and substituted phenyl.
In a compound of Formula (2a),
each R can be independently selected from C alkyl;
R can be a single bond;
3 4 4 8 4
R can be –CH=C(R ) , wherein each R can be –C(O)–O–R , or each R together with the
carbon atom to which they are bonded from a substituted heterocyclohexyl ring; and
each R can be C alkyl.
In a compound of Formula (2a),
each R can be independently selected from C alkyl;
R can be selected from a single bond and methanediyl; and
R can be substituted phenyl, wherein the one or more substituents can be independently
4 4 4
selected from –CH –O–C(O)–R and –O–C(O)–R , wherein R can be selected from C alkyl and
2 1-10
phenyl.
In a compound of Formula (2a),
each R can be independently selected from C alkyl;
2 8 8 8
R can be selected from –C(R ) – and –CH –C(R ) –, wherein each R can be independently
2 2 2
selected from C alkyl; and
3 4 4 4
R can be selected from –C(O)–O–R and –O–C(O)–R , wherein R can be selected from C
1-10
alkyl, C heteroalkyl, substituted C alkyl, substituted C heteroalkyl, and 4(yl-methyl)
1-10 1-10 1-10
methyl-1,3-dioxolone.
In a compound of Formula (2a),
each R together with the carbon atom to which they are bonded form a substituted C
heterocyclic ring;
R can be a single bond; and
R can be C alkyl.
A compound of Formula (1) can be a compound of sub-genus (1A), or a pharmaceutically
acceptable salt thereof, wherein,
6 7
each of R , R , and R can be hydrogen;
A can be a single bond;
each R can be independently selected from C alkyl, or each R together with the carbon
atom to which they are bonded form a C cycloalkyl ring;
R can be selected from single bond, methane-diyl, and ethane-diyl; and
3 4 4 4
R can be selected from –C(O)–O–R and –S–C(O)–R , wherein R can be selected from C
1-10
alkyl, C heteroalkyl, C arylalkyl, C heterocycloalkyl, and substituted C
1-10 5-10 3-6 4-10
heterocycloalkylalkyl.
In compounds of subgenus (1A), each R can be independently selected from C alkyl.
In compounds of subgenus (1A), each R together with the carbon atom to which they are
bonded form a C cycloalkyl ring.
In compounds of subgenus (1A), R a single bond.
In compounds of subgenus (1A), R can be methane-diyl.
In compounds of subgenus (1A), R can be ethane-diyl.
In compounds of subgenus (1A), R can be –C(O)–O–R .
In compounds of subgenus (1A), R can be –S–C(O)–R .
In compounds of subgenus (1A), R can be C alkyl.
1-10
In compounds of subgenus (1A), R can be C heteroalkyl.
1-10
In compounds of subgenus (1A), R can be C arylalkyl.
-10
In compounds of subgenus (1A), R can be C heterocycloalkyl.
In compounds of subgenus (1A), R can be substituted C heterocycloalkylalkyl.
4-10
A compound of Formula (1) can be a compound of sub-genus (1B), or a pharmaceutically
acceptable salt thereof, wherein,
6 7
each of R , R , and R can be hydrogen;
A can be a single bond;
each R can be independently selected from C alkyl, or each R together with the carbon
atom to which they are bonded form a C cycloalkyl ring;
R can be a single bond; and
3 4 4
R can be –C(O)–O–R , where R can be selected from C alkyl, C heteroalkyl, C
1-10 1-10 5-10
arylalkyl, C heterocycloalkyl, and substituted C heterocycloalkylalkyl.
3-6 4-10
In compounds of subgenus (1B), each R can be independently selected from C alkyl.
In compounds of subgenus (1B), each R together with the carbon atom to which they are
bonded form a C cycloalkyl ring.
In compounds of subgenus (1B), R can be selected from C alkyl, C heteroalkyl wherein
1-7 1-10
the one or more heteroatoms can be oxygen, –CH –C cycloalkyl, –(CH ) –C cycloalkyl, C
2 4-6 2 2 4-6 3-6
heterocycloalkyl wherein the one or more heteroatoms can be oxygen, and –CH –C substituted
2 3-6
heterocycloalkyl, and –(CH ) –C substituted heterocycloalkyl.
2 2 3-6
In compounds of subgenus (1B), in the substituted C heterocycloalkyl the one or more
heteroatoms can be oxygen, and the one or more substituents can be independently selected from C
alkyl and =O.
In compounds of subgenus (1B), each R can be methyl, or each R together with the carbon
atom to which they are bonded form a cyclohexyl ring or a cyclopentyl ring.
In compounds of subgenus (1B), R can be selected from methyl, ethyl, n-propyl, iso propyl,
n-butyl, n-hexyl, n-heptyl, –CH –CH –O–CH , benzyl, 3-oxetanyl, and methylmethyl-1,3-dioxol-
2 2 3
2-one.
In compounds of subgenus (1B),
6 7
each of R , R , and R can be hydrogen;
A can be a single bond;
each R can be methyl, or each R together with the carbon atom to which they are bonded
form a cyclohexyl ring or a cyclopentyl ring;
R can be a single bond; and
3 4 4
R can be –C(O)–O–R , wherein R can be selected from methyl, ethyl, n-propyl, iso propyl,
n-butyl, n-hexyl, n-heptyl, –CH –CH –O–CH , –CH -phenyl (benzyl), 3-oxetanyl, and methyl
2 2 3 2
methyl-1,3-dioxolone.
A compound of Formula (1) can be a compound of sub-genus (1C), or a pharmaceutically
acceptable salt thereof, wherein,
6 7
each of R , R , and R can be hydrogen;
A can be a single bond;
each R can be independently selected from C alkyl, or each R together with the carbon
atom to which they are bonded form a C cycloalkyl ring;
R can be –(CH ) –; and
3 4 4
R can be –C(O)–O–R wherein R can be selected from C alkyl, C heteroalkyl, C
1-10 1-10 5-10
arylalkyl, C heterocycloalkyl, and substituted C heterocycloalkylalkyl.
3-6 4-10
In compounds of subgenus (1C), each R can be independently selected from C alkyl.
In compounds of subgenus (1C), each R together with the carbon atom to which they are
bonded form a C cycloalkyl ring.
In compounds of subgenus (1C), R can be selected from C alkyl, C heteroalkyl wherein
1-7 1-10
the one or more heteroatoms can be oxygen, –CH –C cycloalkyl, –(CH ) –C cycloalkyl, C
2 4-6 2 2 4-6 3-6
heterocycloalkyl wherein the one or more heteroatoms can be oxygen, –CH –C substituted
2 3-6
heterocycloalkyl, and –(CH ) –C substituted heterocycloalkyl.
2 2 3-6
In compounds of subgenus (1C), in the substituted C heterocycloalkyl the one or more
heteroatoms can be oxygen, and the one or more substituents can be independently selected from C
alkyl and =O.
In compounds of subgenus (1C), R can be C alkyl.
1-10
In compounds of subgenus (1C),
6 7
each of R , R , and R can be hydrogen;
A can be a single bond;
each R can be methyl;
R can be –(CH ) –; and
3 4 4
R can be –C(O)–O–R wherein R can be selected from n-hexyl and n-heptyl.
A compound of Formula (1) can be a compound of sub-genus (1D), or a pharmaceutically
acceptable salt thereof, wherein,
6 7
each of R , R , and R can be hydrogen;
A can be a single bond;
each R can be selected from C alkyl, or each R together with the carbon atom to which
they are bonded form a C cycloalkyl ring;
R can be –CH –; and
3 4 4
R can be –S–C(O)–R , wherein R can be selected from C alkyl, C heteroalkyl, C
1-10 1-10 5-10
arylalkyl, C heterocycloalkyl, substituted C heterocycloalkylalkyl.
3-6 4-10
In compounds of subgenus (1D), each R can be independently selected from C alkyl.
In compounds of subgenus (1D), each R together with the carbon atom to which they are
bonded form a C cycloalkyl ring.
In compounds of subgenus (1D), R can be selected from C alkyl, C heteroalkyl wherein
1-7 1-10
the one or more heteroatoms can be oxygen, –CH –C cycloalkyl, –(CH ) –C cycloalkyl, C
2 4-6 2 2 4-6 3-6
heterocycloalkyl wherein the one or more heteroatoms can be oxygen, –CH –C substituted
2 3-6
heterocycloalkyl, –(CH ) –C substituted heterocycloalkyl.
2 2 3-6
In compounds of subgenus (1D), in the substituted C heterocycloalkyl the one or more
heteroatoms can be oxygen, and the one or more substituents can be independently selected from C
alkyl and =O.
In compounds of subgenus (1D), R can be C alkyl.
1-10
In compounds of subgenus (1D),
6 7
each of R , R , and R can be hydrogen;
A can be a single bond;
each R can be methyl;
R can be –CH – ; and
3 4 4
R can be –S–C(O)–R , wherein R can be methyl.
A compound of Formula (1) can be a compound of sub-genus (1E), or a pharmaceutically
acceptable salt thereof, wherein,
6 7
each of R , R , and R can be hydrogen;
A can be a single bond;
each R together with the carbon atom to which they are bonded form a C cycloalkyl ring, a
C heterocycloalkyl ring, a C cycloalkyl ring, or a C heterocycloalkyl ring;
3-6 3-6 3-6
R can be a single bond; and
R can be C alkyl.
In compounds of subgenus (1E), each R together with the carbon atom to which they are
bonded form a C heterocycloalkyl ring or a C heterocycloalkyl ring;
3-6 3-6
In compounds of subgenus (1E), the one or more heteroatoms can be oxygen and the one or
more substituents can be =O.
In compounds of subgenus (1E),
each R together with the carbon atom to which they are bonded form a dihydrofuran-2(3H)-
one ring;
R can be a single bond; and
R can be methyl.
A compound of Formula (1) can be a compound of sub-genus (1F), or a pharmaceutically
acceptable salt thereof, wherein,
6 7
each of R , R , and R can be hydrogen;
A can be a single bond;
each R can be independently selected from C alkyl;
R can be selected from a single bond and methanediyl; and
3 4 4 4
R can be selected from –O–C(O)–R and –C(O)–O–R , wherein R can be selected from C
1-10
alkyl and substituted phenyl.
In compounds of subgenus (1F), R can be a single bond.
In compounds of subgenus (1F), R can be methanediyl.
In compounds of subgenus (1F), R can be –O–C(O)–R .
2 3 4
In compounds of subgenus (1F), R can be methanediyl; and R can be –O–C(O)–R .
In compounds of subgenus (1F), R can be –C(O)–O–R .
2 3 4
In compounds of subgenus (1F), R can be a single bond; and R can be –C(O)–O–R .
2 3 4 4
In compounds of subgenus (1E), R can be a single bond; R can be –C(O)–O–R ; and R can
be C alkyl.
In compounds of subgenus (1F), R can be C alkyl.
1-10
In compounds of subgenus (1F), R can be C alkyl.
In compounds of subgenus (1F), R can be substituted phenyl.
2 3 4 4
In compounds of subgenus (1F), R can be methanediyl; R can be –O–C(O)–R ; and R can
be substituted phenyl.
In compounds of subgenus (1F), the one or more substituents can be independently selected
from halogen, C alkyl, and C alkoxy.
1-3 1-3
In compounds of subgenus (1F), the substituted phenyl can be 2,6-substituted phenyl.
In compounds of subgenus (1F), each of the substituents can be selected from C alkyl and
C alkoxy.
In compounds of subgenus (1F), the substituted phenyl can be 2,5,6-substituted phenyl.
In compounds of subgenus (1F), each of the substituents at the 2 and 6 positions can be
independently selected from C alkyl and C alkoxy; and the substituent at the 5 position can be
1-3 1-3
halogen.
A compound of Formula (1) can be a compound of sub-genus (1G), or a pharmaceutically
acceptable salt thereof, wherein,
6 7
each of R , R , and R can be hydrogen;
A can be a single bond;
each R can be independently selected from C alkyl;
R can be a single bond; and
3 4 4 8 4
R can be –CH=C(R ) , wherein each R can be –C(O)–O–R , or each R together with the
carbon atom to which they are bonded from a substituted heterocyclohexyl ring; and
each R can be C alkyl.
In compounds of subgenus (1G), each R can be –C(O)–O–R .
4 8 4
In compounds of subgenus (1G), each R can be –C(O)–O–R , or each R together with the
carbon atom to which they are bonded from a substituted heterocyclohexyl ring.
In compounds of subgenus (1G), in the substituted heterocyclohexyl ring, the one or more
heteroatoms can be oxygen.
In compounds of subgenus (1G), in the substituted heterocyclohexyl ring, the one or more
substituents can be independently selected from C alkyl and =O.
In compounds of subgenus (1G), the substituted heterocycloalkyl ring can be 2,2-dimethyl
yl-1,3-dioxane-4,6-dione.
A compound of Formula (1) can be a compound of sub-genus (1H), or a pharmaceutically
acceptable salt thereof, wherein,
6 7
each of R , R , and R can be hydrogen;
A can be a single bond;
each R can be independently selected from C alkyl;
R can be selected from a single bond and methanediyl; and
R can be substituted phenyl, wherein the one or more substituents can be independently
4 4 4
selected from –CH –O–C(O)–R and –O–C(O)–R , wherein R can be selected from C alkyl and
2 1-10
phenyl.
In compounds of subgenus (1H), R can be a single bond.
In compounds of subgenus (1H), R can be 2-substituted phenyl.
In compounds of subgenus (1H), the one or more substituents can be –CH –O–C(O)–R .
In compounds of subgenus (1H), the one or more substituents can be –O–C(O)–R .
In compounds of subgenus (1H), R can be C alkyl.
1-10
In compounds of subgenus (1H), R can be selected from methyl, ethyl, iso-propyl, pivalolyl,
and phenyl.
A compound of Formula (1) can be a compound of sub-genus (1I), or a pharmaceutically
acceptable salt thereof, wherein,
6 7
each of R , R , and R can be hydrogen;
A can be a single bond;
each R can be independently selected from C alkyl;
2 8 8 8
R can be selected from –C(R ) – and –CH –C(R ) –, wherein each R can be independently
2 2 2
selected from C alkyl; and
3 4 4 4
R can be selected from –C(O)–O–R and –O–C(O)–R , wherein R can be selected from C
1-10
alkyl, C heteroalkyl, substituted C alkyl, substituted C heteroalkyl, and 4(yl-methyl)
1-10 1-10 1-10
methyl-1,3-dioxolone.
In compounds of subgenus (1I), each R can be methyl.
In compounds of subgenus (1I), R can be –C(R ) –.
In compounds of subgenus (1I), R can be –CH –C(R ) –.
In compounds of subgenus (1I), each R can be methyl.
In compounds of subgenus (1I), each R can be methyl; and each R can be methyl.
In compounds of subgenus (1I), R can be –C(O)–O–R .
In compounds of subgenus (1I), R can be –O–C(O)–R .
A compound of Formula (1) can be a compound of sub-genus (1J), or a pharmaceutically
acceptable salt thereof, wherein,
6 7
each of R , R , and R can be hydrogen;
A can be a single bond;
each R together with the carbon atom to which they are bonded form a substituted C
heterocyclic ring;
R can be a single bond; and
R can be C alkyl.
In compounds of subgenus (1J), in the substituted C heterocyclic ring, the one or more
heteroatoms can be oxygen; and the one or more substituents can be independently selected from C
alkyl and =O.
In compounds of subgenus (1J), each R together with the carbon atom to which they are
bonded form a tetrahydro-2H-pyranone ring.
In compounds of subgenus (1J),
6 7
each of R , R , and R can be hydrogen;
A can be a single bond;
each R can be independently selected from C alkyl;
R can be selected from C alkanediyl; and
R can be substituted C heterocycloalkyl, wherein the one or more heteroatoms can be
independently selected from N and O; and the one or more substituents can be independently selected
from C alkyl and =O.
In compounds of subgenus (1J), R can have the structure of Formula (6):
wherein R can be selected from hydrogen, C alkyl, C cycloalkyl, C heteroalkyl, C
1-6 4-6 1-6 4-6
heterocycloalkyl, substituted C alkyl, substituted C cycloalkyl, substituted C heteroalkyl, and
1-6 4-6 1-6
substituted C heterocycloalkyl.
In compounds of subgenus (1J), R can be selected from hydrogen and C alkyl such as C
1-6 1-4
alkyl such as methyl or ethyl.
A compound of Formula (4) can be a compound of sub-genus (4A), or a pharmaceutically
acceptable salt thereof, wherein,
6 7
each of R , R , and R can be hydrogen;
A can be a single bond;
each R can be independently selected from C alkyl, or each R together with the carbon
atom to which they are bonded form a C cycloalkyl ring;
R can be a single bond; and
3 4 4
R can be –C(O)–O–R , wherein R can be selected from C alkyl, C heteroalkyl, C
1-10 1-10 5-10
arylalkyl, C heterocycloalkyl, and substituted C heterocycloalkylalkyl.
3-6 4-10
In compounds of sub-genus (4A), each R can be independently selected from C alkyl.
In compounds of sub-genus (4A), each R together with the carbon atom to which they are
bonded form a C cycloalkyl ring.
In compounds of sub-genus (4A), R can be selected from C alkyl, C heteroalkyl wherein
1-7 1-10
the one or more heteroatoms can be oxygen, –CH –C cycloalkyl, –(CH ) –C cycloalkyl, C
2 4-6 2 2 4-6 3-6
heterocycloalkyl wherein the one or more heteroatoms can be oxygen, –CH –C substituted
2 3-6
heterocycloalkyl, and –(CH ) –C substituted heterocycloalkyl.
2 2 3-6
In compounds of sub-genus (4A), in the substituted C heterocycloalkyl the one or more
heteroatoms can be oxygen, and the one or more substituents can be independently selected from C
alkyl and =O.
In compounds of sub-genus (4A), each R can be methyl, or each R together with the carbon
atom to which they are bonded form a cyclohexyl ring or a cyclopentyl ring.
In compounds of sub-genus (4A), R can be selected from methyl, ethyl, n-propyl, iso propyl,
n-butyl, n-hexyl, n-heptyl, –CH –CH –O–CH , benzyl, 3-oxetanyl, and methylmethyl-1,3-dioxol-
2 2 3
2-one.
In compounds of sub-genus (4A),
6 7
each of R , R , and R can be hydrogen;
A can be a single bond;
R can be a single bond; and
3 4 4
R can be –C(O)–O–R , wherein R can be C alkyl.
1-10
A compound of Formula (4) can be selected from:
ethyl2,2-dimethyl(((((1R,2S,5R)oxo(piperidinylcarbamoyl)-1,6-
diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)propanoate (20);
2-methoxyethyl 2,2-dimethyl(((((1R,2S,5R)oxo(piperidinylcarbamoyl)-1,6-
diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)propanoate (21);
4-((1R,2S,5R)(((3-(hexyloxy)-2,2-dimethyloxopropoxy)sulfonyl)oxy)oxo-1,6-
diazabicyclo[3.2.1]octanecarboxamido)piperidinium 2,2,2-trifluoroacetate (22);
4-((1R,2S,5R)(((3-(heptyloxy)-2,2-dimethyloxopropoxy)sulfonyl)oxy)oxo-1,6-
diazabicyclo[3.2.1]octanecarboxamido)piperidinium 2,2,2-trifluoroacetate (23);
4-((1R,2S,5R)((((1-(ethoxycarbonyl)cyclohexyl)methoxy)sulfonyl)oxy)oxo-1,6-
diazabicyclo[3.2.1]octanecarboxamido)piperidinium 2,2,2-trifluoroacetate (24);
(5-methyloxo-1,3-dioxolyl)methyl 2,2-dimethyl(((((1R,2S,5R)oxo(piperidin
ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)propanoate (25);
a pharmaceutically acceptable salt of any of the foregoing; and
a combination of any of the foregoing.
A compound of Formula (4) can be selected from:
ethyl2,2-dimethyl(((((1R,2S,5R)oxo(piperidinylcarbamoyl)-1,6-
diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)propanoate (20);
4-((1R,2S,5R)(((3-(hexyloxy)-2,2-dimethyloxopropoxy)sulfonyl)oxy)oxo-1,6-
diazabicyclo[3.2.1]octanecarboxamido)piperidinium 2,2,2-trifluoroacetate (22);
4-((1R,2S,5R)(((3-(heptyloxy)-2,2-dimethyloxopropoxy)sulfonyl)oxy)oxo-1,6-
diazabicyclo[3.2.1]octanecarboxamido)piperidinium 2,2,2-trifluoroacetate (23);
(5-methyloxo-1,3-dioxolyl)methyl 2,2-dimethyl(((((1R,2S,5R)oxo(piperidin
ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)propanoate (25);
a pharmaceutically acceptable salt of any of the foregoing; and
a combination of any of the foregoing.
A compound of Formula (5) can be selected from:
ethyl 3-(((((1R,2S,5R)((2-aminoethoxy)carbamoyl)oxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (27);
2-methoxyethyl 3-(((((1R,2S,5R)((2-aminoethoxy)carbamoyl)oxo-1,6-
diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (28);
(5-methyloxo-1,3-dioxolyl)methyl 3-(((((1R,2S,5R)((2-aminoethoxy)carbamoyl)
oxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate TFA salt (29);
hexyl 3-(((((1R,2S,5R)((2-aminoethoxy)carbamoyl)oxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate TFA salt (30);
heptyl 3-(((((1R,2S,5R)((2-aminoethoxy)carbamoyl)oxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate TFA salt (31);
ethyl 1-((((((1R,2S,5R)((2-aminoethoxy)carbamoyl)oxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)cyclohexanecarboxylate TFA salt (32);
a pharmaceutically acceptable salt of any of the foregoing; and
a combination of any of the foregoing.
A compound of Formula (1)-(5) can be a solvate, a pharmaceutically acceptable salt, or a
combination thereof.
In compounds of Formula (1)-(5), a pharmaceutically acceptable salt can be the hydrochloride
salt.
In compounds of Formula (1)-(5), a pharmaceutically acceptable salt can be the
dihydrochloride salt.
A compound of Formula (1)-(5) can be a pharmaceutically acceptable salt of a compound of
Formula (1)-(5), a hydrate thereof, or a solvate of any of the foregoing.
The compound described herein may be synthesized using methods known in the art. The
synthesis of the various diazabicyclo[3.2.1]octane structures described herein are conventional and are
well known to those of skill in the art (Tandiparthi et al., PCT International Application Publication
No. ; Lampilas et al., U.S. Patent No. 7,112,592; King et al., ACS Chemical Biology
2016; 11, 864; and Bush et al., Cold Spring Harb Perspect Med 2016; 6:a025247). Formation of
sulfate esters is also well-known in the art (Simpson et al., J. Am. Chem. Soc. 2006, 128, 1605; Li et
al., U.S. Application Publication No. 2009/0099253; Jandeleit et al., PCT International Application
Publication No. ; Jandeleit et al., PCT International Application Publication No.
; and Jandeleit et al., PCT International Application Publication No. WO
2011/150380).
Sulfate monoester analogs of sulfate-containing compounds can be prepared by reacting a
hydroxyl-substituted sulfate-containing compound with a chlorosulfate monoester to provide the
corresponding sulfate monoester analog. The methods can be useful in preparing prodrugs of sulfate-
containing pharmaceutical compounds.
Prodrugs are derivatized forms of drugs that following administration are converted or
metabolized to an active form of the parent drug in vivo. Prodrugs are used to modify one or more
aspects of the pharmacokinetics of a drug in a manner that enhances the therapeutic efficacy of a
parent drug. For example, prodrugs are often used to enhance the oral bioavailability of a drug. To
be therapeutically effective, drugs exhibiting poor oral bioavailability may require frequent dosing,
large administered doses, or may need to be administered by other than oral routes, such as
intravenously. In particular, many drugs with sulfate groups exhibit poor oral bioavailability.
Intramolecular cyclization prodrug strategies have been used to modify the pharmacokinetics
of drugs. Intramolecular cyclization release prodrug strategies have been applied to drugs containing
sulfonic acid functional groups. For example, prodrugs comprising a substituted neopentyl sulfonate
ester derivative in which the neopentyl group is removed in vivo by unmasking a nucleophilic
heteroatom bonded to a substituted neopentyl moiety followed by intramolecular cyclization to
generate the parent drug in the sulfonic acid or sulfonic salt form have been described, for example, in
U.S. Patent No. 7,994,218 and U.S. Patent No. 8,168,617. In such prodrugs the nucleophilic
heteroatom can be nitrogen or oxygen and the nitrogen or oxygen nucleophile can be masked with an
amine or alcohol protecting group, respectively, capable of being deprotected in vivo.
Sulfate monoester analogs of a sulfate-containing compound can be prepared by reacting a
hydroxyl-substituted analog of the sulfate-containing compound with a chlorosulfate monoester under
basic conditions, to provide the corresponding sulfate monoester analog. A chlorosulfate monoester
can be prepared by reacting sulfuryl chloride with an alcohol having the desired promoiety.
Neopentyl alcohols having neopentyl promoieties can be prepared by standard synthetic methods such
as those described in U.S. Patent Nos. 7,994,218 and 8,168,617.
For example, sulfate monoester analogs of avibactam provided by the present disclosure can
be synthesized by reacting (1R,2S,5R)hydroxyoxo-1,6-diazabicyclo[3.2.1]octanecarboxamide
with a chlorosulfate monoester having a desired promoiety to provide the corresponding (1R,2S,5R)-
2-carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl sulfate monoester.
(1R,2S,5R)Hydroxyoxo-1,6-diazabicyclo[3.2.1]octanecarboxamide can be prepared
by hydrogenating (1R,2S,5R)(benzyloxy)oxo-1,6-diazabicyclo[3.2.1]octanecarboxamide
using the methods described, for example, in U.S. Patent Nos. 8,772,490; 9,035,062; and 9,284,273.
(1R,2S,5R)Hydroxyoxo-1,6-diazabicyclo[3.2.1]octanecarboxamide can be reacted
with the chlorosulfate monoester in the presence of a base to provide the corresponding sulfate
monoester analog of avibactam. Suitable methods are disclosed, for example, in J. Am. Chem. Soc.
2006, 128, 1605-1610.
Similar methods can be adapted to prepare sulfate monoester analogs of relebactam and
nacubactam. For example, the tert-butyl carboxylate protected, 6-hydroxyl analog of relebactam can
be reacted with a chlorosulfate monoester in the presence of a base to provide the corresponding tert-
butyl carboxylate protected sulfate monoester analog of relebactam. The compound can then be
deprotected in the presence of an acid to provide the sulfate monoester analog of relebactam.
Methods similar to those used to prepare sulfate monoester analogs of relebactam can be used to
prepare sulfate monoester analogs of nacubactam.
For example, a sulfate monoester analog of a sulfate monoester of Formula (80a) can be
synthesized by reacting a cyclic hydroxamic acid of Formula (80b) with a chlorosulfonate monoester
of Formula (80c) under basic conditions:
(80a)
(80b)
(80c)
where,
R is selected from C alkyl, C heteroalkyl, C cycloalkyl, C heterocycloalkyl, C
1-8 1-8 5-8 5-8 5-10
cycloalkylalkyl, C heterocycloalkylalkyl, C aryl, C heteroaryl, C arylalkyl, C
-10 6-8 5-8 7-10 5-10
heteroarylalkyl, substituted C alkyl, substituted C heteroalkyl, substituted C cycloalkyl,
1-8 1-8 5-8
substituted C heterocycloalkyl, substituted C cycloalkylalkyl, substituted C
-8 5-10 5-10
heterocycloalkylalkyl, substituted C aryl, substituted C heteroaryl, substituted C arylalkyl, and
6-8 5-8 7-10
substituted C heteroarylalkyl;
-10
R is selected from hydrogen, C alkyl, C cycloalkyl, C cycloalkylalkyl, C
1-6 5-8 6-12 2-6
heteroalkyl, C heterocycloalkyl, C heterocycloalkylalkyl, substituted C alkyl, substituted C
-8 6-12 1-6 5-8
cycloalkyl, substituted C cycloalkylalkyl, substituted C heteroalkyl, substituted C
6-12 2-6 5-8
heterocycloalkyl, and substituted C heterocycloalkylalkyl;
6-12
R is selected from hydrogen, C alkyl, C cycloalkyl, C cycloalkylalkyl, C
1-6 5-8 6-12 2-6
heteroalkyl, C heterocycloalkyl, C heterocycloalkylalkyl, substituted C alkyl, substituted C
-8 6-12 1-6 5-8
cycloalkyl, substituted C cycloalkylalkyl, substituted C heteroalkyl, substituted C
6-12 2-6 5-8
heterocycloalkyl, and substituted C heterocycloalkylalkyl; and
6-12
A is a single bond (–) and R is hydrogen, or A is a double bond (=) and R is C alkyl.
The chlorosulfate monoester can comprise a chlorosulfate neopentyl ester, such as a
chlorosulfate neopentyl ester of Formula (81):
Cl O R
(81)
wherein,
each R is independently selected from C alkyl, or each R and the geminal carbon
atom to which they are bonded forms a C cycloalkyl ring, a C heterocycloalkyl ring, a
3-6 3-6
substituted C cycloalkyl ring, or a substituted C heterocycloalkyl ring;
3-6 3-6
R is selected from a single bond, C alkanediyl, C heteroalkanediyl, C
1-6 1-6 5-6
cycloalkanediyl, C heterocycloalkanediyl, C arenediyl, C heteroarenediyl, substituted C
-6 6 5-6 1-
alkanediyl, substituted C heteroalkanediyl, substituted C cycloalkanediyl, substituted C
6 1-6 5-6 5-
heterocycloalkanediyl, substituted C arenediyl, and substituted C heteroarenediyl; and
6 6 5-6
3 4 4 4
R is selected from C alkyl, –O–C(O)–R , –S–C(O)–R , –NH–C(O)–R , –O–C(O)–
4 4 4 4 4 4
O–R , –S–C(O)–O–R , –NH–C(O)–O–R , –C(O)–O–R , –C(O)–S–R , –C(O)–NH–R , –O–
4 4 4 4 4 4
C(O)–O–R , –O–C(O)–S–R , –O–C(O)–NH–R , –S–S–R , –S–R , –NH–R , –CH(–NH )(–
R ), C heterocycloalkyl, C heteroaryl, substituted C cycloalkyl, substituted C
-6 5-6 5-6 5-6
heterocycloalkyl, substituted C aryl, substituted C heteroaryl, and –CH=C(R ) , wherein,
-6 5-6 2
R is selected from hydrogen, C alkyl, C heteroalkyl, C cycloalkyl, C
1-8 1-8 5-8 5-8
heterocycloalkyl, C cycloalkylalkyl, C heterocycloalkylalkyl, C aryl, C
-10 5-10 6-8 5-8
heteroaryl, C arylalkyl, C heteroarylalkyl, substituted C alkyl, substituted C
7-10 5-10 1-8 1-8
heteroalkyl, substituted C cycloalkyl, substituted C heterocycloalkyl, substituted
-8 5-8
C cycloalkylalkyl, substituted C heterocycloalkylalkyl, substituted C aryl,
-10 5-10 6-8
substituted C heteroaryl, substituted C arylalkyl, and substituted C
-8 7-10 5-10
heteroarylalkyl.
The chlorosulfate monoester can be synthesized by reacting an alcohol such as a neopentyl
alcohol with sulfuryl chloride.
The method can be used to bond any suitable chlorosulfonate ester to a cyclic hydroxamic
acid such as, for example, a chlorosulfonate ester of Formula (82) and a cyclic hydroxamic acid of
Formula (83) to provide the corresponding sulfate monoester analog of Formula (84):
N O O
A S R
(82) (83) (84)
where,
R can be selected from C alkyl, C heteroalkyl, C cycloalkyl, C heterocycloalkyl, C
1-8 1-8 5-8 5-8 5-10
cycloalkylalkyl, C heterocycloalkylalkyl, C aryl, C heteroaryl, C arylalkyl, C
-10 6-8 5-8 7-10 5-10
heteroarylalkyl, substituted C alkyl, substituted C heteroalkyl, substituted C cycloalkyl,
1-8 1-8 5-8
substituted C heterocycloalkyl, substituted C cycloalkylalkyl, substituted C
-8 5-10 5-10
heterocycloalkylalkyl, substituted C aryl, substituted C heteroaryl, substituted C arylalkyl, and
6-8 5-8 7-10
substituted C heteroarylalkyl;
-10
n can be an integer from 1 to 6;
each A can be independently selected from –(CH )–, –(CHR)–, –(CR )–, –NH–, –NR–, O,
and S, where R is independently elected from hydrogen, C alkyl, C heteroalkyl, C cycloalkyl,
1-8 1-8 5-8
C heterocycloalkyl, C cycloalkylalkyl, C heterocycloalkylalkyl, C aryl, C heteroaryl, C
-8 5-10 5-10 6-8 5-8 7-10
arylalkyl, C heteroarylalkyl, substituted C alkyl, substituted C heteroalkyl, substituted C
-10 1-8 1-8 5-8
cycloalkyl, substituted C heterocycloalkyl, substituted C cycloalkylalkyl, substituted C
-8 5-10 5-10
heterocycloalkylalkyl, substituted C aryl, substituted C heteroaryl, substituted C arylalkyl, and
6-8 5-8 7-10
substituted C heteroarylalkyl; or one A is bonded to another A through a group –L–, where L is
-10
selected from C alkyl, C heteroalkyl, substituted C alkyl, and substituted C heteroalkyl.
1-8 1-8 1-8 1-8
R can further include any of the promoieties disclosed herein, such as a promoiety having the
structure:
1 2 3
where R , R , and R are defined as in Formula (1).
The compositions provided herein contain therapeutically effective amounts of one or more of
the compounds provided herein that are useful in the prevention, treatment, or amelioration of one or
more of the symptoms of diseases or disorders described herein and a vehicle. Vehicles suitable for
administration of the compounds provided herein include any such carriers known to those skilled in
the art to be suitable for the particular mode of administration. In addition, the compounds may be
formulated as the sole active ingredient in the composition or may be combined with other active
ingredients.
The compositions contain one or more compounds provided herein. The compounds are, in
some embodiments, formulated into suitable preparations such as solutions, suspensions, tablets,
dispersible tablets, pills, capsules, powders, sustained release formulations or elixirs, for oral
administration or in sterile solutions or suspensions for parenteral administration, as well as topical
administration, transdermal administration and oral inhalation via nebulizers, pressurized metered
dose inhalers and dry powder inhalers. In some embodiments, the compounds described above are
formulated into compositions using techniques and procedures well known in the art (see, e.g., Ansel,
Introduction to Pharmaceutical Dosage Forms, Seventh Edition (1999)).
In the compositions, effective concentrations of one or more compounds or derivatives
thereof is (are) mixed with a suitable vehicle. The compounds may be derivatized as the
corresponding salts, esters, enol ethers or esters, acetals, ketals, orthoesters, hemiacetals, hemiketals,
acids, bases, solvates, ion-pairs, hydrates or prodrugs prior to formulation, as described above. The
concentrations of the compounds in the compositions are effective for delivery of an amount, upon
administration that treats, leads to prevention, or amelioration of one or more of the symptoms of
diseases or disorders described herein. In some embodiments, the compositions are formulated for
single dosage administration. To formulate a composition, the weight fraction of a compound is
dissolved, suspended, dispersed or otherwise mixed in a selected vehicle at an effective concentration
such that the treated condition is relieved, prevented, or one or more symptoms are ameliorated.
The active compound is included in the vehicle in an amount sufficient to exert a
therapeutically useful effect in the absence of undesirable side effects on the patient treated. The
therapeutically effective concentration may be predicted empirically by testing the compounds in in
vitro and in vivo systems well known to those of skill in the art and then extrapolated therefrom for
dosages for humans. Human doses are then typically fine-tuned in clinical trials and titrated to
response.
The concentration of active compound in the composition will depend on absorption,
inactivation and excretion rates of the active compound, the physicochemical characteristics of the
compound, the dosage schedule, and amount administered as well as other factors known to those of
skill in the art. For example, the amount that is delivered is sufficient to ameliorate one or more of the
symptoms of diseases or disorders as described herein.
In instances in which the compounds exhibit insufficient solubility, methods for solubilizing
compounds may be used such as use of liposomes, prodrugs, complexation/chelation, nanoparticles,
or emulsions or tertiary templating. Such methods are known to those of skill in this art, and include,
but are not limited to, using co-solvents, such as dimethyl sulfoxide (DMSO), using surfactants or
surface modifiers, such as TWEEN , complexing agents such as cyclodextrin or dissolution by
enhanced ionization (i.e. dissolving in aqueous sodium bicarbonate). Derivatives of the compounds,
such as prodrugs of the compounds may also be used in formulating effective compositions.
Upon mixing or addition of the compound(s), the resulting mixture may be a solution,
suspension, emulsion or the like. The form of the resulting mixture depends upon a number of
factors, including the intended mode of administration and the solubility of the compound in the
selected vehicle. The effective concentration is sufficient for ameliorating the symptoms of the
disease, disorder or condition treated and may be empirically determined.
The compositions are provided for administration to humans and animals in indication
appropriate dosage forms, such as dry powder inhalers (DPIs), pressurized metered dose inhalers
(pMDIs), nebulizers, tablets, capsules, pills, sublingual tapes/bioerodible strips, tablets or capsules,
powders, granules, lozenges, lotions, salves, suppositories, fast melts, transdermal patches or other
transdermal application devices/preparations, sterile parenteral solutions or suspensions, and oral
solutions or suspensions, and oil-water emulsions containing suitable quantities of the compounds or
derivatives thereof. The therapeutically active compounds and derivatives thereof are, in some
embodiments, formulated and administered in unit-dosage forms or multiple-dosage forms. Unit-dose
forms as used herein refer to physically discrete units suitable for human and animal subjects and
packaged individually as is known in the art. Each unit-dose contains a predetermined quantity of the
therapeutically active compound sufficient to produce the desired therapeutic effect, in association
with the required vehicle. Examples of unit-dose forms include ampoules and syringes and
individually packaged tablets or capsules. Unit-dose forms may be administered in fractions or
multiples thereof. A multiple-dose form is a plurality of identical unit-dosage forms packaged in a
single container to be administered in segregated unit-dose form. Examples of multiple-dose forms
include vials, bottles of tablets or capsules or bottles of pints or gallons. Hence, multiple dose form is
a multiple of unit-doses which are not segregated in packaging.
Liquid compositions can, for example, be prepared by dissolving, dispersing, or otherwise
mixing an active compound as defined above and optional adjuvants in a vehicle, such as, for
example, water, saline, aqueous dextrose, glycerol, glycols, ethanol, and the like, to thereby form a
solution or suspension, colloidal dispersion, emulsion or liposomal formulation. If desired, the
composition to be administered may also contain minor amounts of nontoxic auxiliary substances
such as wetting agents, emulsifying agents, solubilizing agents, pH buffering agents and the like, for
example, acetate, sodium citrate, cyclodextrin derivatives, sorbitan monolaurate, triethanolamine
sodium acetate, triethanolamine oleate, and other such agents.
Actual methods of preparing such dosage forms are known, or will be apparent, to those
skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company,
Easton, Pa., 15th Edition, 1975 or later editions thereof.
Dosage forms or compositions containing active ingredient in the range of 0.005% to 100%
with the balance made up from vehicle or carrier may be prepared. Methods for preparation of these
compositions are known to those skilled in the art. The contemplated compositions may contain
0.001%-100% active ingredient, in one embodiment 0.1-95%, in another embodiment 0.4-10%.
Compositions can be lactose-free compositions containing excipients that are well known in
the art and are listed, for example, in the U.S. Pharmacopeia (USP) 25-NF20 (2002). In general,
lactose-free compositions contain active ingredients, a binder/filler, and a lubricant in compatible
amounts. Particular lactose-free dosage forms contain active ingredients, microcrystalline cellulose,
pre-gelatinized starch, and magnesium stearate.
Further provided are anhydrous compositions and dosage forms comprising active
ingredients, since water can facilitate the degradation of some compounds. For example, the addition
of water (e.g., 5%) is widely accepted as a means of simulating long-term storage in order to
determine characteristics such as shelf-life or the stability of formulations over time. See, e.g., Jens T.
Carstensen, Drug Stability: Principles & Practice, 2d. Ed., Marcel Dekker, NY, NY, 1995, pp.
379-80. In effect, water and heat accelerate the decomposition of some compounds. Thus, the effect
of water on a formulation can be of great significance since moisture and/or humidity are commonly
encountered during manufacture, handling, packaging, storage, shipment, and use of formulations.
Anhydrous compositions and dosage forms provided herein can be prepared using anhydrous
or low moisture containing ingredients and low moisture or low humidity conditions.
An anhydrous composition should be prepared and stored such that its anhydrous nature is
maintained. Accordingly, anhydrous compositions are generally packaged using materials known to
prevent exposure to water such that they can be included in suitable formulary kits. Examples of
suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose
containers (e.g., vials), blister packs, and strip packs.
Oral dosage forms are either solid, gel or liquid. The solid dosage forms are tablets, capsules,
granules, and bulk powders. Types of oral tablets include compressed, chewable lozenges and tablets
which may be enteric-coated, sugar-coated or film-coated. Capsules may be hard or soft gelatin
capsules, while granules and powders may be provided in non-effervescent or effervescent form with
the combination of other ingredients known to those skilled in the art.
Formulations can be solid dosage forms such as for example, capsules or tablets. The tablets,
pills, capsules, troches and the like can contain one or more of the following ingredients, or
compounds of a similar nature: a binder; a lubricant; a diluent; a glidant; a disintegrating agent; a
coloring agent; a sweetening agent; a flavoring agent; a wetting agent; an enteric coating; a film
coating agent and modified release agent. Examples of binders include microcrystalline cellulose,
methyl paraben, polyalkyleneoxides, gum tragacanth, glucose solution, acacia mucilage, gelatin
solution, molasses, polyvinylpyrrolidine, povidone, crospovidones, sucrose and starch and starch
derivatives. Lubricants include talc, starch, magnesium/calcium stearate, lycopodium and stearic acid.
Diluents include, for example, lactose, sucrose, trehalose, lysine, leucine, lecithin, starch, kaolin, salt,
mannitol and dicalcium phosphate. Glidants include, but are not limited to, colloidal silicon dioxide.
Disintegrating agents include crosscarmellose sodium, sodium starch glycolate, alginic acid, corn
starch, potato starch, bentonite, methylcellulose, agar and carboxymethylcellulose. Coloring agents
include, for example, any of the approved certified water-soluble FD and C dyes, mixtures thereof;
and water insoluble FD and C dyes suspended on alumina hydrate and advanced coloring or
anti-forgery color/opalescent additives known to those skilled in the art. Sweetening agents include
sucrose, lactose, mannitol and artificial sweetening agents such as saccharin and any number of spray
dried flavors. Flavoring agents include natural flavors extracted from plants such as fruits and
synthetic blends of compounds which produce a pleasant sensation or mask unpleasant taste, such as,
but not limited to peppermint and methyl salicylate. Wetting agents include propylene glycol
monostearate, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene lauryl ether.
Enteric-coatings include fatty acids, fats, waxes, shellac, ammoniated shellac and cellulose acetate
phthalates. Film coatings include hydroxyethylcellulose, sodium carboxymethylcellulose,
polyethylene glycol 4000 and cellulose acetate phthalate. Modified release agents include polymers
such as the Eudragit series and cellulose esters.
The compound, or derivative thereof, can be provided in a composition that protects it from
the acidic environment of the stomach. For example, the composition can be formulated in an enteric
coating that maintains its integrity in the stomach and releases the active compound in the intestine.
The composition may also be formulated in combination with an antacid or other such ingredient.
When the dosage unit form is a capsule, it can contain, in addition to material of the above
type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various other
materials which modify the physical form of the dosage unit, for example, coatings of sugar and other
enteric agents. The compounds can also be administered as a component of an elixir, suspension,
syrup, wafer, sprinkle, chewing gum or the like. A syrup may contain, in addition to the active
compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
The active materials can also be mixed with other active materials which do not impair the
desired action, or with materials that supplement the desired action, such as antacids, H blockers, and
diuretics. The active ingredient is a compound or derivative thereof as described herein. Higher
concentrations, up to about 98% by weight of the active ingredient may be included.
In all embodiments, tablets and capsules formulations may be coated as known by those of
skill in the art in order to modify or sustain dissolution of the active ingredient. Thus, for example,
they may be coated with a conventional enterically digestible coating, such as phenylsalicylate, waxes
and cellulose acetate phthalate.
Liquid oral dosage forms include aqueous solutions, emulsions, suspensions, solutions and/or
suspensions reconstituted from non-effervescent granules and effervescent preparations reconstituted
from effervescent granules. Aqueous solutions include, for example, elixirs and syrups. Emulsions
are either oil-in-water or water-in-oil.
Elixirs are clear, sweetened, hydroalcoholic preparations. Vehicles used in elixirs include
solvents. Syrups are concentrated aqueous solutions of a sugar, for example, sucrose, and may
contain a preservative. An emulsion is a two-phase system in which one liquid is dispersed in the
form of small globules throughout another liquid. Carriers used in emulsions are non-aqueous liquids,
emulsifying agents and preservatives. Suspensions use suspending agents and preservatives.
Acceptable substances used in non-effervescent granules, to be reconstituted into a liquid oral dosage
form, include diluents, sweeteners and wetting agents. Acceptable substances used in effervescent
granules, to be reconstituted into a liquid oral dosage form, include organic acids and a source of
carbon dioxide. Coloring and flavoring agents are used in all of the above dosage forms.
Solvents include glycerin, sorbitol, ethyl alcohol and syrup. Examples of preservatives
include glycerin, methyl and propylparaben, benzoic acid, sodium benzoate and alcohol. Examples of
non-aqueous liquids utilized in emulsions include mineral oil and cottonseed oil. Examples of
emulsifying agents include gelatin, acacia, tragacanth, bentonite, and surfactants such as
polyoxyethylene sorbitan monooleate. Suspending agents include sodium carboxymethylcellulose,
pectin, tragacanth, Veegum and acacia. Sweetening agents include sucrose, syrups, glycerin and
artificial sweetening agents such as saccharin. Wetting agents include propylene glycol monostearate,
sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene lauryl ether. Organic acids
include citric and tartaric acid. Sources of carbon dioxide include sodium bicarbonate and sodium
carbonate. Coloring agents include any of the approved certified water-soluble FD and C dyes, and
mixtures thereof. Flavoring agents include natural flavors extracted from plants such fruits, and
synthetic blends of compounds which produce a pleasant taste sensation.
For a solid dosage form, the solution or suspension, in for example, propylene carbonate,
vegetable oils or triglycerides, is in some embodiments encapsulated in a gelatin capsule. Such
solutions, and the preparation and encapsulation thereof, are disclosed in U.S. Patent Nos. 4,328,245;
4,409,239; and 4,410,545. For a liquid dosage form, the solution, e.g., for example, in a polyethylene
glycol, may be diluted with a sufficient quantity of a liquid vehicle, e.g., water, to be easily measured
for administration.
Alternatively, liquid or semi-solid oral formulations may be prepared by dissolving or
dispersing the active compound or salt in vegetable oils, glycols, triglycerides, propylene glycol esters
(e.g., propylene carbonate) and other such carriers, and encapsulating these solutions or suspensions
in hard or soft gelatin capsule shells. Other useful formulations include those set forth in U.S. Patent
Nos. RE28,819 and 4,358,603. Briefly, such formulations include, but are not limited to, those
containing a compound provided herein, a dialkylated mono- or polyalkylene glycol, including, but
not limited to, 1,2-dimethoxyethane, diglyme, triglyme, tetraglyme, polyethylene glycoldimethyl
ether, polyethylene glycoldimethyl ether, polyethylene glycoldimethyl ether wherein 350,
550 and 750 refer to the approximate average molecular weight of the polyethylene glycol, and one or
more antioxidants, such as butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), propyl
gallate, vitamin E, hydroquinone, hydroxycoumarins, ethanolamine, lecithin, cephalin, ascorbic acid,
malic acid, sorbitol, phosphoric acid, thiodipropionic acid and its esters, and dithiocarbamates.
Other formulations include, but are not limited to, aqueous alcoholic solutions including an
acetal. Alcohols used in these formulations are any water-miscible solvents having one or more
hydroxyl groups, including, but not limited to, propylene glycol and ethanol. Acetals include, but are
not limited to, di(lower alkyl) acetals of lower alkyl aldehydes such as acetaldehyde diethyl acetal.
Parenteral administration, in some embodiments characterized by injection, either
subcutaneously, intramuscularly or intravenously is also contemplated herein. Injectables can be
prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for
solution or suspension in liquid prior to injection, or as emulsions. The injectables, solutions and
emulsions also contain one or more excipients. Suitable excipients are, for example, water, saline,
dextrose, glycerol or ethanol. In addition, if desired, the compositions to be administered may also
contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH
buffering agents, stabilizers, solubility enhancers, and other such agents, such as for example, sodium
acetate, sorbitan monolaurate, triethanolamine oleate and cyclodextrins.
Implantation of a slow-release or sustained-release system, such that a constant level of
dosage is maintained (see, e.g., U.S. Patent No. 3,710,795) is also contemplated herein. Briefly, a
compound provided herein is dispersed in a solid inner matrix, e.g., polymethylmethacrylate,
polybutylmethacrylate, plasticized or unplasticized polyvinylchloride, plasticized nylon, plasticized
polyethyleneterephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene,
polyethylene, ethylene-vinylacetate copolymers, silicone rubbers, polydimethylsiloxanes, silicone
carbonate copolymers, hydrophilic polymers such as hydrogels of esters of acrylic and methacrylic
acid, collagen, cross-linked polyvinylalcohol and cross-linked partially hydrolyzed polyvinyl acetate,
that is surrounded by an outer polymeric membrane, e.g., polyethylene, polypropylene,
ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers, ethylene/vinylacetate
copolymers, silicone rubbers, polydimethyl siloxanes, neoprene rubber, chlorinated polyethylene,
polyvinylchloride, vinylchloride copolymers with vinyl acetate, vinylidene chloride, ethylene and
propylene, ionomer polyethylene terephthalate, butyl rubber epichlorohydrin rubbers, ethylene/vinyl
alcohol copolymer, ethylene/vinyl acetate/vinyl alcohol terpolymer, and ethylene/vinyloxyethanol
copolymer, that is insoluble in body fluids. The compound diffuses through the outer polymeric
membrane in a release rate controlling step. The percentage of active compound contained in such
parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of
the compound and the needs of the subject.
Parenteral administration of the compositions includes intravenous, subcutaneous and
intramuscular administrations. Preparations for parenteral administration include sterile solutions
ready for injection, sterile dry soluble products, such as lyophilized powders, ready to be combined
with a solvent just prior to use, including hypodermic tablets, sterile suspensions ready for injection,
sterile dry insoluble products ready to be combined with a vehicle just prior to use and sterile
emulsions. The solutions may be either aqueous or nonaqueous.
If administered intravenously, suitable carriers include physiological saline or phosphate
buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose,
polyethylene glycol, and polypropylene glycol and mixtures thereof.
Vehicles used in parenteral preparations include aqueous vehicles, nonaqueous vehicles,
antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and
dispersing agents, emulsifying agents, sequestering or chelating agents and other substances.
Examples of aqueous vehicles include Sodium Chloride Injection, Ringers Injection, Isotonic
Dextrose Injection, Sterile Water Injection, Dextrose and Lactated Ringers Injection. Nonaqueous
parenteral vehicles include fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil and
peanut oil. Antimicrobial agents in bacteriostatic or fungistatic concentrations must be added to
parenteral preparations packaged in multiple-dose containers which include phenols or cresols,
mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoic acid esters,
thimerosal, benzalkonium chloride and benzethonium chloride. Isotonic agents include sodium
chloride and dextrose. Buffers include phosphate and citrate. Antioxidants include sodium bisulfate.
Local anesthetics include procaine hydrochloride. Suspending and dispersing agents include sodium
carboxymethylcellulose, hydroxypropyl methylcellulose and polyvinylpyrrolidone. Emulsifying
agents include Polysorbate 80 (Tween 80). A sequestering or chelating agent of metal ions includes
EDTA. Carriers also include ethyl alcohol, polyethylene glycol and propylene glycol for water
miscible vehicles; and sodium hydroxide, hydrochloric acid, citric acid or lactic acid for pH
adjustment.
The concentration of compound is adjusted so that an injection provides an effective amount
to produce the desired pharmacological effect. The exact dose depends on the age, weight, body
surface area and condition of the patient or animal as is known in the art.
The unit-dose parenteral preparations are packaged in an ampoule, a vial or a syringe with a
needle. All preparations for parenteral administration must be sterile, as is known and practiced in the
art.
Illustratively, intravenous or intraarterial infusion of a sterile aqueous solution containing an
active compound is an effective mode of administration. Another embodiment is a sterile aqueous or
oily solution or suspension containing an active material injected as necessary to produce the desired
pharmacological effect.
Injectables are designed for local and systemic administration. In some embodiments, a
therapeutically effective dosage is formulated to contain a concentration of at least 0.01% w/w up to
90% w/w or more, such as more than 0.1% w/w of the active compound to the treated tissue(s).
The compound may be suspended in micronized or other suitable form or may be derivatized
to produce a more soluble active product or to produce a prodrug. The form of the resulting mixture
depends upon a number of factors, including the intended mode of administration and the solubility of
the compound in the selected carrier or vehicle. The effective concentration is sufficient for
ameliorating the symptoms of the condition and may be empirically determined.
Active ingredients provided herein can be administered by controlled release means or by
delivery devices that are well known to those of ordinary skill in the art. Examples include, but are
not limited to, those described in U.S. Patent Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598,123;
4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354,556; 5,639,480;
,733,566; 5,739,108; 5,891,474; 5,922,356; 5,972,891; 5,980,945; 5,993,855; 6,045,830; 6,087,324;
6,113,943; 6,197,350; 6,248,363; 6,264,970; 6,267,981; 6,376,461; 6,419,961; 6,589,548; 6,613,358;
6,699,500 and 6,740,634. Such dosage forms can be used to provide slow or controlled-release of one
or more active ingredients using, for example, hydroxypropylmethyl cellulose, other polymer
matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles,
liposomes, microspheres, or a combination thereof to provide the desired release profile in varying
proportions. Suitable controlled-release formulations known to those of ordinary skill in the art,
including those described herein, can be readily selected for use with the active ingredients provided
herein.
All controlled-release products have a common goal of improving drug therapy over that
achieved by their non-controlled counterparts. Ideally, the use of an optimally designed
controlled-release preparation in medical treatment is characterized by a minimum of drug substance
being employed to cure or control the condition in a minimum amount of time. Advantages of
controlled-release formulations include extended activity of the drug, reduced dosage frequency, and
increased patient compliance. In addition, controlled-release formulations can be used to affect the
time of onset of action or other characteristics, such as blood levels of the drug, and can thus affect the
occurrence of side (e.g., adverse) effects.
Most controlled-release formulations are designed to initially release an amount of drug
(active ingredient) that promptly produces the desired therapeutic effect, and gradually and
continually release of other amounts of drug to maintain this level of therapeutic or prophylactic effect
over an extended period of time. In order to maintain this constant level of drug in the body, the drug
must be released from the dosage form at a rate that will replace the amount of drug being
metabolized and excreted from the body. Controlled-release of an active ingredient can be stimulated
by various conditions including, but not limited to, pH, temperature, enzymes, water, or other
physiological conditions or compounds.
An agent may be administered using intravenous infusion, an implantable osmotic pump, a
transdermal patch, liposomes, or other modes of administration. In some embodiments, a pump may
be used (see, Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507
(1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)). In other embodiments, polymeric materials
can be used. In other embodiments, a controlled release system can be placed in proximity of the
therapeutic target, i.e., thus requiring only a fraction of the systemic dose (see, e.g., Goodson, Medical
Applications of Controlled Release, vol. 2, pp. 115-138 (1984)). In some embodiments, a controlled
release device is introduced into a subject in proximity of the site of inappropriate immune activation
or a tumor. Other controlled release systems are discussed in the review by Langer (Science
249:1527-1533 (1990)). The active ingredient can be dispersed in a solid inner matrix, e.g.,
polymethylmethacrylate, polybutylmethacrylate, plasticized or unplasticized polyvinylchloride,
plasticized nylon, plasticized polyethyleneterephthalate, natural rubber, polyisoprene,
polyisobutylene, polybutadiene, polyethylene, ethylene-vinylacetate copolymers, silicone rubbers,
polydimethylsiloxanes, silicone carbonate copolymers, hydrophilic polymers such as hydrogels of
esters of acrylic and methacrylic acid, collagen, cross-linked polyvinylalcohol and cross-linked
partially hydrolyzed polyvinyl acetate, that is surrounded by an outer polymeric membrane, e.g.,
polyethylene, polypropylene, ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers,
ethylene/vinylacetate copolymers, silicone rubbers, polydimethyl siloxanes, neoprene rubber,
chlorinated polyethylene, polyvinylchloride, vinylchloride copolymers with vinyl acetate, vinylidene
chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber epichlorohydrin
rubbers, ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl alcohol terpolymer, and
ethylene/vinyloxyethanol copolymer, that is insoluble in body fluids. The active ingredient then
diffuses through the outer polymeric membrane in a release rate controlling step. The percentage of
active ingredient contained in such parenteral compositions is highly dependent on the specific nature
thereof, as well as the needs of the subject.
Of interest herein are also lyophilized powders, which can be reconstituted for administration
as solutions, emulsions and other mixtures. They may also be reconstituted and formulated as solids
or gels.
The sterile, lyophilized powder is prepared by dissolving a compound provided herein, or a
derivative thereof, in a suitable solvent. The solvent may contain an excipient which improves the
stability or other pharmacological component of the powder or reconstituted solution, prepared from
the powder. Excipients that may be used include, but are not limited to, an antioxidant, a buffer and a
bulking agent. In some embodiments, the excipient is selected from dextrose, sorbitol, fructose, corn
syrup, xylitol, glycerin, glucose, sucrose, and other suitable agents. The solvent may contain a buffer,
such as citrate, sodium or potassium phosphate or other such buffer known to those of skill in the art
at, at neutral pH. Subsequent sterile filtration of the solution followed by lyophilization under
standard conditions known to those of skill in the art provides the desired formulation. In some
embodiments, the resulting solution will be apportioned into vials for lyophilization. Each vial will
contain a single dosage or multiple dosages of the compound. The lyophilized powder can be stored
under appropriate conditions, such as at 4 °C to room temperature.
Reconstitution of this lyophilized powder with water for injection provides a formulation for
use in parenteral administration. For reconstitution, the lyophilized powder is added to sterile water
or other suitable carrier. The precise amount depends upon the selected compound. Such amount can
be empirically determined.
Topical mixtures are prepared as described for the local and systemic administration. The
resulting mixture may be a solution, suspension, emulsions or the like and are formulated as creams,
gels, ointments, emulsions, solutions, elixirs, lotions, suspensions, tinctures, pastes, foams, aerosols,
irrigations, sprays, suppositories, bandages, dermal patches or any other formulations suitable for
topical administration.
The compounds or derivatives thereof may be formulated as aerosols for topical application,
such as by inhalation (see, e.g., U.S. Patent Nos. 4,044,126, 4,414,209, and 4,364,923, which describe
aerosols for delivery of a steroid useful for treatment of inflammatory diseases, particularly asthma).
These formulations for administration to the respiratory tract can be in the form of an aerosol or
solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an
inert carrier such as lactose. In such a case, the particles of the formulation will, in some
embodiments, have mass median geometric diameters of less than 5 microns, in other embodiments
less than 10 microns.
Oral inhalation formulations of the compounds or derivatives suitable for inhalation include
metered dose inhalers, dry powder inhalers and liquid preparations for administration from a nebulizer
or metered dose liquid dispensing system. For both metered dose inhalers and dry powder inhalers, a
crystalline form of the compounds or derivatives is the preferred physical form of the drug to confer
longer product stability.
In addition to particle size reduction methods known to those skilled in the art, crystalline
particles of the compounds or derivatives can be generated using supercritical fluid processing which
offers significant advantages in the production of such particles for inhalation delivery by producing
respirable particles of the desired size in a single step (e.g., PCT International Publication No. WO
2005/025506). A controlled particle size for the microcrystals can be selected to ensure that a
significant fraction of the compounds or derivatives is deposited in the lung. In some embodiments,
these particles have a mass median aerodynamic diameter of 0.1 microns to 10 microns, in other
embodiments, 1 micron to 5 microns and still other embodiments, 1.2 microns to 3 microns.
Inert and non-flammable HFA propellants are selected from HFA 134a
(1,1,1,2-tetrafluoroethane) and HFA 227e (1,1,1,2,3,3,3-heptafluoropropane) and provided either
alone or as a ratio to match the density of crystal particles of the compounds or derivatives. A ratio is
also selected to ensure that the product suspension avoids detrimental sedimentation or cream (which
can precipitate irreversible agglomeration) and instead promote a loosely flocculated system, which is
easily dispersed when shaken. Loosely fluctuated systems are well regarded to provide optimal
stability for pMDI canisters. As a result of the formulation's properties, the formulation contained no
ethanol and no surfactants/stabilizing agents.
The compounds may be formulated for local or topical application, such as for topical
application to the skin and mucous membranes, such as in the eye, in the form of gels, creams, and
lotions and for application to the eye or for intracisternal or intraspinal application. Topical
administration is contemplated for transdermal delivery and also for administration to the eyes or
mucosa, or for inhalation therapies. Nasal solutions of the active compound alone or in combination
with other excipients can also be administered.
For nasal administration, the preparation may contain an esterified phosphonate compound
dissolved or suspended in a liquid carrier, in particular, an aqueous carrier, for aerosol application.
The carrier may contain solubilizing or suspending agents such as propylene glycol, surfactants,
absorption enhancers such as lecithin or cyclodextrin, or preservatives.
Solutions, particularly those intended for ophthalmic use, may be formulated as from 0.01%
to 10% isotonic solutions, pH 5 to 7.4, with appropriate salts.
Other routes of administration, such as transdermal patches, including iontophoretic and
electrophoretic devices, and rectal administration, are also contemplated herein.
Transdermal patches, including iontophoretic and electrophoretic devices, are well known to
those of skill in the art. For example, such patches are disclosed in U.S. Patent Nos. 6,267,983,
6,261,595, 6,256,533, 6,167,301, 6,024,975, 6,010715, 5,985,317, 5,983,134, 5,948,433 and
,860,957.
For example, dosage forms for rectal administration are rectal suppositories, capsules and
tablets for systemic effect. Rectal suppositories are used herein mean solid bodies for insertion into
the rectum which melt or soften at body temperature releasing one or more pharmacologically or
therapeutically active ingredients. Substances utilized in rectal suppositories are bases or vehicles and
agents to raise the melting point. Examples of bases include cocoa butter (theobroma oil),
glycerin-gelatin, carbowax (polyoxyethylene glycol) and appropriate mixtures of mono-, di- and
triglycerides of fatty acids. Combinations of the various bases may be used. Agents to raise the
melting point of suppositories include spermaceti and wax. Rectal suppositories may be prepared
either by the compressed method or by molding. The weight of a rectal suppository, in one
embodiment, is 2 gm to 3 gm. Tablets and capsules for rectal administration are manufactured using
the same substance and by the same methods as for formulations for oral administration.
The compounds provided herein, or derivatives thereof, may also be formulated to be targeted
to a particular tissue, receptor, or other area of the body of the subject to be treated. Many such
targeting methods are well known to those of skill in the art. All such targeting methods are
contemplated herein for use in the instant compositions. For non-limiting examples of targeting
methods, see, e.g., U.S. Patent Nos. 6,316,652, 6,274,552, 6,271,359, 6,253,872, 6,139,865,
6,131,570, 6,120,751, 6,071,495, 6,060,082, 6,048,736, 6,039,975, 6,004,534, 5,985,307, 5,972,366,
,900,252, 5,840,674, 5,759,542 and 5,709,874.
In some embodiments, liposomal suspensions, including tissue-targeted liposomes, such as
tumor-targeted liposomes, may also be suitable as carriers. These may be prepared according to
methods known to those skilled in the art. For example, liposome formulations may be prepared as
described in U.S. Patent No. 4,522,811. Briefly, liposomes such as multilamellar vesicles (MLV's)
may be formed by drying down phosphatidyl choline and phosphatidyl serine (7:3 molar ratio) on the
inside of a flask. A solution of a compound provided herein in phosphate buffered saline lacking
divalent cations (PBS) is added and the flask shaken until the lipid film is dispersed. The resulting
vesicles are washed to remove unencapsulated compound, pelleted by centrifugation, and then re-
suspended in PBS.
The compounds or derivatives may be packaged as articles of manufacture containing
packaging material, a compound or derivative thereof provided herein, which is effective for
treatment, prevention or amelioration of one or more symptoms of the diseases or disorders, supra,
within the packaging material, and a label that indicates that the compound or composition or
derivative thereof, is used for the treatment, prevention or amelioration of one or more symptoms of
the diseases or disorders, supra.
The articles of manufacture provided herein contain packaging materials. Packaging
materials for use in packaging products are well known to those of skill in the art. See, e.g., U.S.
Patent Nos. 5,323,907, 5,052,558 and 5,033,252. Examples of packaging materials include, but are
not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, bottles,
and any packaging material suitable for a selected formulation and intended mode of administration
and treatment. A wide array of formulations of the compounds and compositions provided herein are
contemplated as are a variety of treatments for any disease or disorder described herein.
For use to treat or prevent infectious disease, the compounds or compositions described
herein, or pharmaceutical compositions thereof, can be administered or applied in a therapeutically
effective amount. In human therapeutics, the physician will determine the dosage regimen that is
most appropriate according to a preventive or curative treatment and according to the age, weight,
stage of the disease and other factors specific to the subject to be treated. The amount of active
ingredient in the formulations provided herein, which will be effective in the prevention or treatment
of an infectious disease will vary with the nature and severity of the disease or condition, and the
route by which the active ingredient is administered. The frequency and dosage will also vary
according to factors specific for each subject depending on the specific therapy (e.g., therapeutic or
prophylactic agents) administered, the severity of the infection, the route of administration, as well as
age, body, weight, response, and the past medical history of the subject.
Exemplary doses of a formulation include milligram or microgram amounts of the active
compound per kilogram of subject (e.g., from 1 microgram per kilogram to 50 milligrams per
kilogram, from 10 micrograms per kilogram to 30 milligrams per kilogram, from 100 micrograms per
kilogram to 10 milligrams per kilogram, or from 100 micrograms per kilogram to 5 milligrams per
kilogram).
In some embodiments, a therapeutically effective dosage should produce a serum
concentration of active ingredient of from 0.001 ng/mL to 50 µg/mL to 200 µg/mL. The
compositions, in other embodiments, should provide a dosage of from 0.0001 mg to 70 mg of
compound per kilogram of body weight per day. Dosage unit forms are prepared to provide from 0.01
mg to 0.1 mg, form 1 mg to 500 mg, or from 1,000 mg 5,000 mg, and in some embodiments from 10
mg to 500 mg of the active ingredient or a combination of essential ingredients per dosage unit form.
The active ingredient may be administered at once, or may be divided into a number of
smaller doses to be administered at intervals of time. It is understood that the precise dosage and
duration of treatment is a function of the disease being treated and may be determined empirically
using known testing protocols or by extrapolation from in vivo or in vitro test data or subsequent
clinical testing. It is to be noted that concentrations and dosage values may also vary with the severity
of the condition to be alleviated. It is to be further understood that for any particular subject, specific
dosage regimens should be adjusted over time according to the individual need and the professional
judgment of the person administering or supervising the administration of the compositions and that
the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or
practice of the claimed compositions.
It may be necessary to use dosages of the active ingredient outside the ranges disclosed herein
in some cases, as will be apparent to those of ordinary skill in the art. Furthermore, it is noted that the
clinician or treating physician will know how and when to interrupt, adjust, or terminate therapy in
conjunction with subject response.
For systemic administration, a therapeutically effective dose can be estimated initially from in
vitro assays. For example, a dose can be formulated in animal models to achieve a circulating
concentration range that includes the IC as determined in cell culture (i.e., the concentration of test
compound that is lethal to 50% of a cell culture), the MIC as determined in cell culture (i.e., the
minimal inhibitory concentration for growth) or the IC as determined in cell culture (i.e., the
concentration of antimicrobial sulfonamide derivative that is lethal to 100% of a cell culture). Such
information can be used to more accurately determine useful doses in humans.
Initial dosages can also be estimated from in vivo data (e.g., animal models) using techniques
that are well known in the art. One of ordinary skill in the art can readily optimize administration to
humans based on animal data.
Alternatively, initial dosages can be determined from the dosages administered of known
antimicrobial agents by comparing the IC , MIC and/or I of the specific compound disclosed
50 100
herein with that of a known antimicrobial agent, and adjusting the initial dosages accordingly. The
optimal dosage may be obtained from these initial values by routine optimization
In cases of local administration or selective uptake, the effective local concentration
compound used may not be related to plasma concentration. One of skill in the art will be able to
optimize therapeutically effective local dosages without undue experimentation.
Ideally, a therapeutically effective dose of the compounds described herein will provide
therapeutic benefit without causing substantial toxicity. Toxicity of compounds can be determined
using standard pharmaceutical procedures in cell cultures or experimental animals, e.g., by
determining the LD (the dose lethal to 50% of the population) or the LD (the dose lethal to 100%
50 100
of the population). The dose ratio between toxic and therapeutic effect is the therapeutic index.
Compounds which exhibit high therapeutic indices are preferred. The data obtained from these cell
culture assays and animal studies can be used in formulating a dosage range that is not toxic for use in
subjects. The dosage of the compounds described herein lies preferably within a range of circulating
concentrations that include the effective dose with little or no toxicity. The dosage may vary within
this range depending upon the dosage form employed and the route of administration utilized. The
exact formulation, route of administration and dosage can be chosen by the individual physician in
view of the patient's condition (See, e.g., Fingl et al., 1975, In: The Pharmacological Basis of
Therapeutics, Ch.1, p.1).
The therapy may be repeated intermittently while infections are detectable, or even when they
are not detectable. Administration of the same formulation provided herein may be repeated and the
administrations may be separated by at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days,
45 days, 2 months, 75 days, 3 months, or 6 months.
A compound of Formula (1) and/or pharmaceutical composition thereof can generally be used
in an amount effective to achieve the intended purpose. For use to treat a disease such as a bacterial
infection, a compound of Formula (1) and/or pharmaceutical compositions thereof, may be
administered or applied in a therapeutically effective amount.
The amount of a compound of Formula (1) and/or pharmaceutical composition thereof that
will be effective in the treatment of a particular disorder or condition disclosed herein will depend in
part on the nature of the disorder or condition, and can be determined by standard clinical techniques
known in the art. In addition, in vitro or in vivo assays may optionally be employed to help identify
optimal dosage ranges. The amount of a compound of Formula (1) and/or pharmaceutical
composition thereof administered will depend on, among other factors, the subject being treated, the
weight of the subject, the severity of the affliction, the manner of administration and the judgment of
the prescribing physician.
A compound of Formula (1) may be assayed in vitro and in vivo, for the desired therapeutic
activity, prior to use in humans. For example, in vitro assays may be used to determine whether
administration of a specific compound or a combination of compounds is preferred. The compounds
may also be demonstrated to be effective and safe using animal model systems.
A therapeutically effective dose of a compound of Formula (1) and/or pharmaceutical
composition thereof will provide therapeutic benefit without causing substantial toxicity. Toxicity of
compounds of Formula (1) and/or pharmaceutical compositions thereof may be determined using
standard pharmaceutical procedures and may be readily ascertained by the skilled artisan. The dose
ratio between toxic and therapeutic effect is the therapeutic index. A compound of Formula (1) and/or
pharmaceutical composition thereof exhibits a particularly high therapeutic index in treating disease
and disorders. A dose of a compound of Formula (1) and/or pharmaceutical composition thereof will
be within a range of circulating concentrations that include an effective dose with minimal toxicity.
A compound of Formula (1), a pharmaceutically acceptable salt thereof, or a pharmaceutical
composition of any of the foregoing may be included in a kit that may be used to administer the
compound to a patient for therapeutic purposes. A kit may include a pharmaceutical composition
comprising a compound of Formula (1) suitable for administration to a patient and instructions for
administering the pharmaceutical composition to the patient. A kit for use in treating a bacterial
infection in a patient comprises a compound of Formula (1) or a pharmaceutically acceptable salt
thereof, a pharmaceutically acceptable vehicle for administering the compound, and instructions for
administering the compound to a patient. Instructions supplied with a kit may be printed and/or
supplied, for example, as an electronic-readable medium, a video cassette, an audiotape, a flash
memory device, or may be published on an internet web site or distributed to a patient and/or health
care provider as an electronic communication.
The amount of a compound of Formula (1) that will be effective in the treatment of a bacterial
infection will depend, at least in part, on the nature of the disease, and may be determined by standard
clinical techniques known in the art. In addition, in vitro or in vivo assays may be employed to help
identify optimal dosing ranges. Dosing regimens and dosing intervals may also be determined by
methods known to those skilled in the art. The amount of compound of Formula (1) administered
may depend on, among other factors, the subject being treated, the weight of the subject, the severity
of the disease, the route of administration, and the judgment of the prescribing physician.
For systemic administration, a therapeutically effective dose may be estimated initially from
in vitro assays. Initial doses may also be estimated from in vivo data, e.g., animal models, using
techniques that are known in the art. Such information may be used to more accurately determine
useful doses in humans. One having ordinary skill in the art may optimize administration to humans
based on animal data.
A dose of compound of Formula (1) and appropriate dosing intervals may be selected to
maintain a sustained therapeutically effective concentration of the compound of Formula (1) in the
blood of a patient, and in certain embodiments, without exceeding a minimum adverse concentration.
Pharmaceutical compositions comprising a compound of Formula (1) may be administered
once per day, twice per day, or at intervals of more than once per day. Dosing may be provided alone
or in combination with other drugs and may continue as long as required for effective treatment of the
disease. Dosing may also be undertaken using continuous or semi-continuous administration over a
period of time. Dosing includes administering a pharmaceutical composition to a mammal, such as a
human, in a fed or fasted state.
A pharmaceutical composition may be administered in a single dosage form or in multiple
dosage forms or as a continuous or an accumulated dose over a period of time. When multiple dosage
forms are used the amount of compound of Formula (1) contained within each of the multiple dosage
forms may be the same or different.
Suitable daily dosage ranges for administration may range from 2 µg to 20 mg of a compound
of Formula (1) per kilogram body weight.
Suitable daily dosage ranges for administration may range from 1 µg to 50 mg of a compound
of Formula (1) per square meter (m ) of body surface.
A compound of Formula (1) may be administered to treat a bacterial infection in a patient in
an amount from 1 mg to 2,000 mg per day, from 100 µg to 1,500 mg per day, from 20 µg to 1,000 mg
per day, or in any other appropriate daily dose.
A pharmaceutical composition comprising a compound of Formula (1) may be administered
to treat a bacterial infection in a subject to provide a therapeutically effective concentration of a
compound of Formula (1) in the blood or plasma of the subject. A therapeutically effective
concentration of a compound of Formula (1) in the blood or plasma of a subject is from 1 μg/mL to 60
μg/mL, from 2 μg/mL to 50 μg/mL, from 5 μg/mL to 40 μg/mL, from 5 μg/mL to 20 μg/mL, or from
μg/mL to 10 μg/mL. A therapeutically effective concentration of a compound of Formula (1) in the
blood or plasma of a subject is at least 2 μg/mL, at least 5 μg/mL, at least 10 μg/mL, at least 15
μg/mL, at least 25 μg/mL, or at least 30 μg/mL. A therapeutically effective concentration of a
compound of Formula (1) in the blood or plasma of a subject is less than an amount that causes
unacceptable adverse effects including adverse effects to homeostasis. A therapeutically effective
concentration of a compound of Formula (1) in the blood or plasma of a subject is an amount
sufficient to restore and/or maintain homeostasis in the subject.
A pharmaceutical composition comprising a compound of Formula (1) may be administered
to treat a bacterial infection in a patient so as to provide a therapeutically effective concentration of a
compound of Formula (1) in the blood or plasma of a subject for an extended period of time such as,
for example, for at least 4 hours, for at least 6 hours, for at least 8 hours, for at least 10 hours, or for at
least 12 hours.
The amount of a compound of Formula (1) administered may vary during a treatment
regimen.
Pharmaceutical compositions provided by the present disclosure may further comprise one or
more pharmaceutically active compounds in addition to a compound of Formula (1). Such
compounds may be provided to treat the bacterial infection being treated with the compound of
Formula (1) or to treat a disease, disorder, or condition other than a bacterial infection being treated
with the compound of Formula (1).
The compounds and compositions described herein can be used in a wide variety of
applications to treat infectious diseases in a subject. The methods generally involve administering a
therapeutically effective amount of a compound of Formula (1) or a pharmaceutical composition
thereof to the subject, or administering a therapeutically effective amount of a compound of Formula
(1) and an antibiotic, or a pharmaceutical composition thereof to the subject.
Compounds provided by the present disclosure are prodrugs of β-lactamase inhibitors.
Compounds and compositions provided by the present disclosure can be used to treat a disease in
which the etiology of the disease is associated with the expression of β-lactamases. For example,
certain bacterial infections are resistant to β-lactamase antibiotics because β-lactamases produced by
the bacteria hydrolyze the β-lactam ring of the β-lactam antibiotic.
Compounds and compositions provided by the present disclosure can be used to treat a
bacterial disease in a patient.
Compounds and compositions provided by the present disclosure can be used to treat a
bacterial infection. For example, compounds and composition provided by the present disclosure can
be used to treat a bacterial infection associated with bacteria such as obligate aerobic bacteria, obligate
anaerobic bacteria, faculatitive anaerobic bacteria, and microaerophilic bacteria.
Examples of obligate aerobic bacteria include gram-negative cocci such as Moraxella
catarrhalis, Neisseria gonorrhoeae, and N. meningitidi; gram-positive bacilli such as
Corynebacterium jeikeium; acid-fast bacilli such as Mycobacterium avium complex, M. kansasii, M.
leprae, M. tuberculosis, and Nocardia sp; nonfermentative, non-enterobacteriaceae such as
Acinetobacter calcoaceticus, Elizabethkingia meningoseptica (previously Flavobacterium
meningosepticum), Pseudomonas aeruginosa, P. alcaligenes, other Pseudomonas sp, and
Stenotrophomonas maltophilia; fastidious gram-negative coccobacilli and bacilli such as Brucella,
Bordetella, Francisella, and Legionella spp; and treponemataceae (spiral bacteria) such as Leptospira
Examples of obligate anaerobic bacteria include gram-negative bacilli such as Bacteroides
fragilis, other Bacteroides sp, and Fusobacterium sp, Prevotella sp; gram-negative cocci such as
Veillonella sp.; gram-positive cocci such as Peptococcus niger, and Peptostreptococcus sp.; non–
spore-forming gram-positive bacilli such as Clostridium botulinum, C. perfringens, C. tetani, other
Clostridium sp; and endospore-forming gram-positive bacilli such as Clostridium botulinum, C.
perfringens, C. tetani, and other Clostridium sp.
Examples of facultative anaerobic bacteria include gram-positive cocci, catalase-positive such
as Staphylococcus aureus (coagulase-positive), S. epidermidis (coagulase-negative), and other
coagulase-negative staphylococci; gram-positive cocci, catalase-negative such as Enterococcus
faecalis, E. faecium, Streptococcus agalactiae (group B streptococcus), S. bovis, S. pneumoniae, S.
pyogenes (group A streptococcus), viridans group streptococci (S. mutans, S. mitis, S. salivarius, S.
sanguis), S. anginosus group (S. anginosus, S. milleri, S. constellatus), and Gemella morbillorum;
gram-positive bacilli such as Bacillus anthracis, Erysipelothrix rhusiopathiae, and Gardnerella
vaginalis(gram-variable); gram-negative bacilli such as Enterobacteriaceae (Citrobacter sp,
Enterobacter aerogenes, Escherichia coli, Klebsiella sp, Morganella morganii, Proteus sp,
Plesiomonas shigelloides, Providencia rettgeri, Salmonella typhi, other Salmonella sp, Serratia
marcescens, and Shigella sp, Yersinia enterocolitica, Y. pestis); fermentative, non-Enterobacteriaceae
such as Aeromonas hydrophila, Chromobacterium violaceum, and Pasteurella multocida; fastidious
gram-negative coccobacilli and bacilli such as Actinobacillus actinomycetemcomitans, Bartonella
bacilliformis, B. henselae, B. quintana, Eikenella corrodens, Haemophilus influenzae, and other
Haemophilus sp; mycoplasma such as Mycoplasma pneumoniae; and treponemataceae (spiral
bacteria) such as Borrelia burgdorferi, and Treponema pallidum.
Examples of microaerophilic bacteria include curved bacilli such as Campylobacter jejuni,
Helicobacter pylori, Vibrio cholerae, and V. vulnificus; obligate intracellular parasitic; chlamydiaceae
such as Chlamydia trachomatis, Chlamydophila pneumoniae, and C. psittaci; coxiellaceae such as
Coxiella burnetii; and rickettsiales such as Rickettsia prowazekii, R. rickettsii, R. typhi, R.
tsutsugamushi, Ehrlichia chaffeensis, and Anaplasma phagocytophilum.
Compounds and compositions provided by the present disclosure can be used to treat a
bacterial disease in which the bacteria produce a β-lactamase. Examples of bacteria that produce a β-
lactamase include Mycobacterium tuberculosis, methicillin-resistant Staphylococcus aureus,
Staphyloccus, Enterobacteriaceae, Pseudomonas aeruginosa, Haemophilus influenzae, Klebsiella
pneumoniae, Citrobacter, and Morganella.
Compounds and compositions provided by the present disclosure can be used to treat a
bacterial disease in which a β-lactamase inhibitor is effective in treating the bacterial disease such as a
bacterial infection.
An infectious disease can be a bacterial infection. A bacterial infection can be an infection of
a gram-positive bacteria. A bacterial infection can be an infection of a gram-negative bacteria.
Examples of gram-negative bacteria include Acinetobacter, Aeromonas, Bacteroides, Burkholderia,
Citrobacter, Enterobacter, Escherichia, Fusobacterium, Haemophilus, Klebsiella, Moraxella,
Morganella, Mycoplasma, Neisseria, Pantoea, Pasteurella, Plesiomonas, Porphyromonas, Prevotella,
Proteus, Providencia, Pseudomonas, Salmonella, Serratia, Shigella, Spirillum, Stenotrophomonas,
Streptobacillus, Treponema, or Yersinia. Examples of gram-negative bacteria include Acinetobacter
baumannii, Aeromonas hydrophila, Arizona hinshawii, Bacteroides fragilis, Branhamella catarrhalis,
Burkholderia cepacia, Citrobacter diversus, Citrobacter freundii, Enterobacter aerogenes,
Enterobacter cloacae, Escherichia coli, Fusobacterium nucleatum, Haemophilus influenzae,
Haemophilus parainfluenzae, Klebsiella oxytoca, Klebsiella pneumoniae, Moraxella catarrhalis,
Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Pantoea agglomerans,
Pasteurella multocida, Plesiomonas shigelloides, Prevotella melaninogenica, Proteus mirabilis,
Proteus rettgeri, Proteus vulgaris, Pseudomonas aeruginosa, Pseudomonas diminuta, Pseudomonas
fluorescens, Pseudomonas stutzeri, Salmonella enterica, Salmonella enteritidis, Salmonella typhi,
Serratia marcescens, Spirillum minus, Stenotrophomonas maltophilia, Streptobacillus moniliformis,
Treponema pallidum, or Yersinia enterocolitica.
The development of antibiotic resistance continues to grow as a problem facing patients and
clinicians. Accordingly, the U.S. Food and Drug Administration has identified the following
pathogens as presenting a potentially serious threat to public health: Acinetobacter species,
Aspergillus species, Burkholderia cepacia complex, Campylobacter species, Candida species,
Clostridium difficile, Coccidioides species, Cryptococcus species, Enterobacteriaceae (e.g.,
Klebsiella pneumoniae), Enterococcus species, Helicobacter pylori, Mycobacterium tuberculosis
complex, Neisseria gonorrhoeae, N. meningitidis, non-tuberculous mycobacteria species,
Pseudomonas species, Staphylococcus aureus, Streptococcus agalactiae, S. pneumoniae, S. pyogenes,
and Vibrio cholerae. The FDA has designated these organisms “qualifying pathogens” for purposes
of the Generating Antibiotic Incentives Now (GAIN) Act, intended to encourage development of new
antibacterial and antifungal drugs for the treatment of serious or life-threatening infections. Other
types of bacteria can be added or subtract from the list of “qualifying pathogens” and the methods
provided by the present disclosure encompass any newly added bacteria. The compounds,
compositions, methods, and kits, disclosed herein are useful for the treatment of diseases, infections,
etc. caused by many of these organisms as well.
The compounds and compositions described herein may be used treat or prevent various
diseases caused by the above bacteria. These include, but are not limited to, venereal disease,
pneumonia, complicated urinary tract infections, urinary tract infections, complicated intra-abdominal
infections and intra-abdominal infections.
Methods provided by the present disclosure can also be administered to a patient to inhibit a
β-lactamase. Compounds and compositions provided by the present disclosure can be administered to
a patient to inhibit any suitable type of β-lactamase. Examples of types of β-lactamases include
extended-spectrum β-lactamases such asTEM β-lactamases (Class A), SHV β-lactamases (Class A),
CTX-M β-lactamases (Class A), OXA β-lactamases (Class D), and other extended spectrum β-
lactamases such as PER, VEB, GES, and IBC β-lactamases; inhibitor-resistant β-lactamases; AmpC-
type- β lactamases (Class C); carbapenemases such as IMP-type carbapenemases (metallo- β-
lactamases) (Class B), VIM (verona integron-encoded metallo- β-lactamase (Class B), OXA
(oxcillinase) group β-lactamases (Class D), KPC (K. pneumoniae carbapenemase) (Class A), CMY
(Class C), SME, IMI, NMC, and CcrA , and NDM-1 (New Delhi metallo- β-lactamase) (Class B).
Examples of types of β-lactamases include cephalosporinases, penicillinases,
cephalosporinases, broad-spectrum β-lactamases, extended-spectrum β-lactamases, inhibitor-resistant
β-lactamases, carbenicillinase, cloxicillinases, oxacillinases, carbapenemases, and metalloenzymes.
Types of β-lactamases include Class A, Class B, Class C, and Class D β-lactamases.
Compounds and compositions provided by the present disclosure can be administered orally.
Compounds provided by the present disclosure, when orally administered, provide an
enhanced oral bioavailability of the β-lactamase inhibitor compared to the oral bioavailability of the
parent Β-lactamase inhibitor. For example, compounds of Formula (1) can exhibit an oral
bioavailability (%F) of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, or at least
60%.
Pharmaceutical compositions provided by the present disclosure may further comprise one or
more pharmaceutically active compounds in addition to a compound of Formula (1). Such
compounds may be provided to treat a bacterial infection being treated with the compound of Formula
(1) or to treat a disease, disorder, or condition other than the bacterial infection being treated with the
compound of Formula (1).
A compound of Formula (1) may be used in combination with at least one other therapeutic
agent. A compound of Formula (1) may be administered to a patient together with another compound
for treating a bacterial infection in the patient. The at least one other therapeutic agent may be a
different compound of Formula (1). A compound of Formula (1) and the at least one other
therapeutic agent may act additively or synergistically. The at least one additional therapeutic agent
may be included in the same pharmaceutical composition or vehicle comprising the compound of
Formula (1) or may be in a separate pharmaceutical composition or vehicle. Accordingly, methods
provided by the present disclosure further include, in addition to administering a compound of
Formula (1), administering one or more therapeutic agents effective for treating a bacterial infection
or a different disease, disorder or condition than a bacterial infection. Methods provided by the
present disclosure include administration of a compound of Formula (1) and one or more other
therapeutic agents provided that the combined administration does not inhibit the therapeutic efficacy
of a compound of Formula (1) and/or does not produce adverse combination effects.
Pharmaceutical compositions comprising a compound of Formula (1) may be administered
concurrently with the administration of another therapeutic agent, which may be part of the same
pharmaceutical composition as, or in a different pharmaceutical composition than that comprising a
compound of Formula (1). A compound of Formula (1) may be administered prior or subsequent to
administration of another therapeutic agent. In certain embodiments of combination therapy, the
combination therapy may comprise alternating between administering a compound of Formula (1) and
a composition comprising another therapeutic agent, e.g., to minimize adverse drug effects associated
with a particular drug. When a compound of Formula (1) is administered concurrently with another
therapeutic agent that potentially may produce an adverse drug effect including, for example, toxicity,
the other therapeutic agent may be administered at a dose that falls below the threshold at which the
adverse drug reaction is elicited.
Pharmaceutical compositions comprising a compound of Formula (1) may be administered
with one or more substances to enhance, modulate and/or control release, bioavailability, therapeutic
efficacy, therapeutic potency, stability, and the like of a compound of Formula (1). For example, to
enhance the therapeutic efficacy of a compound of Formula (1), a compound of Formula (1) or a
pharmaceutical composition comprising a compound of Formula (1) may be co-administered with one
or more active agents to increase the absorption or diffusion of the compound of Formula (1) from the
gastrointestinal tract to the systemic circulation, or to inhibit degradation of the compound of Formula
(1) in the blood of a subject. A pharmaceutical composition comprising a compound of Formula (1)
may be co-administered with an active agent having pharmacological effects that enhance the
therapeutic efficacy of the compound of Formula (1).
A compound of Formula (1) may be administered together with another therapeutic
compound, where the compound of Formula (1) enhances the efficacy of the other therapeutic
compound. For example, the other therapeutic compound can be an antibiotic such as a β-lactam
antibiotic, and the compound of Formula (1), which provides a systemic β-lactamase inhibitor, can
enhance the efficacy fo the β-lactam antibiotic by inhibiting the hydrolysis of the β-lactam ring by β-
lactamases.
Compounds and compositions provided by the present disclosure can be administered in
combination with an antibiotic such as a β-lactam antibiotic.
Antibiotics include, for example, aminoglycosides such as amikacin, gentamicin, neomycin,
streptomycin, and tobramycin; β-lactams (cephalosporins, first generation) such as cefadroxil,
cefazolin, cephalexin; β-lactams (cephalosporins, second generation) such as cefaclor, cefotetan,
cefoxitin, cefprozil, and cefuroxime; β-lactams (cephalosporins, third generation) such as cefotaxime,
cefpodoxime, ceftazidime, ceftibuten, and ceftriaxone; β-lactams (cephalosporins, sixth generation)
such as cefepime; β-lactams (cephalosporins, fifth generation) such as ceftaroline; β-lactams
(penicillins) such as amoxicillin, ampicillin, dicloxacillin, nafcillin, and oxacillin, penicillin G,
penicillin G benzathine, penicillin G procaine, piperacillin, and ticarcillin; β-lactam monobactams
such as aztreonam; β-lactam carbapenems such as ertapenem, imipenem, meropenem, and doripenem;
fluoroquiniolones such as ciprofloxacin, gemifloxacin, levofloxacin, moxifloxacin, norfloxacin, and
ofloxacin; macrolides such as azithromycin, clarithromycin, erythromycin, fidaxomicin, lactobionate,
gluceptate, and telithromycin; sulfonamides such as sulfisoxazole, sulfamethizole, sulfamethoxazole,
and trimethoprim; tetracyclines such as doxycycline, minocycline, tetracycline, and tigecycline; and
other antibiotics such as clindamycin, chlorramphenicol, colistin (poloymyxin E), dalbavancin,
daptomycin, fosfomycin, linezolid, metronidazole, nitrofurantoin, oritavancin, quinupristin,
dalfoprisin, rifampin, rifapentine, tedizolid, telavancin, and vancomycin. The antibiotic can be
ceftazidime.
Other examples of antibiotics include penicillins such as aminopenicillins including
amoxicillin and ampicillin, antipseudomonal penicillins including carbenicillin, peperacillin, and
ticarcillin, β-lactamase inhibitors including amoxicillin, ampicillin, piperacillin, and clavulanate,
natural penicillins including penicillin g benzathine, penicillin v potassium, and procaine penicillin,
and penicillinase resistant penicillin including oxacillin, dicloxacillin, and nafcillin; tetracyclines;
cephalosporins such as avibactam, tazobactam, cefadroxil, defazolin, cephalexin, and cefazolin;
quinolones such as lomefloxacin, ofloxacin, norfloxacin, gatifloxacin, ciprofloxacin, moxifloxacin,
levofloxacin, gemifloxacin, delafoxacin, cinoxacin, nalidixic acid, trovafloxacin, and sparfloxacin;
lincomycins such as lincomycin and clindamycin; macrolides such as detolides including
telithromycin and macrolides such as erythromycin, azithromycin, clarithromycin, and fidaxomicin;
sulfonamides such as sulfamethoxazole/trimethoprim, sulfisoxazole; glycopeptides; aminoglycosides
such as paromomycin, tobramycin, gentamycin, amikacin, kanamycin, and neomycin; and
carbapenems such as doripenem, meropenem, ertapenem, and cilastatin/imipenem. Examples of
suitable β-lactam antibiotics include penams such as β-lactamase-sensitive penams such as benzathine
penicillin, benzylpenicillin, phenoxymethyl pencillin, and procain penicillin; β-lactamase-resistant
penams such as cloxacillin, dicloxacillin, flucloxacillin, methicillin, nafcillin, oxacillin, and
temocillin; broad spectrum penams such as amoxicillin and ampicillin; extended-spectrum penams
such as mecillanam; carboxypenicillins such as carbenicillin and ticarcillin, and ureidopenicillins such
as azlocillin, mezlocillin, and peperacillin.
Examples of suitable β-lactam antibiotics include cephams such as first generation cephams
including cefazolin, cephalexin, cephalosporin C, cephalothin; second generation cephams such as
cefaclor, cefamoandole, cefuroxime, cefotetan, and cefoxitin; third generation cephams such as
cefixime, cefotaxime, cefpodoxime, ceflazidime, and ceftriaxone; fourth generation cephams such as
cefipime and cefpirome; and fifth generation cephams such as ceftaroline.
Examples of suitable β-lactam antibiotics include carbapenems and penems such as
biapenem, doripenem, ertapenem, faropenem, imipenem, meropenem, panipernem, razupenem,
tebipenem, and thienamycin.
Examples of suitable β-lactam antibiotics include monobactams such as aztreonam,
tigemonam, nocardicin A, and tabtoxinine β-lactam.
Compounds and pharmaceutical compositions provided by the present disclosure can be
administered with β-lactamase inhibitors and/or carbapenemase inhibitors or pharmaceutical
compositions thereof. Examples of suitable β-lactamase inhibitors and/or carbapenemase inhibitors
include clavulanic acid, sulbactam, avibactam, tazobactam, relebactam, vaborbactam, ETX 2514,
RG6068 (i.e., OP0565) (Livermore et al., J AntiMicrob Chemother 2015, 70: 3032) and RPX7009
(Hecker et al., J Med Chem 2015 58: 3682-3692).
Compounds and compositions provided by the present disclosure be used in combination with
one or more other active ingredients. A compound may be administered in combination, or
sequentially, with another therapeutic agent. Such other therapeutic agents include those known for
treatment, prevention, or amelioration of infectious disease.
It should be understood that any suitable combination of the compounds and pharmaceutical
compositions provided herein with one or more of the above therapeutic agents and optionally one or
more further pharmacologically active substances are considered to be within the scope of the present
disclosure. In some embodiments, the compounds and pharmaceutical compositions provided by the
present disclosure are administered prior to or subsequent to the one or more additional active
ingredients.
ASPECTS OF THE INVENTION
Aspect 1. A compound of Formula (1):
wherein,
each R is independently selected from C alkyl, or each R and the geminal carbon atom to
which they are bonded forms a C cycloalkyl ring, a C heterocycloalkyl ring, a substituted C
3-6 3-6 3-6
cycloalkyl ring, or a substituted C heterocycloalkyl ring;
R is selected from a single bond, C alkanediyl, C heteroalkanediyl, C cycloalkanediyl,
1-6 1-6 5-6
C heterocycloalkanediyl, C arenediyl, C heteroarenediyl, substituted C alkanediyl, substituted
-6 6 5-6 1-6
C heteroalkanediyl, substituted C cycloalkanediyl, substituted C heterocycloalkanediyl,
1-6 5-6 5-6
substituted C arenediyl, and substituted C heteroarenediyl;
6 5-6
3 4 4 4 4
R is selected from C alkyl, –O–C(O)–R , –S–C(O)–R , –NH–C(O)–R , –O–C(O)–O–R , –
4 4 4 4 4 4
S–C(O)–O–R , –NH–C(O)–O–R , –C(O)–O–R , –C(O)–S–R , –C(O)–NH–R , –O–C(O)–O–R , –O–
4 4 4 4 4 4
C(O)–S–R , –O–C(O)–NH–R , –S–S–R , –S–R , –NH–R , –CH(–NH )(–R ), C heterocycloalkyl,
2 5-6
C heteroaryl, substituted C cycloalkyl, substituted C heterocycloalkyl, substituted C aryl,
-6 5-6 5-6 5-6
substituted C heteroaryl, and –CH=C(R ) , wherein,
-6 2
R is selected from hydrogen, C alkyl, C heteroalkyl, C cycloalkyl, C
1-8 1-8 5-8 5-8
heterocycloalkyl, C cycloalkylalkyl, C heterocycloalkylalkyl, C aryl, C heteroaryl,
-10 5-10 6-8 5-8
C arylalkyl, C heteroarylalkyl, substituted C alkyl, substituted C heteroalkyl,
7-10 5-10 1-8 1-8
substituted C cycloalkyl, substituted C heterocycloalkyl, substituted C cycloalkylalkyl,
-8 5-8 5-10
substituted C heterocycloalkylalkyl, substituted C aryl, substituted C heteroaryl,
-10 6-8 5-8
substituted C arylalkyl, and substituted C heteroarylalkyl;
7-10 5-10
R is selected from hydrogen, C alkyl, C cycloalkyl, C cycloalkylalkyl, C
1-6 5-8 6-12 2-6
heteroalkyl, C heterocycloalkyl, C heterocycloalkylalkyl, substituted C alkyl, substituted C
-8 6-12 1-6 5-8
cycloalkyl, substituted C cycloalkylalkyl, substituted C heteroalkyl, substituted C
6-12 2-6 5-8
heterocycloalkyl, and substituted C heterocycloalkylalkyl;
6-12
R is selected from hydrogen, C alkyl, C cycloalkyl, C cycloalkylalkyl, C
1-6 5-8 6-12 2-6
heteroalkyl, C heterocycloalkyl, C heterocycloalkylalkyl, substituted C alkyl, substituted C
-8 6-12 1-6 5-8
cycloalkyl, substituted C cycloalkylalkyl, substituted C heteroalkyl, substituted C
6-12 2-6 5-8
heterocycloalkyl, and substituted C heterocycloalkylalkyl; and
6-12
A is a single bond (–) and R is hydrogen, or A is a double bond (=) and R is C alkyl.
Aspect 2. The compound of aspect 1, wherein each substituent is independently
selected from –OH, –CN, –CF , –OCF , =O, –NO , C alkoxy, C alkyl, –COOR, –NR , and –
3 3 2 1-6 1-6 2
CONR ; wherein each R is independently selected from hydrogen and C alkyl.
2 1-6
Aspect 3. The compound of any one of aspects 1 to 2, wherein each substituent is
4 4 4
independently selected from –OH, –CF , –O–CF , –NO ,–O–C(O)–R , –S–C(O)–R , –NH–C(O)–R ,
3 3 2
4 4 4 4 4 4
–O–C(O)–O–R , –S–C(O)–O–R , –NH–C(O)–O–R , –C(O)–O–R , –C(O)–S–R , –C(O)–NH–R , –
4 4 4 4 4 4 4
O–C(O)–O–R , –O–C(O)–S–R , –O–C(O)–NH–R , –S–S–R , –S–R , –NH–R , –CH(–NH )(–R ),
wherein each R is selected from hydrogen, C alkyl, and C heteroalkyl.
1-8 1-8
Aspect 4. The compound of any one of aspects 1 to 3, wherein A is a single bond (–)
and R is hydrogen.
Aspect 5. The compound of any one of aspects 1 to 4, wherein A is a double bond (=)
and R is C alkyl.
Aspect 6. The compound of any one of aspects 1 to 5, wherein the compound has the
structure of Formula (2):
Aspect 7. The compound of any one of aspects 1 to 5, wherein the compound has the
structure of Formula (2a):
(2a)
Aspect 8. The compound of any one of aspects 1 to 5, wherein the compound has the
structure of Formula (3):
Aspect 9. The compound of any one of aspects 1 to 5, wherein the compound has the
structure of Formula (3a):
(3a)
Aspect 10. The compound of any one of aspects 1 to 5, wherein the compound has the
structure of Formula (4):
Aspect 11. The compound of any one of aspects 1 to 5, wherein the compound has the
structure of Formula (5):
Aspect 12. The compound of any one of aspects 1 to 11, wherein, R is hydrogen; and R
is hydrogen.
Aspect 13. The compound of any one of aspects 1 to 12, wherein, R is C heteroalkyl
comprising a terminal amine group; and R is hydrogen.
Aspect 14. The compound of any one of aspects 1 to 13, wherein, R is –O–(CH ) –NH ;
2 2 2
and R is hydrogen.
Aspect 15. The compound of any one of aspects 1 to 14, wherein, R is C
heterocycloalkyl comprising at least one –NH– moiety; and R is hydrogen.
Aspect 16. The compound of any one of aspects 1 to 15, wherein, R is 4-yl-piperidine;
and R is hydrogen.
Aspect 17. The compound of any one of aspects 1 to 16, wherein, A is a single bond; R
is selected from hydrogen, –O–(CH ) –NH , and 4-yl-piperidine; R is hydrogen; and R is hydrogen.
2 2 2
Aspect 18. The compound of any one of aspects 1 to 17, wherein each R is
independently C alkyl.
Aspect 19. The compound of any one of aspects 1 to 18, wherein each R is methyl.
Aspect 20. The compound of any one of aspects 1 to 19, wherein each R together with
the geminal carbon atom to which they are bonded form a C cycloalkyl ring or a substituted C
3-6 3-6
cycloalkyl ring.
Aspect 21. The compound of any one of aspects 1 to 20, wherein each R together with
the geminal carbon atom to which they are bonded form a C cycloalkyl ring.
Aspect 22. The compound of any one of aspects 1 to 21, wherein each R together with
the geminal carbon atom to which they are bonded form a cyclopropyl ring, a cyclobutyl ring, a
cyclopentyl ring, or a cyclohexyl ring.
Aspect 23. The compound of any one of aspects 1 to 22, wherein each R together with
the geminal carbon atom to which they are bonded form a C heterocycloalkyl ring or a substituted
C heterocycloalkyl ring.
Aspect 24. The compound of any one of aspects 1 to 23, wherein R is a single bond.
Aspect 25. The compound of any one of aspects 1 to 24, wherein R is a single bond; and
R is C alkyl.
Aspect 26. The compound of any one of aspects 1 to 25, wherein R is selected from C
alkanediyl and substituted C alkanediyl.
Aspect 27. The compound of aspect 26, wherein the substituent group is selected from –
OH, –CN, –CF , –OCF , =O, –NO , C alkoxy, C alkyl, –COOR, –NR , and –CONR ; wherein
3 3 2 1-6 1-6 2 2
each R is independently selected from hydrogen and C alkyl.
Aspect 28. The compound of aspect 26, wherein the substituent group is selected from –
4 4 4 4 4 4
OH, –O–C(O)–R , –S–C(O)–R , –NH–C(O)–R , –C(O)–O–R , –C(O)–S–R , –C(O)–NH–R , –S–S–
4 4 4 4 4 4
R , –S–R , –NH–R , –CH(–NH )(–R ), and –CH(–NH )(–R ); and R is selected from hydrogen and
C alkyl.
Aspect 29. The compound of any one of aspects 26-28, wherein, R is substituted C
alkanediyl; and the stereochemistry of the carbon atom to which the substituent group is bonded is of
the (S) configuration.
Aspect 30. The compound of any one of aspects 26-28, wherein, R is substituted C
alkanediyl; and the stereochemistry of the carbon atom to which the substituent group is bonded is of
the (R) configuration.
Aspect 31. The compound of any one of aspects 1 to 30, wherein R is selected from C
cycloalkanediyl, C heterocycloalkanediyl, C arenediyl, and C heterocycloalkanediyl.
-6 6 5-6
Aspect 32. The compound of any one of aspects 1 to 31, wherein R is selected from –
4 4 4 4 4 4 4
O–C(O)–R , –C(O)–O–R , –S–C(O)–R , –C(O)–S–R , –S–S–R , –NH–R , and –CH(–NH )(–R ).
Aspect 33. The compound of any one of aspects 1 to 32, wherein R is –C(O)–O–R .
Aspect 34. The compound of any one of aspects 1 to 33, wherein R is selected from C
alkyl, C heteroalkyl, C cycloalkyl, C heterocycloalkyl, C aryl, C arylalkyl, substituted C
1-8 5-7 5-7 6 7-9 1-8
alkyl, substituted C heteroalkyl, substituted C cycloalkyl, substituted C heterocycloalkyl,
1-8 5-6 5-6
substituted C aryl, and C arylalkyl.
6 7-9
Aspect 35. The compound of any one of aspects 1 to 34, wherein R is selected from C
alkyl, C heteroalkyl, C arylalkyl, C heterocycloalkyl, substituted C alkyl, substituted C
1-8 7-9 5-7 1-8 1-8
heteroalkyl, substituted C arylalkyl, and substituted C heterocycloalkyl.
7-9 5-7
Aspect 36. The compound of any one of aspects 1 to 35, wherein R is selected from C
alkyl, C heteroalkyl, C arylalkyl, and C heterocycloalkyl.
1-8 7-9 5-7
Aspect 37. The compound of any one of aspects 1 to 36, wherein R is selected from
methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl isobutyl, tert-butyl, 2-methoxyethyl,
methylbenzene, oxetaneoxy-yl, cyclopentyl, cyclohexyl, and 2-pyrrolidinyl.
Aspect 38. The compound of any one of aspects 1 to 37, wherein, R is –C(O)–O–R ;
and R is selected from C alkyl, C heteroalkyl, C cycloalkyl, C heterocycloalkyl, C aryl, C
1-8 1-8 5-7 5-7 6 7-9
arylalkyl, substituted C alkyl, substituted C heteroalkyl, substituted C cycloalkyl, substituted
1-8 1-8 5-6
C heterocycloalkyl, substituted C aryl, and C arylalkyl.
-6 6 7-9
Aspect 39. The compound of any one of aspects 1 to 38, wherein, R is –C(O)–O–R ;
and R is selected from C alkyl, C heteroalkyl, C arylalkyl, C heterocycloalkyl, substituted C
1-8 1-8 7-9 5-7 1-
alkyl, substituted C heteroalkyl, substituted C arylalkyl, and substituted C heterocycloalkyl.
8 1-8 7-9 5-7
Aspect 40. The compound of any one of aspects 1 to 39, wherein, R is –C(O)–O–R ;
and R is selected from C alkyl, C heteroalkyl, C arylalkyl, and C heterocycloalkyl.
1-8 1-8 7-9 5-7
Aspect 41. The compound of any one of aspects 1 to 40, wherein each R together with
the carbon atom to which they are bonded form a C heterocycloalkyl ring comprising two adjacent
S atoms or a substituted C heterocycloalkyl ring comprising at least one heteroatom selected from O
and S, and a =O substituent group bonded to a carbon atom adjacent the at least one heteroatom.
Aspect 42. The compound of any one of aspects 1 to 41, wherein, R is a single bond; R
is C alkyl; and each R together with the carbon atom to which they are bonded form a C
1-3 4-6
heterocycloalkyl ring or a substituted C heterocycloalkyl ring.
Aspect 43. The compound of any one of aspects 1 to 42, wherein, R is a single bond; R
is C alkyl; and each R together with the carbon atom to which they are bonded form a C
1-3 4-6
heterocycloalkyl ring comprising two adjacent S atoms or a substituted C heterocycloalkyl ring
comprising at least one heteroatom selected from O and S, and a =O substituent group bonded to a
carbon atom adjacent the heteroatom.
Aspect 44. The compound of any one of aspects 1 to 43, wherein, R is a single bond; R
is C alkyl; and each R together with the carbon atom to which they are bonded form a 1,2-
dithiolante, 1,2-dithane ring, thietanone ring, dihydrothiophen-2(3H)-one ring, tetrahydro-2H-
thipyranone ring, oxetanone ring dihydrofuran-2(3H)-one ring, or tetrahydro-2H-pyranone
ring.
Aspect 45. The compound of any one of aspects 1 to 44, wherein, each R is methyl; R
is selected from a single bond, methanediyl, ethanediyl, –CH(–OH)–, –CH(–O–C(O)–CH CH )–, and
3 4 4 4 4
1,2-benzene-diyl; and R is selected from –O–C(O)–R , –C(O)–O–R , –S–C(O)–R , –C(O)–S–R , –
4 4 4 4
S–S–R , –NHR , and –CH(–NH )(–R ); wherein R is selected from C alkyl, C heteroalkyl, C
2 1-8 1-8 7-9
arylalkyl, and C heterocycloalkyl.
Aspect 46. The compound of any one of aspects 1 to 45, wherein, each R is methyl; R
is selected from a single bond, methanediyl, ethanediyl, –CH(–OH)–, –CH(–O–C(O)–CH CH )–, and
3 4 4
1,2-benzene-diyl; and R is selected from –C(O)–O–R ; wherein R is selected from C alkyl, C
1-8 1-8
heteroalkyl, C arylalkyl, and C heterocycloalkyl.
7-9 5-7
Aspect 47. The compound of any one of aspects 1 to 46, wherein, each R is methyl; R
is selected from a single bond, methanediyl, ethanediyl, –CH(–OH)–, –CH(–O–C(O)–CH CH )–, and
3 4 4 4 4
1,2-benzene-diyl; and R is selected from –O–C(O)–R , –C(O)–O–R , –S–C(O)–R , –C(O)–S–R , –
4 4 4 4
S–S–R , –NHR , and –CH(–NH )(–R ); wherein R is selected from methyl, ethyl, n-propyl,
isopropyl, n-butyl, sec-butyl isobutyl, tert-butyl, 2-methoxyethyl, methylbenzene, oxetaneoxy-yl,
cyclopentyl, cyclohexyl, and 2-pyrrolidinyl.
Aspect 48. The compound of any one of aspects 1 to 47, wherein, each R is methyl; R
is selected from a single bond, methanediyl, ethanediyl, –CH(–OH)–, –CH(–O–C(O)–CH CH )–, and
3 4 4
1,2-benzene-diyl; and R is selected from –C(O)–O–R ; wherein R is selected from methyl, ethyl, n-
propyl, isopropyl, n-butyl, sec-butyl isobutyl, tert-butyl, 2-methoxyethyl, methylbenzene, oxetane
oxy-yl, cyclopentyl, cyclohexyl, and 2-pyrrolidinyl.
Aspect 49. The compound of any one of aspects 1 to 48, wherein A is a single bond, and
6 7
each of R , R , and R is hydrogen.
Aspect 50. The compound of any one of aspects 1 to 49, wherein, A is a single bond;
1 2 5 6 7
each R is independently C alkyl; each R is a single bond; and each of R , R , and R is hydrogen.
Aspect 51. The compound of any one of aspects 1 to 50, wherein, each R is methyl; R
3 4 4
is a single bond; and R can be–C(O)–O–R ; wherein R is selected from C alkyl, C heteroalkyl,
1-10 1-10
C alkylarene, and C heteroalkylcycloalkyl.
7-10 5-10
Aspect 52. The compound of any one of aspects 1 to 51, wherein, each R is methyl; R
3 4 4
is a single bond; R can be–C(O)–O–R ; wherein R is selected from C alkyl, C heteroalkyl, C
1-10 1-10 7-
6 7
alkylarene, and C heteroalkylcycloalkyl; each of R , R , and R is hydrogen; and A is a single
5-10
bond.
Aspect 53. The compound of aspect 1, wherein the compound is selected from:
3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2-dimethylpropyl benzoate (2);
ethyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (3);
benzyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (4);
4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
3,3-dimethylbutyl benzoate (6);
4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
3,3-dimethylbutyl propionate (7);
benzyl (4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-3,3-dimethylbutyl) adipate (8);
6-(4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
3,3-dimethylbutoxy)oxohexanoic acid (9);
methyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (10);
isopropyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (11);
hexyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (12);
heptyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (13);
tert-butyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (14);
2-methoxyethyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (15);
oxetanyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (16);
ethyl 1-((((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)cyclohexanecarboxylate (17);
ethyl 1-((((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)cyclopropanecarboxylate (18);
ethyl 1-((((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)cyclobutanecarboxylate (19);
(1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl 1H-imidazolesulfonate
(34);
ethyl 5-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-4,4-dimethylpentanoate (35);
hexyl 5-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-4,4-dimethylpentanoate (36);
heptyl 5-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-4,4-dimethylpentanoate (37);
2-methoxyethyl 5-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-4,4-dimethylpentanoate (38);
-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2,4,4-tetramethylpentyl propionate (39);
-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2,4,4-tetramethylpentyl benzoate (40);
-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2,4,4-tetramethylpentyl 2,6-dimethylbenzoate (41);
(1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl ((3-methyl
oxotetrahydrofuranyl)methyl) sulfate (42);
3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2-dimethylpropyl pivalate (43);
3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2-dimethylpropyl 3-chloro-2,6-dimethoxybenzoate (44);
4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2,3,3-tetramethylbutyl 2,6-dimethylbenzoate (45);
4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2,3,3-tetramethylbutyl benzoate (46);
4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2,3,3-tetramethylbutyl propionate (47);
(1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl ((3-methyl
oxotetrahydro-2H-pyranyl)methyl) sulfate (48);
2-(3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2-dimethylpropyl)phenyl acetate (49);
2-(3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2-dimethylpropyl)phenyl pivalate (50);
(4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
3,3-dimethylbutyl) ethanethioate (51);
S-(5-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
4,4-dimethylpentyl) ethanethioate (52);
S-(3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2-dimethylpropyl) ethanethioate (53);
3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2-dimethylpropyl 2,6-dimethylbenzoate (54);
3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2-dimethylpropyl adamantanecarboxylate (55);
diethyl 2-((((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)methylmalonate (56);
propyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (57);
butyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (58);
(5-methyloxo-1,3-dioxolyl)methyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-
diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (59);
4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
3,3-dimethylbutyl pivalate (60);
ethyl 2-((((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)ethylbutanoate (61);
4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
3,3-dimethylbutyl 2,6-dimethylbenzoate (62);
4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
3,3-dimethylbutyl adamantanecarboxylate (63);
4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
3,3-dimethylbutyl 2,6-dimethoxybenzoate (64);
-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
4,4-dimethylpentyl benzoate (65);
-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
4,4-dimethylpentyl 2,6-dimethoxybenzoate (66);
-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
4,4-dimethylpentyl 2,6-dimethylbenzoate (67);
-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
4,4-dimethylpentyl 2-methylbenzoate (68);
4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2,3,3-tetramethylbutyl 3-chloro-2,6-dimethoxybenzoate (69);
2-((((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)methylpropane-1,3-diyl dibenzoate (70);
2-((((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)methylpropane-1,3-diyl diacetate (71);
-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2,4,4-tetramethylpentyl 2,6-dimethoxybenzoate (72);
ethyl 3-((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylbutanoate (73);
(1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl ((3,5,5-trimethyl
oxotetrahydrofuranyl)methyl) sulfate (74);a pharmaceutically acceptable salt of any of the
foregoing; and
a combination of any of the foregoing.
Aspect 54. A pharmaceutical composition comprising the compound of any one of
aspects 1 to 53 and a pharmaceutically acceptable vehicle.
Aspect 55. The pharmaceutical composition of aspect 54, further comprising an
antibiotic.
Aspect 56. The pharmaceutical composition of aspect 55, wherein the antibiotic
comprises a β-lactam antibiotic.
Aspect 57. The pharmaceutical composition of any one of aspects 54 to 56, wherein the
pharmaceutical composition comprises an oral dosage formulation.
Aspect 58. The pharmaceutical composition of any one of aspects 54 to 57, wherein the
pharmaceutical composition comprises an oral dosage form.
Aspect 59. The pharmaceutical composition of any one of aspects 54 to 58, comprising
an amount of the compound of claim 1 effective for treating a bacterial infection in a patient.
Aspect 60. A method of treating a bacterial infection in a patient comprising
administering to a patient in need of such treatment a therapeutically effective amount of the
compound of any one of aspects 1 to 53.
Aspect 61. The method of aspect 60, wherein administering comprises orally
administering.
Aspect 62. The method of any one of aspects 60 to 61, wherein administering comprises
administering an oral dosage form.
Aspect 63. The method of any one of aspects 60 to 62, further comprising administering
an antibiotic to the patient.
Aspect 64. The method of any one of aspects 60 to 63, wherein the antibiotic comprises
a β-lactam antibiotic.
Aspect 65. A method of treating a bacterial infection in a patient comprising
administering to a patient in need of such treatment a therapeutically effective amount of the
pharmaceutical composition of any one of aspects 54 to 59.
Aspect 66. The method of aspect 65, wherein administering comprises orally
administering.
Aspect 67. The method of any one of aspects 65 to 66, wherein administering comprises
administering an oral dosage form.
Aspect 68. The method of any one of aspects 65 to 67, further comprising administering
an antibiotic to the patient.
Aspect 69. The method of aspect 66, wherein the antibiotic comprises a β-lactam
antibiotic.
Aspect 70. A method of inhibiting a β-lactamase in a patient comprising administering to
the patient an effective amount of the compound of any one of aspects 1 to 53.
Aspect 71. The method of aspect 70, wherein administering comprises orally
administering.
Aspect 72. The of any one of aspects 70 to 71, wherein administering comprises
administering an oral dosage form.
Aspect 73 A method of inhibiting a β-lactamase in a patient comprising administering to
the patient an effective amount of the pharmaceutical composition of any one of aspects 54 to 59.
Aspect 74. The method of aspect 73, wherein administering comprises orally
administering.
Aspect 75. The method of any one of aspects 73 to 74, wherein administering comprises
administering an oral dosage form.
Aspect 76. A compound of Formula (1):
or a pharmaceutically acceptable salt thereof, wherein,
6 7
each of R , R , and R is hydrogen;
A is a single bond;
each R is independently selected from C alkyl, or each R together with the carbon
atom to which they are bonded form a C cycloalkyl ring;
R is selected from single bond, methane-diyl, and ethane-diyl; and
3 4 4 4
R is selected from –C(O)–O–R and –S–C(O)–R , wherein R is selected from C
1-10
alkyl, C heteroalkyl, C arylalkyl, C heterocycloalkyl, and substituted C
1-10 5-10 3-6 4-10
heterocycloalkylalkyl.
Aspect 77. The compound of aspect 76, wherein each R is independently selected from
C alkyl.
Aspect 78. The compound of aspect 76, wherein each R together with the carbon atom
to which they are bonded form a C cycloalkyl ring.
Aspect 79. The compound of aspect 76, wherein R a single bond.
Aspect 80. The compound of any one of aspects 76 to 79, wherein R is methane-diyl.
Aspect 81. The compound of any one of aspects 76 to 79, wherein R is ethane-diyl.
Aspect 82. The compound of any one of aspects 76 to 81, wherein R is –C(O)–O–R .
Aspect 83. The compound of any one of aspects 76 to 81, wherein R is –S–C(O)–R .
Aspect 84. The compound of any one of aspects 76 to 83, wherein R is C alkyl.
1-10
Aspect 85. The compound of any one of aspects 76 to 83, wherein R is C heteroalkyl.
1-10
Aspect 86. The compound of any one of aspects 76 to 83, wherein R is C arylalkyl.
-10
Aspect 87. The compound of any one of aspects 76 to 83, wherein R is C
heterocycloalkyl.
Aspect 88. The compound of any one of aspects 76 to 83, wherein R is substituted C
4-10
heterocycloalkylalkyl.
Aspect 89. A compound of Formula (1):
or a pharmaceutically acceptable salt thereof, wherein,
6 7
each of R , R , and R is hydrogen;
A is a single bond;
each R is independently selected from C alkyl, or each R together with the carbon
atom to which they are bonded form a C cycloalkyl ring;
R is a single bond; and
3 4 4
R is –C(O)–O–R , where R is selected from C alkyl, C heteroalkyl, C
1-10 1-10 5-10
arylalkyl, C heterocycloalkyl, and substituted C heterocycloalkylalkyl.
3-6 4-10
Aspect 90. The compound of aspect 89, wherein each R is independently selected from
C alkyl.
Aspect 91. The compound of aspect 89, wherein each R together with the carbon atom
to which they are bonded form a C cycloalkyl ring.
Aspect 92. The compound of any one of aspects 89 to 91, wherein R is selected from
C alkyl, C heteroalkyl wherein the one or more heteroatoms is oxygen, –CH –C cycloalkyl, –
1-7 1-10 2 4-6
(CH ) –C cycloalkyl, C heterocycloalkyl wherein the one or more heteroatoms is oxygen, and –
2 2 4-6 3-6
CH –C substituted heterocycloalkyl, and –(CH ) –C substituted heterocycloalkyl.
2 3-6 2 2 3-6
Aspect 93. The compound of aspect 92, wherein in the substituted C heterocycloalkyl
the one or more heteroatoms is oxygen, and the one or more substituents is independently selected
from C alkyl and =O.
Aspect 94. The compound of any one of aspects 89 to 94, wherein each R is methyl, or
each R together with the carbon atom to which they are bonded form a cyclohexyl ring or a
cyclopentyl ring.
Aspect 95. The compound of any one of aspects 89 to 95, wherein R is selected from
methyl, ethyl, n-propyl, iso propyl, n-butyl, n-hexyl, n-heptyl, –CH –CH –O–CH , benzyl, 3-
2 2 3
oxetanyl, and methylmethyl-1,3-dioxolone.
Aspect 96. The compound of aspect 89, wherein
6 7
each of R , R , and R is hydrogen;
A is a single bond;
each R is methyl, or each R together with the carbon atom to which they are bonded form a
cyclohexyl ring or a cyclopentyl ring;
R is a single bond; and
3 4 4
R is –C(O)–O–R , wherein R is selected from methyl, ethyl, n-propyl, iso propyl, n-butyl, n-
hexyl, n-heptyl, –CH –CH –O–CH , –CH -phenyl (benzyl), 3-oxetanyl, and methylmethyl-1,3-
2 2 3 2
dioxolone.
Aspect 97. A compound of Formula (1):
or a pharmaceutically acceptable salt thereof, wherein,
6 7
each of R , R , and R is hydrogen;
A is a single bond;
each R is independently selected from C alkyl, or each R together with the carbon
atom to which they are bonded form a C cycloalkyl ring;
R is –(CH ) –; and
3 4 4
R is –C(O)–O–R wherein R is selected from C alkyl, C heteroalkyl, C
1-10 1-10 5-10
arylalkyl, C heterocycloalkyl, and substituted C heterocycloalkylalkyl.
3-6 4-10
Aspect 98. The compound of aspect 97, wherein each R is independently selected from
C alkyl.
Aspect 99. The compound of aspect 97, wherein each R together with the carbon atom
to which they are bonded form a C cycloalkyl ring.
Aspect 100. The compound of any one of aspects 97 to 99, wherein R is selected from
C alkyl, C heteroalkyl wherein the one or more heteroatoms is oxygen, –CH –C cycloalkyl, –
1-7 1-10 2 4-6
(CH ) –C cycloalkyl, C heterocycloalkyl wherein the one or more heteroatoms is oxygen, –CH –
2 2 4-6 3-6 2
C substituted heterocycloalkyl, and –(CH ) –C substituted heterocycloalkyl.
3-6 2 2 3-6
Aspect 101. The compound of aspect 100, wherein in the substituted C heterocycloalkyl
the one or more heteroatoms is oxygen, and the one or more substituents is independently selected
from C alkyl and =O.
Aspect 102. The compound of any one of aspects 97 to 99, wherein R is C alkyl.
1-10
Aspect 103. The compound of aspect 97, wherein,
6 7
each of R , R , and R is hydrogen;
A is a single bond;
each R is methyl;
R is –(CH ) –; and
3 4 4
R is –C(O)–O–R where R is selected from n-hexyl and n-heptyl.
Aspect 104. A compound of Formula (1):
or a pharmaceutically acceptable salt thereof, wherein,
6 7
each of R , R , and R is hydrogen;
A is a single bond;
each R is selected from C alkyl, or each R together with the carbon atom to which
they are bonded form a C cycloalkyl ring;
R is –CH –; and
3 4 4
R is –S–C(O)–R , wherein R is selected from C alkyl, C heteroalkyl, C
1-10 1-10 5-10
arylalkyl, C heterocycloalkyl, substituted C heterocycloalkylalkyl.
3-6 4-10
Aspect 105. The compound of aspect 104, wherein each R is independently selected from
C alkyl.
Aspect 106. The compound of aspect 104, wherein each R together with the carbon atom
to which they are bonded form a C cycloalkyl ring.
Aspect 107. The compound of any one of aspects 104 to 106, wherein R is selected from
C alkyl, C heteroalkyl wherein the one or more heteroatoms is oxygen, –CH –C cycloalkyl, –
1-7 1-10 2 4-6
(CH ) –C cycloalkyl, C heterocycloalkyl wherein the one or more heteroatoms is oxygen, –CH –
2 2 4-6 3-6 2
C substituted heterocycloalkyl, –(CH ) –C substituted heterocycloalkyl.
3-6 2 2 3-6
Aspect 108. The compound of aspect 107, wherein, in the substituted C
heterocycloalkyl the one or more heteroatoms is oxygen, and the one or more substituents is
independently selected from C alkyl and =O.
Aspect 109. The compound of any one of aspects 104 to 106, wherein R is C alkyl.
1-10
Aspect 110. The compound of aspect 104, wherein,
6 7
each of R , R , and R is hydrogen;
A is a single bond;
each R is methyl;
R is –CH –; and
3 4 4
R is –S–C(O)–R , wherein R is methyl
Aspect 111. A compound of Formula (1):
or a pharmaceutically acceptable salt thereof, wherein,
6 7
each of R , R , and R is hydrogen;
A is a single bond;
each R together with the carbon atom to which they are bonded form a C
cycloalkyl ring, a C heterocycloalkyl ring, a C cycloalkyl ring, or a C heterocycloalkyl
3-6 3-6 3-6
ring;
R is a single bond; and
R is C alkyl.
Aspect 112. The compound of aspect 111 wherein each R together with the carbon atom
to which they are bonded form a C heterocycloalkyl ring or a C heterocycloalkyl ring;
3-6 3-6
Aspect 113. The compound of aspect 112, wherein the one or more heteroatoms is oxygen
and the one or more substituents is =O.
Aspect 114. The compound of aspect 111, wherein,
each R together with the carbon atom to which they are bonded form a dihydrofuran-2(3H)-
one ring;
R is a single bond; and
R is methyl.
Aspect 115. A compound of Formula (1):
or a pharmaceutically acceptable salt thereof, wherein,
6 7
each of R , R , and R is hydrogen;
A is a single bond;
each R is independently selected from C alkyl;
R is selected from a single bond and methanediyl; and
3 4 4 4
R is selected from –O–C(O)–R and –C(O)–O–R , wherein R is selected from C
1-10
alkyl and substituted phenyl.
Aspect 116. The compound of aspect 115, wherein R is a single bond.
Aspect 117. The compound of aspect 115, wherein R is methanediyl.
Aspect 118. The compound of any one of aspects 115 to 117, wherein R is –O–C(O)–R .
Aspect 119. The compound of any one of aspects 115 to 117, wherein R is methanediyl;
and R is –O–C(O)–R .
Aspect 120. The compound of any one of aspects 115 to 117, wherein R is –C(O)–O–R .
Aspect 121. The compound of any one of aspects 115 to 117, wherein R is a single bond;
and R is –C(O)–O–R .
Aspect 122. The compound of aspect 115, wherein R is a single bond; R is –C(O)–O–
R ; and R is C alkyl.
Aspect 123. The compound of any one of aspects 115 to 122, wherein R is C alkyl.
1-10
Aspect 124. The compound of any one of aspects 115 to 122, wherein R is C alkyl.
Aspect 125. The compound of any one of aspects 115 to 122, wherein R is substituted
phenyl.
2 3 4
Aspect 126. The compound of aspect 115, wherein R is methanediyl; R is –O–C(O)–R ;
and R is substituted phenyl.
Aspect 127. The compound of aspect 126, wherein the one or more substituents is
independently selected from halogen, C alkyl, and C alkoxy.
1-3 1-3
Aspect 128. The compound of aspect 126, wherein the substituted phenyl is 2,6-
substituted phenyl.
Aspect 129. The compound of aspect 128, wherein each of the substituents is selected
from C alkyl and C alkoxy.
1-3 1-3
Aspect 130. The compound of aspect 126, wherein the substituted phenyl is 2,5,6-
substituted phenyl.
Aspect 131. The compound of aspect 130, wherein each of the substituents at the 2 and 6
positions is independently selected from C alkyl and C alkoxy; and the substituent at the 5
1-3 1-3
position is halogen.
Aspect 132. A compound of Formula (1):
or a pharmaceutically acceptable salt thereof, wherein,
6 7
each of R , R , and R is hydrogen;
A is a single bond;
each R is independently selected from C alkyl;
R is a single bond; and
3 4 4 8 4
R is –CH=C(R ) , wherein each R is –C(O)–O–R , or each R together with the
carbon atom to which they are bonded from a substituted heterocyclohexyl ring; and
each R is C alkyl.
Aspect 133. The compound of aspect 132, each R is –C(O)–O–R .
4 8 4
Aspect 134. The compound of aspect 132, each R is –C(O)–O–R , or each R together
with the carbon atom to which they are bonded from a substituted heterocyclohexyl ring.
Aspect 135. The compound of aspect 133, wherein in the substituted heterocyclohexyl
ring, the one or more heteroatoms is oxygen.
Aspect 136. The compound of any one of aspects 134 to 135, wherein in the substituted
heterocyclohexyl ring, the one or more substituents is independently selected from C alkyl and =O.
Aspect 137. The compound of aspect 134, wherein the substituted heterocycloalkyl ring is
2,2-dimethylyl-1,3-dioxane-4,6-dione.
Aspect 138. A compound of Formula (1):
or a pharmaceutically acceptable salt thereof, wherein,
6 7
each of R , R , and R is hydrogen;
A is a single bond;
each R is independently selected from C alkyl;
R is selected from a single bond and methanediyl; and
R is substituted phenyl, wherein the one or more substituents is independently
4 4 4
selected from –CH –O–C(O)–R and –O–C(O)–R , wherein R is selected from C alkyl
2 1-10
and phenyl.
Aspect 139. The compound of aspect 138, wherein R is a single bond.
Aspect 140. The compound of aspect 138, wherein R is methanediyl;
Aspect 141. The compound of aspect 138, wherein R is 2-substituted phenyl.
Aspect 142. The compound of any one of aspects 138 to 141, wherein the one or more
substituents is –CH –O–C(O)–R .
Aspect 143. The compound of any one of aspects 138 to 141, wherein the one or more
substituents is –O–C(O)–R .
Aspect 144. The compound of any one of aspects 138 to 143, wherein R is C alkyl.
1-10
Aspect 145. The compound of any one of aspects 138 to 143, wherein R is selected from
methyl, ethyl, iso-propyl, pivalolyl, and phenyl.
Aspect 146. A compound of Formula (1):
or a pharmaceutically acceptable salt thereof, wherein,
6 7
each of R , R , and R is hydrogen;
A is a single bond;
each R is independently selected from C alkyl;
2 8 8 8
R is selected from –C(R ) – and –CH –C(R ) –, wherein each R is independently
2 2 2
selected from C alkyl; and
3 4 4 4
R is selected from –C(O)–O–R and –O–C(O)–R , wherein R is selected from C
1-10
alkyl, C heteroalkyl, substituted C alkyl, substituted C heteroalkyl, and 4(yl-methyl)-
1-10 1-10 1-10
-methyl-1,3-dioxolone.
Aspect 147. The compound of aspect 146, wherein each R is methyl.
Aspect 148. The compound of any one of aspects 146 to 147, wherein R is –C(R ) –.
Aspect 149. The compound of any one of aspects 146 to 147, wherein R is –CH –C(R ) –
Aspect 150. The compound of any one of aspects 146 to 149, wherein each R is methyl.
Aspect 151. The compound of any one of aspects 146 to 149, wherein each R is methyl;
and each R is methyl.
Aspect 152. The compound of any one of aspects 146 to 151, wherein R is –C(O)–O–R .
Aspect 153. The compound of any one of aspects 146 to 151, wherein R is –O–C(O)–R .
Aspect 154. A compound of Formula (1):
or a pharmaceutically acceptable salt thereof, wherein,
6 7
each of R , R , and R is hydrogen;
A is a single bond;
each R together with the carbon atom to which they are bonded form a substituted
C heterocyclic ring;
R is a single bond; and
R is C alkyl.
Aspect 155. The compound of aspect 155, wherein in the substituted C heterocyclic
ring, the one or more heteroatoms is oxygen; and the one or more substituents is independently
selected from C alkyl and =O.
Aspect 156. The compound of aspect 155, wherein each R together with the carbon atom
to which they are bonded form a tetrahydro-2H-pyranone ring.
Aspect 157. The compound of aspect 155, wherein,
6 7
each of R , R , and R is hydrogen;
A is a single bond;
each R is independently selected from C alkyl;
R is selected from C alkanediyl; and
R is substituted C heterocycloalkyl, wherein the one or more heteroatoms is independently
selected from N and O; and the one or more substituents is independently selected from C alkyl and
Aspect 158. The compound of aspect 157, wherein R has the structure of Formula (6):
wherein R is selected from hydrogen, C alkyl, C cycloalkyl, C heteroalkyl, C
1-6 4-6 1-6 4-6
heterocycloalkyl, substituted C alkyl, substituted C cycloalkyl, substituted C heteroalkyl, and
1-6 4-6 1-6
substituted C heterocycloalkyl.
Aspect 159. The compound of aspect 158, wherein R is selected from hydrogen and C
alkyl.
Aspect 160. The compound of aspect 1, wherein the compound is selected from:
ethyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (3);
benzyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (4);
methyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (10);
isopropyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (11);
hexyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (12);
heptyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (13);
tert-butyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (14);
2-methoxyethyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (15);
oxetanyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (16);
ethyl 1-((((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)cyclohexanecarboxylate (17);
ethyl 1-((((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)cyclopropanecarboxylate (18);
ethyl 1-((((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)cyclobutanecarboxylate (19);
hexyl 5-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-4,4-dimethylpentanoate (36);
heptyl 5-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-4,4-dimethylpentanoate (37);
(1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl ((3-methyl
oxotetrahydrofuranyl)methyl) sulfate (42);
S-(3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-
2,2-dimethylpropyl) ethanethioate (53);
propyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (57);
butyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (58);
(5-methyloxo-1,3-dioxolyl)methyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-
diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (59);
a pharmaceutically acceptable salt of any of the foregoing; and
a combination of any of the foregoing.
Aspect 161. A compound of Formula (4):
or a pharmaceutically acceptable salt thereof, wherein,
each R is independently selected from C alkyl, or each R together with the carbon
atom to which they are bonded form a C cycloalkyl ring;
R is a single bond; and
3 4 4
R is –C(O)–O–R , wherein R is selected from C alkyl, C heteroalkyl, C
1-10 1-10 5-10
arylalkyl, C heterocycloalkyl, and substituted C heterocycloalkylalkyl.
3-6 4-10
Aspect 162. The compound of aspect 161, wherein each R is independently selected from
C alkyl.
Aspect 163. The compound of aspect 161, wherein each R together with the carbon atom
to which they are bonded form a C cycloalkyl ring.
Aspect 164. The compound of any one of aspects 161 to 163, wherein R is selected from
C alkyl, C heteroalkyl wherein the one or more heteroatoms is oxygen, –CH –C cycloalkyl, –
1-7 1-10 2 4-6
(CH ) –C cycloalkyl, C heterocycloalkyl wherein the one or more heteroatoms is oxygen, –CH –
2 2 4-6 3-6 2
C substituted heterocycloalkyl, and –(CH ) –C substituted heterocycloalkyl.
3-6 2 2 3-6
Aspect 165. The compound of aspect 163, wherein in the substituted C heterocycloalkyl
the one or more heteroatoms is oxygen, and the one or more substituents is independently selected
from C alkyl and =O.
Aspect 166. The compound of aspect 161, wherein each R is methyl, or each R together
with the carbon atom to which they are bonded form a cyclohexyl ring or a cyclopentyl ring.
Aspect 167. The compound of any one of aspects 161 to 166, wherein R is selected from
methyl, ethyl, n-propyl, iso propyl, n-butyl, n-hexyl, n-heptyl, –CH –CH –O–CH , benzyl, 3-
2 2 3
oxetanyl, and methylmethyl-1,3-dioxolone.
Aspect 168. The compound of aspect 161, wherein,
6 7
each of R , R , and R is hydrogen;
A is a single bond;
R is a single bond; and
3 4 4
R is –C(O)–O–R , wherein R is C alkyl.
1-10
Aspect 169. A compound of Formula (4) is selected from:
ethyl2,2-dimethyl(((((1R,2S,5R)oxo(piperidinylcarbamoyl)-1,6-
diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)propanoate (20);
2-methoxyethyl 2,2-dimethyl(((((1R,2S,5R)oxo(piperidinylcarbamoyl)-1,6-
diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)propanoate (21);
4-((1R,2S,5R)(((3-(hexyloxy)-2,2-dimethyloxopropoxy)sulfonyl)oxy)oxo-1,6-
diazabicyclo[3.2.1]octanecarboxamido)piperidinium 2,2,2-trifluoroacetate (22);
4-((1R,2S,5R)(((3-(heptyloxy)-2,2-dimethyloxopropoxy)sulfonyl)oxy)oxo-1,6-
diazabicyclo[3.2.1]octanecarboxamido)piperidinium 2,2,2-trifluoroacetate (23);
4-((1R,2S,5R)((((1-(ethoxycarbonyl)cyclohexyl)methoxy)sulfonyl)oxy)oxo-1,6-
diazabicyclo[3.2.1]octanecarboxamido)piperidinium 2,2,2-trifluoroacetate (24);
(5-methyloxo-1,3-dioxolyl)methyl 2,2-dimethyl(((((1R,2S,5R)oxo(piperidin
ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)propanoate (25);
a pharmaceutically acceptable salt of any of the foregoing; and
a combination of any of the foregoing.
Aspect 170. A compound of Formula (4) is selected from:
ethyl2,2-dimethyl(((((1R,2S,5R)oxo(piperidinylcarbamoyl)-1,6-
diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)propanoate (20);
4-((1R,2S,5R)(((3-(hexyloxy)-2,2-dimethyloxopropoxy)sulfonyl)oxy)oxo-1,6-
diazabicyclo[3.2.1]octanecarboxamido)piperidinium 2,2,2-trifluoroacetate (22);
4-((1R,2S,5R)(((3-(heptyloxy)-2,2-dimethyloxopropoxy)sulfonyl)oxy)oxo-1,6-
diazabicyclo[3.2.1]octanecarboxamido)piperidinium 2,2,2-trifluoroacetate (23);
(5-methyloxo-1,3-dioxolyl)methyl 2,2-dimethyl(((((1R,2S,5R)oxo(piperidin
ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)propanoate (25);
a pharmaceutically acceptable salt of any of the foregoing; and
a combination of any of the foregoing.
Aspect 171. A compound of Formula (5) is selected from:
ethyl 3-(((((1R,2S,5R)((2-aminoethoxy)carbamoyl)oxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (27);
2-methoxyethyl 3-(((((1R,2S,5R)((2-aminoethoxy)carbamoyl)oxo-1,6-
diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (28);
(5-methyloxo-1,3-dioxolyl)methyl 3-(((((1R,2S,5R)((2-aminoethoxy)carbamoyl)
oxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate TFA salt (29);
hexyl 3-(((((1R,2S,5R)((2-aminoethoxy)carbamoyl)oxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate TFA salt (30);
heptyl 3-(((((1R,2S,5R)((2-aminoethoxy)carbamoyl)oxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate TFA salt (31);
ethyl 1-((((((1R,2S,5R)((2-aminoethoxy)carbamoyl)oxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)cyclohexanecarboxylate TFA salt (32);
a pharmaceutically acceptable salt of any of the foregoing; and
a combination of any of the foregoing.
Aspect 172. A pharmaceutical composition comprising the compound of any one of
aspects 76 to 171 and a pharmaceutically acceptable vehicle.
Aspect 173. The pharmaceutical composition of aspect 172, further comprising an
antibiotic.
Aspect 174. The pharmaceutical composition of aspect 173, wherein the antibiotic
comprises a β-lactam antibiotic.
Aspect 175. The pharmaceutical composition of any one of aspects 172 to 174, wherein
the pharmaceutical composition comprises an oral dosage formulation.
Aspect 176. The pharmaceutical composition of any one of aspects 172 to 175, wherein
the pharmaceutical composition comprises an oral dosage form.
Aspect 177. The pharmaceutical composition of any one of aspects 172 to 176,
comprising an amount of the compound of any one of aspects 76 to 171 effective for treating a
bacterial infection in a patient.
Aspect 178. A method of treating a bacterial infection in a patient comprising
administering to a patient in need of such treatment a therapeutically effective amount of the
compound of any one of aspects 76 to 171.
Aspect 179. The method of aspect 178, wherein administering comprises orally
administering.
Aspect 180. The method of any one of aspects 178 to 179, wherein administering
comprises administering an oral dosage form.
Aspect 181. The method of any one of aspects 178 to 180, further comprising
administering an antibiotic to the patient.
Aspect 182. The method of any one of aspects 178 to 181, wherein the antibiotic
comprises a β-lactam antibiotic.
Aspect 183. A method of treating a bacterial infection in a patient comprising
administering to a patient in need of such treatment a therapeutically effective amount of the
pharmaceutical composition of any one of aspects 172 to 177.
Aspect 184. The method of aspect 183, wherein administering comprises orally
administering.
Aspect 185. The method of any one of aspects 183 to 184, wherein administering
comprises administering an oral dosage form.
Aspect 186. The method of any one of aspects 183 to 185, further comprising
administering an antibiotic to the patient.
Aspect 187. The method of aspect 184, wherein the antibiotic comprises a β-lactam
antibiotic.
Aspect 188. A method of inhibiting a β-lactamase in a patient comprising administering to
the patient an effective amount of the compound of any one of aspects 76 to 171.
Aspect 189. The method of aspect 188, wherein administering comprises orally
administering.
Aspect 190. The of any one of aspects 188 to 189, wherein administering comprises
administering an oral dosage form.
Aspect 191 A method of inhibiting a β-lactamase in a patient comprising administering to
the patient an effective amount of the pharmaceutical composition of any one of aspects 172 to 177.
Aspect 192. The method of aspect 191, wherein administering comprises orally
administering.
Aspect 193. The method of any one of aspects 191 to 192, wherein administering
comprises administering an oral dosage form.
Aspect 194. A method of preparing a sulfate monoester analog of a cyclic hydroxamic
acid comprising reacting the cyclic hydroxamic acid with a chlorosulfonate ester in the presence of a
base to provide sulfate monoester analog.
Aspect 195. The method of aspect 194, wherein the cyclic hydroxamic acid has the
structure of Formula (82) and the chlorosulfate ester has the structure of Formula (83):
(82) (83)
where,
R is selected from C alkyl, C heteroalkyl, C cycloalkyl, C heterocycloalkyl, C
1-8 1-8 5-8 5-8 5-10
cycloalkylalkyl, C heterocycloalkylalkyl, C aryl, C heteroaryl, C arylalkyl, C
-10 6-8 5-8 7-10 5-10
heteroarylalkyl, substituted C alkyl, substituted C heteroalkyl, substituted C cycloalkyl,
1-8 1-8 5-8
substituted C heterocycloalkyl, substituted C cycloalkylalkyl, substituted C
-8 5-10 5-10
heterocycloalkylalkyl, substituted C aryl, substituted C heteroaryl, substituted C arylalkyl, and
6-8 5-8 7-10
substituted C heteroarylalkyl;
-10
n is an integer from 1 to 6;
each A is independently selected from –(CH )–, –(CHR)–, –(CR )–, –NH–, –NR–, O, and S,
where R is independently elected from hydrogen, C alkyl, C heteroalkyl, C cycloalkyl, C
1-8 1-8 5-8 5-8
heterocycloalkyl, C cycloalkylalkyl, C heterocycloalkylalkyl, C aryl, C heteroaryl, C
-10 5-10 6-8 5-8 7-10
arylalkyl, C heteroarylalkyl, substituted C alkyl, substituted C heteroalkyl, substituted C
-10 1-8 1-8 5-8
cycloalkyl, substituted C heterocycloalkyl, substituted C cycloalkylalkyl, substituted C
-8 5-10 5-10
heterocycloalkylalkyl, substituted C aryl, substituted C heteroaryl, substituted C arylalkyl, and
6-8 5-8 7-10
substituted C heteroarylalkyl; or one A is bonded to another A through a group –L–, where L is
-10
selected from C alkyl, C heteroalkyl, substituted C alkyl, and substituted C heteroalkyl.
1-8 1-8 1-8 1-8
Aspect 196. The method of aspect 194, wherein the sulfate monoester analog comprises a
compound of Formula (80a) and the cyclic hydroxamic acid comprises a compound of Formula (80b):
(80a) (80b)
wherein,
R is selected from C alkyl, C heteroalkyl, C cycloalkyl, C heterocycloalkyl,
1-8 1-8 5-8 5-8
C cycloalkylalkyl, C heterocycloalkylalkyl, C aryl, C heteroaryl, C arylalkyl, C
-10 5-10 6-8 5-8 7-10 5-
heteroarylalkyl, substituted C alkyl, substituted C heteroalkyl, substituted C
1-8 1-8 5-8
cycloalkyl, substituted C heterocycloalkyl, substituted C cycloalkylalkyl, substituted C
-8 5-10 5-
heterocycloalkylalkyl, substituted C aryl, substituted C heteroaryl, substituted C
6-8 5-8 7-10
arylalkyl, and substituted C heteroarylalkyl;
-10
R is selected from hydrogen, C alkyl, C cycloalkyl, C cycloalkylalkyl, C
1-6 5-8 6-12 2-6
heteroalkyl, C heterocycloalkyl, C heterocycloalkylalkyl, substituted C alkyl,
-8 6-12 1-6
substituted C cycloalkyl, substituted C cycloalkylalkyl, substituted C heteroalkyl,
-8 6-12 2-6
substituted C heterocycloalkyl, and substituted C heterocycloalkylalkyl;
-8 6-12
R is selected from hydrogen, C alkyl, C cycloalkyl, C cycloalkylalkyl, C
1-6 5-8 6-12 2-6
heteroalkyl, C heterocycloalkyl, C heterocycloalkylalkyl, substituted C alkyl,
-8 6-12 1-6
substituted C cycloalkyl, substituted C cycloalkylalkyl, substituted C heteroalkyl,
-8 6-12 2-6
substituted C heterocycloalkyl, and substituted C heterocycloalkylalkyl; and
-8 6-12
A is a single bond (–) and R is hydrogen, or A is a double bond (=) and R is C
alkyl.
Aspect 197. The method of any one of aspects 194 to 196, wherein the chlorosulfonate
monoester comprises a chlorosulfonate neopentyl ester.
Aspect 198. The method of any one of aspects 194 to 197, wherein the chlorosulfonate
neopentyl ester has the structure of Formula (81):
(81)
wherein,
each R is independently selected from C alkyl, or each R and the geminal carbon
atom to which they are bonded forms a C cycloalkyl ring, a C heterocycloalkyl ring, a
3-6 3-6
substituted C cycloalkyl ring, or a substituted C heterocycloalkyl ring;
3-6 3-6
R is selected from a single bond, C alkanediyl, C heteroalkanediyl, C
1-6 1-6 5-6
cycloalkanediyl, C heterocycloalkanediyl, C arenediyl, C heteroarenediyl, substituted C
-6 6 5-6 1-
alkanediyl, substituted C heteroalkanediyl, substituted C cycloalkanediyl, substituted C
6 1-6 5-6 5-
heterocycloalkanediyl, substituted C arenediyl, and substituted C heteroarenediyl; and
6 6 5-6
3 4 4 4
R is selected from C alkyl, –O–C(O)–R , –S–C(O)–R , –NH–C(O)–R , –O–C(O)–
4 4 4 4 4 4
O–R , –S–C(O)–O–R , –NH–C(O)–O–R , –C(O)–O–R , –C(O)–S–R , –C(O)–NH–R , –O–
4 4 4 4 4 4
C(O)–O–R , –O–C(O)–S–R , –O–C(O)–NH–R , –S–S–R , –S–R , –NH–R , –CH(–NH )(–
R ), C heterocycloalkyl, C heteroaryl, substituted C cycloalkyl, substituted C
-6 5-6 5-6 5-6
heterocycloalkyl, substituted C aryl, substituted C heteroaryl, and –CH=C(R ) , wherein,
-6 5-6 2
R is selected from hydrogen, C alkyl, C heteroalkyl, C cycloalkyl, C
1-8 1-8 5-8 5-8
heterocycloalkyl, C cycloalkylalkyl, C heterocycloalkylalkyl, C aryl, C
-10 5-10 6-8 5-8
heteroaryl, C arylalkyl, C heteroarylalkyl, substituted C alkyl, substituted C
7-10 5-10 1-8 1-8
heteroalkyl, substituted C cycloalkyl, substituted C heterocycloalkyl, substituted
-8 5-8
C cycloalkylalkyl, substituted C heterocycloalkylalkyl, substituted C aryl,
-10 5-10 6-8
substituted C heteroaryl, substituted C arylalkyl, and substituted C
-8 7-10 5-10
heteroarylalkyl.
Aspect 199. The method of any one of aspects 194 to 198, wherein the chlorosulfate
monoester is prepared by reacting an alcohol with sulfuryl chloride.
Aspect 200. The method of aspect 199, wherein the alcohol comprises a neopentyl
alcohol.
Aspect 201. The method of aspect 194, wherein the sulfate monoester analog has the
structure of Formula (1):
or a pharmaceutically acceptable salt thereof, wherein,
each R is independently selected from C alkyl, or each R and the geminal carbon atom to
which they are bonded forms a C cycloalkyl ring, a C heterocycloalkyl ring, a substituted C
3-6 3-6 3-6
cycloalkyl ring, or a substituted C heterocycloalkyl ring;
R is selected from a single bond, C alkanediyl, C heteroalkanediyl, C cycloalkanediyl,
1-6 1-6 5-6
C heterocycloalkanediyl, C arenediyl, C heteroarenediyl, substituted C alkanediyl, substituted
-6 6 5-6 1-6
C heteroalkanediyl, substituted C cycloalkanediyl, substituted C heterocycloalkanediyl,
1-6 5-6 5-6
substituted C arenediyl, and substituted C heteroarenediyl;
6 5-6
3 4 4 4 4
R is selected from C alkyl, –O–C(O)–R , –S–C(O)–R , –NH–C(O)–R , –O–C(O)–O–R , –
4 4 4 4 4 4
S–C(O)–O–R , –NH–C(O)–O–R , –C(O)–O–R , –C(O)–S–R , –C(O)–NH–R , –O–C(O)–O–R , –O–
4 4 4 4 4 4
C(O)–S–R , –O–C(O)–NH–R , –S–S–R , –S–R , –NH–R , –CH(–NH )(–R ), C heterocycloalkyl,
2 5-6
C heteroaryl, substituted C cycloalkyl, substituted C heterocycloalkyl, substituted C aryl,
-6 5-6 5-6 5-6
substituted C heteroaryl, and –CH=C(R ) , wherein,
-6 2
R is selected from hydrogen, C alkyl, C heteroalkyl, C cycloalkyl, C
1-8 1-8 5-8 5-8
heterocycloalkyl, C cycloalkylalkyl, C heterocycloalkylalkyl, C aryl, C heteroaryl,
-10 5-10 6-8 5-8
C arylalkyl, C heteroarylalkyl, substituted C alkyl, substituted C heteroalkyl,
7-10 5-10 1-8 1-8
substituted C cycloalkyl, substituted C heterocycloalkyl, substituted C cycloalkylalkyl,
-8 5-8 5-10
substituted C heterocycloalkylalkyl, substituted C aryl, substituted C heteroaryl,
-10 6-8 5-8
substituted C arylalkyl, and substituted C heteroarylalkyl;
7-10 5-10
R is selected from hydrogen, C alkyl, C cycloalkyl, C cycloalkylalkyl, C
1-6 5-8 6-12 2-6
heteroalkyl, C heterocycloalkyl, C heterocycloalkylalkyl, substituted C alkyl, substituted C
-8 6-12 1-6 5-8
cycloalkyl, substituted C cycloalkylalkyl, substituted C heteroalkyl, substituted C
6-12 2-6 5-8
heterocycloalkyl, and substituted C heterocycloalkylalkyl;
6-12
R is selected from hydrogen, C alkyl, C cycloalkyl, C cycloalkylalkyl, C
1-6 5-8 6-12 2-6
heteroalkyl, C heterocycloalkyl, C heterocycloalkylalkyl, substituted C alkyl, substituted C
-8 6-12 1-6 5-8
cycloalkyl, substituted C cycloalkylalkyl, substituted C heteroalkyl, substituted C
6-12 2-6 5-8
heterocycloalkyl, and substituted C heterocycloalkylalkyl; and
6-12
A is a single bond (–) and R is hydrogen, or A is a double bond (=) and R is C alkyl.
EXAMPLES
The following examples describe in detail the synthesis of compounds of Formula (1),
characterization of compounds of Formula (1), and uses of compounds of Formula (1). It will be
apparent to those skilled in the art that many modifications, both to materials and methods, may be
practiced without departing from the scope of the disclosure.
Example 1
Synthesis of (1R,2S,5R)hydroxyoxo-1,6-diazabicyclo[3.2.1]octanecarboxamide (1)
Reference is made to International Application Publication No. and
International Application No. PCT/2012/016553, together with related procedures from the patent
literature. A stirred mixture of (1R,2S,5R)(benzyloxy)oxo-1,6-diazabicyclo[3.2.1]octane
carboxamide (550 mg, 2.0 mmol), palladium on carbon (10% by weight; 340 mg, 0.3 mmol) and
MeOH (18 mL) was hydrogenated under 1 atm (balloon) until analysis by thin-layer chromatography
(TLC) indicated completion of the reaction (approximately, 30 min; reaction monitored by TLC using
MeOH / CH Cl 5:95 as eluent). The mixture was filtered through a pad of Celite® and the pad was
rinsed thoroughly with MeOH (ca. 20 mL). The filtrate was concentrated under vacuum (water bath
temperature not exceeding 25 °C) to give the product as a clear and colorless oil. The oil was dried
under vacuum for 1 h, and the residue was used immediately in the next step without further
purification. Yield assumed quantitative. LC-MS: m/z = 186.0 [M+H] .
Example 2
Synthesis of 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropyl benzoate (2)
Step 1: Synthesis of 3-hydroxy-2,2-dimethylpropyl benzoate (2a).
Benzoyl chloride (4.0 mL, 34.5 mmol) was added dropwise to a stirred solution of 2,2-
dimethylpropane-1,3-diol (10.8 g, 103.4 mmol), pyridine (5.8 mL, 71.6 mmol) and N,N
dimethylaminopyridine (840 mg, 6.9 mmol) in dichloromethane (207 mL) at ca. 0 °C. The mixture
was stirred overnight with gradual warming to room temperature, quenched by addition of 1N HCl
(100 mL) at 0 °C and extracted twice with dichloromethane. The combined organic extracts were
washed with saturated aqueous NaHCO (100 mL), brine (100 mL), dried (Na SO ), filtered and the
3 2 4
solvent concentrated under vacuum to leave a crude residue. The residue was split into two batches
and purified by column chromatography on silica gel using EtOAc/hexanes (0:1 to 1:4) as eluent to
give the product (5.95 g, 99%) as a colorless oil (note: oil dried under vacuum for 2 days). LC-MS:
m/z = 209.0 [M+H] . H NMR (300 MHz, CDCl ): 8.05 (m, 2H), 7.58 (m, 1H), 7.45 (m, 2H), 4.19 (s,
2H), 3.38 (d, J = 6.3 Hz, 2H), 2.29 (t, J = 6.3 Hz, 1H), 1.02 (s, 6H).
Step 2: Synthesis of 3-((chlorosulfonyl)oxy)-2,2-dimethylpropyl benzoate (2b).
Reference is made to J. Am. Chem. Soc. 2006, 128, 1605-1610. A solution of
distilled sulfuryl chloride (1.2 mL, 15.8 mmol) in Et O (15 mL) was cooled to -78 °C under an
atmosphere of argon. A solution of 3-hydroxy-2,2-dimethylpropyl benzoate (2a) (3.0 g, 14.4 mmol)
and pyridine (1.2 mL, 14.4 mmol) in Et O (3.0 mL) was then added dropwise over 1 h via a syringe.
The syringe was rinsed with Et O (3 × 1 mL), each rinse being added to the reaction mixture. The
acetone/CO bath was removed, and the mixture allowed to warm to room temperature, then stirred at
room temperature for 4 h. TLC analysis (EtOAc/hexanes; 3:7) did not indicate complete reaction, so
re-cooled to -78 °C and added more SO Cl (0.1 mL), then allowed to warm to room temperature, and
stirred for an additional 2 h. The mixture was filtered and the filtrate was concentrated under vacuum
to give the product (3.97 g, 89%) as an oil. H NMR (300 MHz, CDCl ): 8.03 (m, 2H), 7.61-7.57 (m,
1H), 7.49-7.44 (m, 2H), 4.41 (s, 2H), 4.18 (s, 2H), 1.16 (s, 6H).
Step 3: Synthesis of 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropyl benzoate (2).
Reference is made to J. Am. Chem. Soc. 2006, 128, 1605-1610. (1R,2S,5R)Hydroxy
oxo-1,6-diazabicyclo[3.2.1]octanecarboxamide (1) (370 mg, 2.0 mmol) was dissolved in THF (7.0
mL) and 1,3-dimethyltetrahydropyrimidin-2(1H)-one (3.0 mL), and the resulting solution was cooled
to -78 °C under an atmosphere of argon. A solution of NaHMDS in THF (1M; 2.2 mL, 2.2 mmol)
was added dropwise, and the mixture was stirred at -78 °C for 10 min. 3-((Chlorosulfonyl)oxy)-2,2-
dimethylpropyl benzoate (2b) (674 mg, 2.2 mmol) was then added quickly to the reaction mixture.
After 10 min at -78 °C, the reaction mixture was allowed to warm to room temperature and stirred at
room temperature until judged complete by LC-MS and TLC analysis. EtOAc (20 mL) and saturated
aqueous NaHCO (20 mL) were added, and the organic and aqueous layers were partitioned. The
organic layer was washed with water (3 × 20 mL), brine (20 mL), dried (Na SO ), and concentrated
under vacuum to leave a crude residue. The residue was purified by column chromatography on silica
gel using EtOAc/hexanes (1:9 to 1:0) as eluent to give the product (400 mg, 43%) as a solid. After
purification by column chromatography, the product appeared to degrade to a certain extent after
drying the compound under vacuum over the weekend - one degradant was presumably avibactam by
LC-MS, m/z = 529.0 [2M-H] . A portion of the material was subsequently re-purified by column
chromatography on silica gel using the eluent system detailed above. The product was then stored at -
°C immediately after isolation. LC-MS: m/z = 456.2 [M+H] . H NMR (300 MHz, CDCl ): δ 8.05
(d, J = 6.9 Hz, 2H), 7.59-7.54 (m, 1H), 7.47-7.42 (m, 2H), 6.49 (s, 1H), 5.91 (s, 1H), 4.69 (d, J = 9.3
Hz, 1H), 4.44 (d, J = 9.3 Hz, 1H), 4.16-4.14 (m, 3H), 4.00 (d, J = 7.5 Hz, 1H), 3.24-3.20 (m, 1H),
2.96 (d, J = 11.7 Hz, 1H), 2.43-2.36 (m, 1H), 2.16-2.09 (m, 1H), 1.97-1.80 (m, 2H), 1.13 (s, 3H), 1.12
(s, 3H). C NMR (300 MHz, CDCl ): δ 171.1, 167.1, 166.4, 133.3, 130.0, 129.8, 128.6, 80.7, 69.1,
62.0, 60.2, 47.1, 35.7, 21.5, 20.8, 17.6.
Example 3
Synthesis of ethyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (3)
Step 1: Synthesis of ethyl 3-((chlorosulfonyl)oxy)-2,2-dimethylpropanoate (3a).
A solution of distilled sulfuryl chloride (0.55 mL, 7.5 mmol) in Et O (10 mL) was cooled to -
78 °C under an atmosphere of argon. A solution of ethyl 3-hydroxy-2,2-dimethylpropanoate (2a) (1.0
g, 6.8 mmol) and pyridine (0.55 mL, 6.8 mmol) in Et O (1.0 mL) was then added dropwise over 1 h
via a syringe. The syringe was rinsed with Et O (3 × 1 mL), each rinse being added to the reaction
mixture. The acetone/CO bath was removed, and the mixture was allowed to warm to room
temperature, then stirred at room temperature for 4 h. TLC analysis (EtOAc/hexanes; 3:7) did not
indicate that the reaction was complete. The mixture was re-cooled to -78 °C and more SO Cl (0.11
mL) was added, and the mixture allowed to warm to room temperature and stirred for an additional 2
h. The mixture was filtered and the filtrate was concentrated under vacuum to give the product (yield
assumed quantitative). H NMR (300 MHz, CDCl ): δ 4.50 (s, 2H), 4.19 (q, J = 6.9 Hz, 2H), 1.31 (s,
6H), 1.28 (t, J = 6.9 Hz, 3H).
Step 2: Synthesis of ethyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan-
6-yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (3).
(1R,2S,5R)Hydroxyoxo-1,6-diazabicyclo[3.2.1]octanecarboxamide (1) (370 mg, 2.0
mmol) was dissolved in THF (7.0 mL) and 1,3-dimethyltetrahydropyrimidin-2(1H)-one (3.0 mL) and
the resulting solution was cooled to -78 °C under an atmosphere of argon. A solution of NaHMDS in
THF (1M; 2.2 mL, 2.2 mmol) was added dropwise, and the mixture was stirred at -78 °C for 10 min.
A solution of ethyl 3-((chlorosulfonyl)oxy)-2,2-dimethylpropanoate (3a) (538 mg, 2.2 mmol) in THF
(1 mL) was then added quickly to the reaction mixture via syringe. The syringe was rinsed with THF
(3 × 0.5 mL), each rinse being added to the reaction mixture. After 10 min at -78 °C, the reaction
mixture was allowed to warm to room temperature and stirred at room temperature until judged
complete by LC-MS and TLC analysis (ca. 2 h). EtOAc (20 mL) and saturated aqueous NaHCO (20
mL) were added and the organic and aqueous layers were partitioned. The organic layer was washed
with saturated NaHCO (20 mL), water (3 × 20 mL), brine (20 mL), dried (Na SO ) and concentrated
3 2 4
under vacuum to leave a crude residue. The residue was purified by column chromatography on silica
gel using EtOAc/hexanes (1:9 to 1:0) as eluent to give the product (318 mg, 39%) as a solid. LC-MS:
m/z = 394.1 [M+H] . H NMR (CDCl , 300 MHz): δ 6.50 (s, 1H), 5.78 (s, 1H), 4.71 (d, J = 8.7 Hz,
1H), 4.59 (d, J = 8.7 Hz, 1H), 4.22-4.12 (m, 3H), 4.05 (d, J = 6.9 Hz, 1H), 3.34-3.30 (m, 1H), 3.01 (d,
J = 12.3 Hz, 1H), 2.46-2.40 (m, 1H), 2.18-2.12 (m, 1H), 2.00-1.79 (m, 2H), 1.28-1.24 (m, 9H). C
NMR (300 MHz, CDCl ): δ 174.2, 171.2, 167.1, 80.5, 61.9, 61.4, 60.2, 47.2, 42.8, 22.2, 21.7, 20.8,
17.5, 14.2.
Example 4
Synthesis of benzyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (4)
Step 1: Synthesis of benzyl 3-((chlorosulfonyl)oxy)-2,2-dimethylpropanoate (4a).
A solution of distilled sulfuryl chloride (0.77 mL, 10.6 mmol) in Et O (10 mL) was cooled to
-78 °C under an atmosphere of argon. A solution of ethyl 3-hydroxy-2,2-dimethylpropanoate (2a)
(Sigma-Aldrich; 2.0 g, 9.6 mmol) and pyridine (0.85 mL, 10.6 mmol) in Et O (2.0 mL) was then
added dropwise over 1 h via a syringe. The syringe was rinsed with Et O with each rinse being added
to the reaction mixture. The acetone/CO bath was removed and the mixture allowed to warm to
room temperature, then stirred at room temperature for 30 min. TLC analysis (EtOAc/hexanes; 3:7)
did not indicate complete reaction, so re-cooled to -78 °C and added more SO Cl (0.07 mL), then
allowed to warm to room temperature and stirred for an additional 1 h. Et O (5 mL) was added and
the mixture stirred for a few min, then filtered and the filtrate concentrated under vacuum to give the
product (2.19 g, 75%). H NMR (300 MHz, CDCl ): δ 7.41-7.32 (m, 4H), 5.18 (s, 2H), 4.52 (s, 2H),
1.34 (s, 6H).
Step 2: Synthesis of benzyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-
diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (4).
(1R,2S,5R)Hydroxyoxo-1,6-diazabicyclo[3.2.1]octanecarboxamide (1) (370 mg, 2.0
mmol) was dissolved in THF (7.0 mL) and 1,3-dimethyltetrahydropyrimidin-2(1H)-one (2.0 mL) was
added, and the resulting solution was cooled to -78 °C under an atmosphere of argon. A solution of
NaHMDS in THF (1M; 2.2 mL, 2.2 mmol) was added dropwise, and the mixture was stirred at -78 °C
for 10 min. A solution of ethyl benzyl 3-((chlorosulfonyl)oxy)-2,2-dimethylpropanoate (4a) (674 mg,
2.2 mmol) in THF (1 mL) was then added quickly to the reaction mixture via syringe. The syringe
was rinsed with THF (3 × 0.5 mL), each rinse being added to the reaction mixture. After 10 min at -
78 °C, the reaction mixture was allowed to warm to room temperature and stirred at room temperature
until judged complete by LC-MS and TLC analysis. EtOAc (20 mL) and saturated aqueous NaHCO
(20 mL) were added, and the organic and aqueous layers were partitioned. The organic layer was
washed with saturated NaHCO (20 mL), water (3 × 20 mL), brine (20 mL), dried (Na SO ) and
3 2 4
concentrated under vacuum to leave a crude residue. The residue was purified by column
chromatography on silica gel using EtOAc/hexanes (1:9 to 1:0) as eluent to give the product (244 mg,
26%) as a solid. LC-MS: m/z = 456.2 [M+H] . H NMR (CDCl , 300 MHz): δ 7.39-7.28 (m, 4H),
6.49 (s, 1H), 5.84 (s, 1H), 5.20-5.11 (m, 2H), 4.74 (d, J = 9.0 Hz, 1H), 4.61 (d, J = 9.0 Hz, 1H), 4.15-
4.14 (m, 1H), 4.04 (d, J = 6.9 Hz, 1H), 3.29-3.25 (m, 1H), 2.99 (d, J = 11.7 Hz, 1H), 2.45-2.38 (m,
1H), 2.17-2.10 (m, 1H), 1.99-1.78 (m, 2H), 1.30 (s, 3H), 1.29 (s, 3H). C NMR (CDCl , 75 MHz): δ
174.1, 171.1, 167.1, 135.7, 128.7, 128.4, 128.0, 80.3, 67.0, 62.0, 60.2, 47.2, 43.0, 22.2, 21.7, 20.8,
17.5.
Example 5
Synthesis of (1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl phenyl sulfate (5)
Step 1: Synthesis of phenyl sulfochloridate (5a).
Reference is made to J. Am. Chem. Soc. 2013, 135, 10638-10641. A solution of
distilled sulfuryl chloride (2.6 mL, 35.1 mmol) in Et O (30 mL) was cooled to -78 °C under an
atmosphere of argon. A solution of phenol (3.0 g, 31.9 mmol) in Et O (3.0 mL) and pyridine (2.6 mL,
31.9 mmol) were then added concurrently, but from different syringes, dropwise over 1 h. The
syringes were each rinsed with Et O and each rinse was added to the reaction mixture. The mixture
was allowed to warm to room temperature slowly, and stirred at room temperature overnight. The
mixture was filtered, and the filtrate concentrated under vacuum to give the product (4.65 g),
contaminated with other products and phenol starting material. The phenyl sulfochloridate product
was not purified further and was used directly in the next step.
Step 2: Synthesis of (1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl phenyl
sulfate (5).
(1R,2S,5R)Hydroxyoxo-1,6-diazabicyclo[3.2.1]octanecarboxamide (1) (370 mg, 2.0
mmol) was dissolved in THF (7.0 mL) and 1,3-dimethyltetrahydropyrimidin-2(1H)-one (2.0 mL) and
the resulting solution was cooled to -78 °C under an atmosphere of argon. A solution of NaHMDS in
THF (1M; 2.2 mL, 2.2 mmol) was added dropwise and the mixture was stirred at -78 °C for 10 min.
Neat phenyl sulfochloridate (5a) (423 mg, 2.2 mmol) was then added quickly to the reaction mixture
via syringe. The syringe was rinsed with THF (3 × 0.5 mL), each rinse being added to the reaction
mixture. After 10 min at -78 °C, the reaction mixture was allowed to warm to room temperature and
stirred at room temperature until judged complete by LC-MS and TLC analysis (ca. 1 h). EtOAc (20
mL) and saturated aqueous NaHCO (20 mL) were added, and the organic and aqueous layers were
partitioned. The organic layer was washed with saturated NaHCO (20 mL), water (3 × 20 mL), brine
(20 mL), dried (Na SO ), and concentrated under vacuum to leave a crude residue. The residue was
purified by column chromatography on silica gel using EtOAc/hexanes (1:9 to 1:0) as eluent to give
the product (126 mg, 18%) as a solid. LC-MS: m/z = 342.2 [M+H] . 1H NMR (300 MHz, CDCl3):
δ 7.54-7.51 (m, 2H), 7.47-7.42 (m, 2H), 7.39-7.33 (m, 1H), 6.53 (s, 1H), 5.88 (s, 1H), 4.24 (fd, J = 2.4
Hz, 1H), 4.09 (d, J = 6.9 Hz, 1H), 3.34 (d, J = 11.7 Hz, 1H), 3.05 (d, J = 12.3 Hz, 1H), 2.46-2.39 (m,
1H), 2.19-2.11 (m, 1H), 2.02-1.81 (m, 2H). C NMR (75 MHz, CDCl ): δ 171.2, 166.8, 150.9, 130.2,
128.1, 121.3, 62.1, 60.6, 47.0, 20.8, 17.6.
Example 6
Synthesis of 4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-3,3-dimethylbutyl benzoate (6)
Step 1: Synthesis of 2,2-dimethylbutane-1,4-diol (6a).
A solution of 2,2-dimethylsuccinic acid (10.0 g, 68.4 mmol) in THF (150 mL) was added
dropwise to a suspension of lithium aluminum hydride (8.3 g, 219.0 mmol) in THF (80 mL) at 0 °C
(ice bath). The mixture was warmed to room temperature over 20 min and then heated at reflux for
1.5 h. Upon completion (reaction monitored by TLC using MeOH/CH Cl 5:95 as eluent) the reaction
was quenched very carefully and dropwise by the addition of water (10 mL), 3 M NaOH (15 mL), and
water (20 mL). The mixture was stirred at room temperature for 20 min, and the solids filtered over a
pad of Celite®. The filter cake was rinsed thoroughly with THF. The filtrate was concentrated under
vacuum giving a mixture of the title compound and unidentified by-products as a crude oil. The oil
was purified by column chromatography on silica gel using MeOH/CH Cl (0:1 to 1:9) as eluent to
afford the product (4.649 g, 57%) as an oil. H-NMR (300 MHz, CDCl ): δ 4.11 (s, 2H), 3.66 (t, J =
.9 Hz, 2H), 3.30 (s, 2H), 1.52 (t, J = 5.6 Hz, 2H), 0.89 (s, 6H).
Step 2: Synthesis of 4-hydroxy-3,3-dimethylbutyl benzoate (6b).
To a stirred solution of 2,2-dimethylbutane-1,4-diol (6a) (0.30 g, 2.5 mmol) in anhydrous
dichloromethane (9 mL) was added benzoyl chloride (0.30 mL, 2.5 mmol), Et N (0.71 mL, 5.1
mmol), and a catalytic amount of N,Ndimethylaminopyridine at 0 °C (ice bath). The mixture was
gradually warmed to room temperature and stirred overnight. After the starting material was
completely consumed (reaction monitored by TLC using EtOAc/hexanes 2:8 as eluent), the reaction
was quenched by the addition of 1N HCl (20 mL) at 0 °C (ice bath), and the mixture was extracted
twice with dichloromethane. The combined organic layers were washed with saturated aqueous
NaHCO , brine, dried (Na SO ), filtered and the solvent concentrated to yield a mixture, of at least
3 2 4
two products, as a clear and colorless oil. The oil was purified by column chromatography on silica
gel using EtOAc/hexanes (0:1 to 4:6) as eluent to give the product (0.29 g, 51%) as an oil (which was
dried under high vacuum for 2 d). H-NMR (300 MHz, CDCl ): δ 8.04-8.01 (m, 2H), 7.58-7.53 (m,
1H), 7.46-7.41 (m, 2H), 4.41 (t, J = 7.4 Hz, 2H), 3.41 (s, 2H), 1.78 (t, J = 7.4 Hz, 2H), 1.70 (s, 1H),
0.99 (s, 6H).
Step 3: Synthesis of 4-((chlorosulfonyl)oxy)-3,3-dimethylbutyl benzoate (6c).
A solution of freshly distilled sulfuryl chloride (0.11 mL, 1.5 mmol) in Et O (3 mL) was
cooled to -78 °C under an atmosphere of Ar. A solution of 4-hydroxy-3,3-dimethylbutyl benzoate
(6b) (0.28 g, 1.3 mmol) and pyridine (0.10 ml, 1.3 mmol) in Et O (2 mL) was added dropwise (over 1
h) to the cooled solution. The mixture was warmed to room temperature and stirred for 30 min
(reaction was monitored by TLC using EtOAc/hexanes 2:8 as eluent). The mixture was re-cooled to -
78 °C and sulfuryl chloride (0.02 mL) was added. The mixture was allowed to warm to room
O (5 mL) was added and the mixture stirred for a few minutes.
temperature, and stirred for 30 min. Et
The mixture was filtered and the filtrate concentrated under vacuum to give the product (0.305 g,
75%). H-NMR (300 MHz, CDCl ): δ 8.03 (d, J = 8.1 Hz, 2H), 7.60-7.54 (m, 1H), 7.47-7.42 (m, 2H),
4.44-4.38 (m, 2H), 4.29 (s, 2H), 1.89-1.85 (m, 2H), 1.13 (s, 6H).
Step 4: Synthesis of 4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-3,3-dimethylbutyl benzoate (6).
(1R,2S,5R)Hydroxyoxo-1,6-diazabicyclo[3.2.1]octanecarboxamide (1) (176 mg, 1.0
mmol) was dissolved in THF (4 mL) and 1,3-dimethyltetrahydropyrimidin-2(1H)-one (1 mL) and the
resulting solution was cooled to -78 °C under an atmosphere of Argon. NaHMDS (1.0 M in THF;
1.05 mL, 1.05 mmol) was added dropwise to the cooled solution and the mixture was stirred at -78°C
for 10 min. 4-((chlorosulfonyl)oxy)-3,3-dimethylbutyl benzoate (6c) (305 mg, 1.0 mmol) in THF (0.5
mL) was added quickly to the mixture. The syringe was rinsed with THF (3 × 0.5 mL) and this was
also added to the mixture. After 10 min, the mixture was warmed to room temperature and stirred
until judged complete by TLC analysis. EtOAc (10 mL) and saturated aqueous NaHCO (10 mL)
were added to the mixture and the organic and aqueous layers were partitioned. The organic layer
was washed with saturated aqueous NaHCO (10 mL), water (6 × 10 mL), brine (10 mL), dried
(Na SO ), filtered and concentrated under vacuum. Purification by column chromatography on silica
gel using EtOAc/hexanes (1:9 to 1:0) as eluent gave the product (6) (215 mg, 18%) as a solid. LC-
MS: 470.2 [M+H] . 1H-NMR (300 MHz, CDCl3): δ 8.04-8.01 (m, 2H), 7.58-7.53 (m, 1H), 7.46-7.41
(m, 2H), 6.48 (s, 1H), 5.80 (s, 1H), 4.60 (d, J = 9.3 Hz, 1H), 4.40 (t, J = 6.9 Hz, 2H), 4.29 (d, J = 9.3
Hz, 1H), 4.17-4.16 (m, 1H), 4.02 (d, J = 7.8 Hz, 1H), 3.34-3.30 (m, 1H), 3.00 (d, J = 12.3 Hz, 1H),
2.45-2.35 (m, 1H), 2.17-2.11 (m, 1H), 1.98-1.78 (m, 4H), 1.10 (s, 6H). C-NMR (75 MHz,
CDCl ): δ 171.1, 167.1, 166.6, 133.1, 130.2, 129.7, 128.5, 83.7, 61.9, 61.5, 60.2, 47.2, 36.9, 34.1,
24.1, 23.8, 20.8, 17.5.
Example 7
Synthesis of 4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-3,3-dimethylbutyl propionate (7)
Step 1: Synthesis of 4-hydroxy-3,3-dimethylbutyl propionate (7a).
A solution of propionyl chloride (0.74 mL, 8.5 mmol) in anhydrous dichloromethane (5 mL)
was added to a stirred solution of 2,2-dimethylbutane-1,4-diol (6a) (1.00 g, 8.5 mmol), Et N (2.4 mL,
16.9 mmol), and 4-N,N-dimethylaminopyridine (52 mg) in anhydrous dichloromethane (20 mL) at -78
°C under an atmosphere of argon. The mixture was stirred for 10 min and then allowed to warm to
room temperature, stirred at room temperature for 1 h, then re-cooled to -78°C, and allowed to warm
to room temperature slowly by allowing the mixture to stay in the cold bath and letting the dry ice
sublime (recommended to allow warming to room temperature from -78 °C after addition of all the
reagents). After the starting material was completely consumed (TLC 50% EtOAc/hexanes), the
reaction was quenched by the addition of 0.5 N HCl (10 mL) at 0 °C. The organic and aqueous layers
were partitioned, and the aqueous layer was extracted with dichloromethane (2 × 20 mL). The
combined organic layers were washed with saturated aqueous NaHCO (20 mL), brine (20 mL), then
dried (Na SO ), filtered and the solvent concentrated under vacuum to leave a crude oil. The oil was
purified by column chromatography on silica gel using EtOAc/hexanes (0:1 to 4:1) as eluent to give
the product (7a) (463 mg, 22%) as an oil, contaminated with significant EtOAc solvent residues. H-
NMR (300 MHz, CDCl ): δ 4.14 (t, J = 7.4 Hz, 2H), 3.32 (s, 2H), 2.30 (q, J = 7.6 Hz, 2H), 1.88 (s,
1H), 1.61 (t, J = 7.7 Hz, 2H), 1.13 (t, J = 7.5 Hz, 3H), 0.91 (fd, J = 1.2 Hz, 6H).
Step 2: Synthesis of 4-((chlorosulfonyl)oxy)-3,3-dimethylbutyl propionate (7b).
A solution of freshly distilled sulfuryl chloride (0.15 mL, 2.0 mmol) in Et O (3.5 mL) was
cooled to -78 °C under an atmosphere of argon. A solution of 4-hydroxy-3,3-dimethylbutyl
propionate (7a) (73% purity, the remainder being EtOAc; 441 mg, 1.8 mmol) and pyridine (0.15 mL,
1.8 mmol) in Et O (2.5 mL) was added dropwise over 1 h to the cooled solution. The mixture was
allowed to warm to room temperature and was stirred for 30 min (monitored by TLC, 30%
EtOAc/hexanes), re-cooled to -78 °C and sulfuryl chloride (0.03 mL) and pyridine (0.03 mL) was
added, warmed to room temperature, and stirred for 30 min. Again, the mixture was re-cooled to -
78°C and another portion of sulfuryl chloride (0.15 mL) was added. The mixture was allowed to
warm to room temperature, and stirred for 30 min. Et O (5 mL) was added and the mixture stirred for
a few min. The mixture was filtered and the filtrate was concentrated under vacuum to give the
product (7b) (401 mg, 79%). H-NMR: (300 MHz, CDCl ): 4.22 (s, 2H), 4.14 (t, J = 6.8 Hz, 2H),
2.30 (q, J = 7.6 Hz, 2H), 1.70 (t, J = 6.8 Hz, 2H), 1.11 (t, J = 7.7 Hz, 3H), 1.05 (s, 6H).
Step 3: Synthesis of 4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-3,3-dimethylbutyl propionate (7).
(1R,2S,5R)Hydroxyoxo-1,6-diazabicyclo[3.2.1]octanecarboxamide (1) (185 mg, 1.0
mmol) was dissolved in THF (4 mL) and 1,3-dimethyltetrahydropyrimidin-2(1H)-one (1 mL) under
an atmosphere of argon. The resulting solution was cooled to -78 °C. NaHMDS (1.0 M in THF; 1.1
mL, 1.1 mmol) was added dropwise to the cooled solution and the mixture stirred for 10 min. 4-
((chlorosulfonyl)oxy)-3,3-dimethylbutyl propionate (7b) (272 mg, 1.0 mmol) in THF (1 mL) was
added quickly to the reaction mixture. The syringe was rinsed with THF (3 × 0.5 mL) and this was
also added to the mixture. Further THF (3 mL) was added to the mixture to allow efficient stirring of
the reaction. After 10 min, the mixture was allowed to warm to room temperature. Upon completion
(1 h; TLC, 70% EtOAc/hexanes), EtOAc (10 mL) and saturated aqueous NaHCO (10 mL) were
added to the mixture. The aqueous and organic layers were partitioned, and the organic layer was
washed with saturated aqueous NaHCO (10 mL), water (6 × 10 mL), brine (10 mL), then dried
(Na SO ), filtered and the solvent concentrated under vacuum to leave a crude residue. The residue
was purified by column chromatography on silica gel using EtOAc / hexanes (1:0 to 1:0) as eluent to
+ + 1
give the product (7) (93 mg, 22%) as a solid. LC-MS: 422.1 [M H] . H-NMR (300 MHz, CDCl ): δ
6.51 (s, 1H), 5.76 (s, 1H), 4.54 (d, J = 8.7 Hz, 1H), 4.25 (d, J = 8.7 Hz, 1H), 4.17-4.12 (m, 3H), 4.04
(d, J = 6.9 Hz, 1H), 3.36-3.32 (m, 1H), 3.02 (d, J = 12.3 Hz, 1H), 2.47-2.40 (m, 1H), 2.32 (q, J = 7.6
Hz, 2H), 2.18-2.15 (m, 1H), 2.00-1.79 (m, 2H), 1.75-1.61 (m, 2H), 1.13 (t, J = 7.7 Hz, 3H), 1.03 (s,
6H). C-NMR (75 MHz, CDCl ): δ 174.5, 171.0, 167.1, 83.6, 62.0, 60.8, 60.2, 47.2, 36.8, 34.0, 27.7,
24.1, 23.7, 20.8, 17.6, 9.2.
Example 8
Synthesis of benzyl (4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-3,3-dimethylbutyl) adipate (8)
O S N
Step 1: Synthesis of benzyl (perfluorophenyl) adipate (8a).
To a stirring solution of adipic acid monobenzyl ester (1.03 g, 4.3 mmol) and
pentafluorophenol (0.87 g, 4.7 mmol) in EtOAc (18.7 mL) at 0 °C was added N,N'-
dicyclohexylcarbodiimide (0.97 g, 4.7 mmol). The mixture was allowed to warm to room
temperature and then stirred overnight. The resulting solid was removed by vacuum filtration through
a pad of Celite®. The filter cake was washed with EtOAc. The filtrate was dry-loaded on to silica gel
and purified by column chromatography on silica gel using EtOAc / hexanes (0:1 to 4:6) as eluent, to
give the product (8a) (1.59 g, 93%) as a solid. H NMR (300 MHz, CDCl ): δ 7.37-7.35 (m, 5 H),
.13 (s, 2H), 2.68 (t, J = 6.8 Hz, 2H), 2.44 (t, J = 6.5 Hz, 2H), 1.82-1.78 (m, 4H).
Step 2: Synthesis of benzyl (4-hydroxy-3,3-dimethylbutyl) adipate (8b).
To a stirred solution of 2,2-dimethylbutane-1,4-diol (6a) (0.22 g, 1.8 mmol) in anhydrous
dichloromethane (4 mL) at ca. 0 °C (ice bath), under an atmosphere of argon, was added benzyl
(perfluorophenyl) adipate (8a) (0.36 g, 0.9 mmol), Et N (0.25 mL, 1.8 mmol), and a catalytic amount
of 4-N,N-dimethylaminopyridine (small unweighed amount). The mixture was gradually warmed to
room temperature, and then at room temperature overnight. The mixture was dry-loaded on to silica
gel and purified by column chromatography on silica gel using EtOAc / hexanes (0:1 to 3:7) as eluent
to give the product contaminated with regio-isomeric product. This mixture was re-purified by
column chromatography on silica gel using EtOAc/hexanes (0:1 to 3:7) as eluent to give pure product
(8b) (113 mg 38%). H-NMR (300 MHz, CDCl ): 7.36-7.34 (m, 5H), 5.11 (s, 2H), 4.14 (t, J = 7.2
Hz, 2H), 3.34 (d, J = 5.7 Hz, 2H), 2.38-2.31 (m, 4H), 1.68-1.59 (m, 6H), 0.92 (s, 6H). The reaction
could be repeated to give larger amounts of material.
Step 3: Synthesis of benzyl (4-((chlorosulfonyl)oxy)-3,3-dimethylbutyl) adipate (8c).
A solution of freshly distilled sulfuryl chloride (0.12 ml, 1.6 mmol) in Et O (5 mL) was
cooled to -78 °C under an atmosphere of argon. A solution of benzyl (4-hydroxy-3,3-dimethylbutyl)
adipate (8b) (446 mg, 1.3 mmol) and pyridine (0.11 mL, 1.3 mmol) in Et O (3.5 mL) was added
dropwise over 1 h to the cooled solution. The mixture was allowed to warm to room temperature and
was stirred for 30 min (monitored by TLC, 30% EA/hex). The reaction was not complete, so the
mixture was recooled to -78 °C, then sulfuryl chloride (0.05 mL) and pyridine (0.05 mL) were added.
The mixture was allowed to warm to room temperature, and stirred for 30 min. Et O (5 mL) was
added, and the mixture was stirred for a few mins. The mixture was filtered and the filtrate was
concentrated under vacuum to give the product (8c) (446 mg, 77%). H-NMR (300 MHz, CDCl ): δ
7.39-7.29 (m, 5H), 5.11 (s, 2H), 4.22 (s, 2H), 4.15 (t, J = 6.8 Hz, 2H), 2.40-2.29 (m, 4H), 1.73-1.59
(m, 6H), 1.06 (s, 6H).
Step 4: Synthesis of benzyl (4-(((((1R,2S,5R)carbamoyloxo-1,6-
diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-3,3-dimethylbutyl) adipate (8).
(1R,2S,5R)Hydroxyoxo-1,6-diazabicyclo[3.2.1]octanecarboxamide (1) (185 mg, 1.0
mmol) was dissolved in THF (9 mL) and 1,3-dimethyltetrahydropyrimidin-2(1H)-one (1 mL), and the
resulting solution was cooled to -78 °C under an atmosphere of argon. NaHMDS (1.0 M solution in
THF; 1.1 mL, 1.1 mmol) was added dropwise to the cooled solution and stirred for 10 min. Benzyl
(4-((chlorosulfonyl)oxy)-3,3-dimethylbutyl) adipate (8c) (435 mg, 1.0 mmol) in THF (1 mL) was
added quickly to the mixture. The syringe was rinsed with THF (3 × 0.5 mL) and this was also added
to the mixture. After 10 min, the mixture was allowed to warm to room temperature. Upon
completion (30 min; TLC, 70% EtOAc/hexanes), EtOAc (10 mL) and saturated aqueous NaHCO (10
mL) were added. The aqueous and organic layers were partitioned and the organic layer was washed
with saturated aqueous NaHCO (10 mL), water (3 × 10 mL), brine (10 mL), then dried (Na SO ),
3 2 4
filtered and concentrated under vacuum to leave a crude residue. The residue was purified by column
chromatography on silica gel using EtOAc / hexanes (1:9 to 1:0) as eluent to give a solid. The solid
was triturated with Et O (2 × 2 mL) to give the product (8) (43 mg, 7%) as a solid [together with less
pure material (99 mg, 93% purity), which was used in the next step without further purification].
Data for the 43 mg of pure product is detailed below. LC-MS: 584.2 [M+H] . H-NMR (300 MHz,
CDCl ): δ 7.39-7.30 (m, 5H), 6.52 (s, 1H), 5.65 (s, 1H), 5.11 (s, 2H), 4.54 (d, J = 9.6 Hz, 1H), 4.24 (d,
J = 8.7 Hz, 1H), 4.16-4.08 (m, 3H), 4.04 (d, J = 7.2 Hz, 1H), 3.35-3.31 (m, 1H), 3.01 (d, J = 12.3 Hz,
1H), 2.47-2.30 (m, 5H), 2.18-2.12 (m, 1H), 1.99-1.77 (m, 2H), 1.74-1.65 (m, 6H), 1.03 (s, 6H). C-
NMR (75 MHz, CDCl ): δ 173.34, 173.31, 171.0, 167.1, 136.1, 128.7, 128.4, 128.3, 83.5, 66.4, 62.0,
60.9, 60.2, 47.2, 36.8, 34.0, 24.5, 24.4, 24.2, 23.8, 20.8, 17.6.
Example 9
Synthesis of 6-(4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-3,3-dimethylbutoxy)oxohexanoic acid (9)
Palladium on carbon (10% by weight; 13 mg) was added to a Parr flask charged with benzyl
(4-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-3,3-
dimethylbutyl) adipate (8) (93% purity; 50 mg, 0.1 mmol) in MeOH (14 mL). The mixture was
hydrogenated at 1 atm of H (balloon), at room temperature for 30 min (monitored by TLC, 100%
EtOAc; PMA stain; LC-MS: product room temperature = 4.66 min and m/z = 494.2 [M+H] , starting
material room temperature = 5.48 min and m/z = 584.3 [M+H] ). The mixture was filtered through a
pad of Celite®, and the filter cake was rinsed with MeOH (ca. 20 mL). The filtrate was concentrated
under vacuum, then purified by column chromatography on silica gel using MeOH/CH Cl (0:1 to
4:96) as eluent, to give the product (9) (12 mg) as a solid [ca. 73% purity by LC/MS]. LC-MS: 494.2
[M+H] .
Example 10
Synthesis of methyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (10)
Step 1: Reaction to produce methyl 3-((chlorosulfonyl)oxy)-2,2-dimethylpropanoate (10a).
A solution of freshly distilled sulfuryl chloride (3.3 mL, 45.4 mmol) in Et O (45 mL) was
cooled to -78 °C under an atmosphere of Ar. A solution of methyl 2,2-dimethylhydroxypropionate
(3.0 g, 22.7 mmol) and pyridine (2.2 mL, 27.2 mmol) in Et O (20 mL) was added dropwise to the
sulfuryl chloride solution over 30 min. The flask was rinsed with Et O (3 × 5 mL) and the rinse was
added to the reaction mixture. The mixture was stirred at -78 °C until completion (monitored by TLC,
% EA/hex, 30 min). The precipitate was filtered, and the filtrate was concentrated under vacuum to
afford methyl 3-((chlorosulfonyl)oxy)-2,2-dimethylpropanoate (10a) (5.6 g, 70% yield). The mixture
was stored at -78 °C and was used immediately for the next step without further purification. H-
NMR (300 MHz, CDCl ) δ 4.50 (s, 2H), 3.74 (s, 3H), 1.31 (s, 6H).
Step 2: Reaction to produce methyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-
diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (10).
(1R,2S,5R)Hydroxyoxo-1,6-diazabicyclo[3.2.1]octanecarboxamide (1) (673 mg, 3.6
mmol) was dissolved in THF (35 mL) and 1,3-dimethyltetrahydropyrimidin-2(1H)-one (5 mL), and
the resulting solution was cooled to -78 °C under an atmosphere of Ar. A 1.0M solution of NaHMDS
solution in THF (4.0 mL, 4.0 mmol) was added dropwise to the cooled solution. After complete
addition, the mixture was stirred for 10 min. Neat methyl 3-((chlorosulfonyl)oxy)-2,2-
dimethylpropanoate (10a) (1.27 g, 3.6 mmol, 1.0 equiv., 66% pure) was added quickly to the reaction
mixture. The syringe was rinsed with THF (3 × 2.5 mL) and the rinse added to the mixture. After 10
min, the reaction mixture was allowed to warm to 23 °C. Upon completion by TLC (30 min; 70%
EtOAc/hexanes), EtOAc (50 mL) and saturated aqueous NaHCO (50 mL) were added to the reaction
mixture. The layers were partitioned and the organic layer washed with saturated aqueous NaHCO
(50 mL), water (3 × 50 mL), brine (50 mL), then dried (Na SO ), and concentrated under vacuum to
leave a crude residue. The residue was purified by column chromatography on silica gel using
EtOAc/hexanes as eluent (1:9 to 1:0) to give the product (10) (98 mg, 7% yield). LC-MS: 380.2
[M+H] . H-NMR (300 MHz, CDCl ): δ 6.47 (s, 1H), 5.61 (s, 1H), 4.72 (d, J = 9.3 Hz, 1H), 4.58 (d,
J = 9.3 Hz, 1H), 4.18 (m, 1H), 4.05 (d, J = 6.9 Hz, 1H), 3.72 (s, 3H), 3.35-3.31 (m, 1H), 3.02 (d, J =
12.3 Hz, 1H), 2.47-2.41 (m, 1H), 2.19-2.13 (m, 1H), 2.01-1.79 (m, 2H), 1.29 (s, 3H), 1.28 (s, 3H). C-
NMR (75 MHz, CDCl ): δ 174.7, 171.1, 167.1, 80.4, 62.0, 60.2, 52.6, 47.2, 43.0, 22.2, 21.8, 20.9,
17.6
Example 11
Synthesis of isopropyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (11)
Step 1: Reaction to produce isopropyl 3-hydroxy-2,2-dimethylpropanoate (11a).
HO O
Reference is made to German Application Publication No. DE3045373. A mixture of 3-
hydroxy-2,2-dimethylpropionic acid (4.7 g, 40 mmol), isopropanol (70 mL) and concentrated sulfuric
acid (or fuming sulfuric acid; 1 mL) was heated to reflux and stirred overnight. After allowing to
cool, the mixture was concentrated under vacuum and the residue partitioned between EtOAc (100
mL) and saturated aqueous NaHCO (100 mL). The aqueous mixture was washed with H O (50 mL),
saturated NaHCO (50 mL) and brine (50 mL), then dried (Na SO ), filtered and concentrated under
3 2 4
vacuum to leave provide the product as an oil. The product (11a) was used directly in the next step
without further purification. H-NMR (300 MHz, CDCl ): δ 5.08-4.95 (m, 1H), 3.53 (fd, J = 1.8 Hz,
2H), 2.49 (s, 1H), 1.25 (fd, J = 2.4 Hz, 3H), 1.22 (fd, J = 2.4 Hz, 3H), 1.17 (s, 3H), 1.16 (s, 3H).
Step 2: Reaction to produce isopropyl 3-((chlorosulfonyl)oxy)-2,2-dimethylpropanoate (11b).
A solution of sulfuryl chloride (2.7 mL, 37.5 mmol) in Et O (45 mL) was cooled to -78°C
under an atmosphere of Ar. A solution of isopropyl 3-hydroxy-2,2-dimethylpropanoate (11a) (3.0 g,
18.7 mmol) and pyridine (1.82 mL, 22.5 mmol) in Et O (20 mL) was added dropwise to the sulfuryl
chloride solution over the course of 30 min. The flask was rinsed with Et O (3 × 5 mL) and the rinse
added to the reaction mixture. The mixture was stirred at -78 °C until completion by TLC (30 min;
% EA/hex). The precipitate was filtered, and the filtrate was concentrated under vacuum to afford
isopropyl 3-((chlorosulfonyl)oxy)-2,2-dimethylpropanoate (11b) (4.1 g, 85% yield). The mixture was
stored at -78 °C and was used immediately for the next step without further purification. H-NMR
(300 MHz, CDCl ): δ 5.10-4.98 (m, 1H), 4.49 (s, 2H), 1.29 (s, 6H), 1.26 (s, 3H), 1.24 (s, 3H).
Step 3: Reaction to produce isopropyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-
diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (11).
(1R,2S,5R)Hydroxyoxo-1,6-diazabicyclo[3.2.1]octanecarboxamide (1) (673 mg, 3.6
mmol) was dissolved in THF (35 mL) and 1,3-dimethyltetrahydropyrimidin-2(1H)-one (5 mL), and
the resulting solution was cooled to -78°C under an atmosphere of Ar. A 1.0M solution of NaHMDS
in THF (4.0 mL, 4.0 mmol) was added dropwise to the cooled solution and stirred for 20 min.
Neat isopropyl 3-((chlorosulfonyl)oxy)-2,2-dimethylpropanoate (11b) (0.94 g, 3.6 mmol) was added
quickly to the reaction mixture. The syringe was rinsed with THF (3 × 3 mL) and the rinse was also
added to the mixture. After 20 min, the mixture was allowed to warm to rt. Upon completion of the
reaction by TLC (30 min; 70% EtOAc/hexanes), EtOAc (50 mL) and saturated aqueous NaHCO (50
mL) were added to the reaction mixture. The aqueous and organic layers were separated, and the
organic layer was washed with saturated aqueous NaHCO (50 mL), water (3 × 50 mL), brine (50
mL), then dried (Na SO ), and concentrated under vacuum to leave a crude residue. The residue was
purified by column chromatography (40 g ISCO column) on silica gel using EtOAc/hexanes (1:9 to
1:0) as eluent to give the product (11) (63 mg, 4%) as a solid. LC-MS: 408.2 [M+H] . H-NMR (300
MHz, CDCl ): δ 6.50 (s, 1H), 5.74 (s, 1H), 5.02 (quint, J = 6.3 Hz, 1H), 4.70 (d, J = 8.7 Hz, 1H), 4.60
(d, J = 9.3 Hz, 1H), 4.17 (m, 1H), 4.05 (d, J = 7.2 Hz, 1H), 3.34-3.30 (m, 1H), 3.02 (d, J = 11.7 Hz,
1H), 2.47-2.40 (m, 1H), 2.19-2.12 (m, 1H), 2.04-1.66 (m, 2H), 1.26-1.23 (m, 12H). C-NMR (75
MHz, CDCl ): δ 173.7, 171.1, 167.0, 80.6, 68.8, 62.0, 60.2, 47.2, 42.9, 22.2, 21.7, 21.6, 20.9, 17.5.
Example 12
Synthesis of hexyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (12)
Step 1: Reaction to produce hexyl 3-hydroxy-2,2-dimethylpropanoate (12a).
Reference is made to German Application Publication No. DE3045373. A mixture of 3-
hydroxy-2,2-dimethylpropionic acid (4.7 g, 40 mmol), 1-hexanol (70 mL) and concentrated sulfuric
acid (or fuming sulfuric acid; 1 mL) was heated to 80 °C and stirred overnight. After allowing to
cool, the mixture was concentrated under vacuum (high vacuum pump required) and the residue
partitioned between EtOAc (100 mL) and saturated aqueous NaHCO (100 mL). The aqueous
mixture was washed with H O (50 mL), saturated NaHCO (50 mL) and brine (50 mL), then dried
(Na SO ), filtered and concentrated under vacuum to provide the product (12a) as an oil. The product
was used directly in the next step without further purification. H-NMR (300 MHz, CDCl ): δ 4.04-
3.98 (m, 2H), 3.47-3.45 (m, 2H), 2.26 (s, 1H), 1.58-1.32 (m, 2H), 1.32-1.23 (m, 6H), 1.12 (s, 3H),
1.11 (s, 3H).
Step 2: Reaction to produce hexyl 3-((chlorosulfonyl)oxy)-2,2-dimethylpropanoate (12b).
A solution of sulfuryl chloride (2.1 mL, 29.7 mmol) in Et O (40 mL) was cooled to -78°C
under an atmosphere of argon. A solution of hexyl 3-hydroxy-2,2-dimethylpropanoate (12a) (3.0 g,
14.8 mmol) and pyridine (1.4 mL, 17.8 mmol) in Et O (15 mL) was added dropwise to the sulfuryl
chloride solution over the course of 30 min. The flask was rinsed with Et O (3 × 5 mL) and the rinse
added to the reaction mixture. The mixture was stirred at -78 °C until completion by TLC (30 min;
% EA/hex). The precipitate was filtered, and the filtrate was concentrated under vacuum to afford
the product (12b) (3.7 g, 83% yield). The mixture was stored at -78 °C and was used immediately for
the next step without further purification. H-NMR (300 MHz, CDCl ): 4.50 (s, 2H), 4.13 (t, J = 6.8
Hz, 2H), 1.69-1.60 (m, 2H), 1.40-1.27 (m, 12H), 0.91-0.87 (m, 3H).
Step 3: Reaction to produce hexyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-
diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (12).
(1R,2S,5R)Hydroxyoxo-1,6-diazabicyclo[3.2.1]octanecarboxamide (1) (673 mg, 3.6
mmol) was dissolved in THF (35 mL) and 1,3-dimethyltetrahydropyrimidin-2(1H)-one (5 mL), and
the resulting solution was cooled to -78°C under an atmosphere of Ar. A 1.0 M solution of NaHMDS
in THF (4.0 mL, 4.0 mmol) was added dropwise to the cooled solution and stirred for 20 min.
Neat hexyl 3-((chlorosulfonyl)oxy)-2,2-dimethylpropanoate (12b) (1.1 g, 3.6 mmol) was added
quickly to the reaction mixture. The syringe was rinsed with THF (3 × 3 mL) and the rinse was also
added to the mixture. After 10 min, the reaction mixture was warmed to 23 °C and stirred until the
reaction was complete as determined by TLC and LC-MS. EtOAc (50 mL) and saturated aqueous
NaHCO (50 mL) were added to the mixture. The layers were partitioned, and the organic layer was
washed with saturated aqueous NaHCO (50 mL), water (3 × 50 mL), brine (50 mL), then dried
(Na SO ), filtered and concentrated under vacuum to leave a crude residue. The residue was purified
by column chromatography on silica gel using EtOAc/hexanes (1:9 to 1:0) as eluent followed by high-
performance liquid chromatography to give the product (12) (44 mg, 3%) as a solid. LC-MS: 450.1
[M+H] . H-NMR (300 MHz, CDCl ): δ 6.49 (s, 1H), 5.71 (s, 1H), 4.71 (d, J = 8.7 Hz, 1H), 4.60 (d,
J = 9.3 Hz, 1H), 4.17-4.04 (m, 4H), 3.34-3.30 (m, 1H), 3.04-3.00 (d, J = 12.6 Hz, 1H), 2.47-2.40 (m,
1H), 2.18-2.13 (m, 1H), 2.01-1.79 (m, 2H), 1.66-1.59 (m, 2H), 1.37-1.27 (m, 12H), 0.91-0.86 (m,
3H). C-NMR (75 MHz, CDCl3): δ 174.3, 171.1, 167.0, 80.5, 65.6, 62.0, 60.2, 47.2, 43.0, 31.5, 28.6,
.6, 22.6, 22.3, 21.8, 20.9, 17.6, 14.1.
Example 13
Synthesis of heptyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (13)
Step 1: Reaction to produce heptyl 3-hydroxy-2,2-dimethylpropanoate (13a).
Reference is made to German Application Publication No. DE3045373. A mixture of 3-
hydroxy-2,2-dimethylpropionic acid (4.7 g, 40 mmol), 1-heptanol (70 mL) and concentrated sulfuric
acid (or fuming sulfuric acid; 1 mL) was heated to 80 °C and stirred overnight. After allowing the
mixture to cool, the mixture was concentrated under vacuum (high vacuum pump required) and the
residue partitioned between EtOAc (100 mL) and saturated aqueous NaHCO (100 mL). The aqueous
was washing with H O (50 mL), saturated NaHCO (50 mL) and brine (50 mL), then dried (Na SO ),
2 3 2 4
filtered and concentrated under vacuum to provide the product (13a) as an oil. The product was used
directly in the next step without further purification. H-NMR (300 MHz, CDCl ): δ 4.31 (t, J = 6.5
Hz, 2H), 3.77 (s, 2H), 1.87-1.81 (m, 2H), 1.53-1.50 (m, 8H), 1.41 (s, 6H), 1.12-1.08 (m, 3H).
Step 2: Reaction to produce heptyl 3-((chlorosulfonyl)oxy)-2,2-dimethylpropanoate (13b).
A solution of sulfuryl chloride (2.0 mL, 27.7 mmol) in Et O (40 mL) was cooled to -78°C
under an atmosphere of argon. A solution of heptyl 3-hydroxy-2,2-dimethylpropanoate (13a) (3.0 g,
13.9 mmol) and pyridine (1.4 mL, 16.6 mmol) in Et O (15 mL) was added dropwise to the sulfuryl
chloride solution over the course of 30 min. The flask was rinsed with Et O (3 × 5 mL) and the rinse
added to the reaction mixture. The mixture was stirred at -78 °C until completion as monitored by
TLC (30 min; 30% EA/hex). The precipitate was filtered, and the filtrate was concentrated under
vacuum to afford heptyl 3-((chlorosulfonyl)oxy)-2,2-dimethylpropanoate (13b) (3.3 g, 75%). The
mixture was stored at -78 °C and was used immediately for the next step without further purification.
H-NMR (300 MHz, CDCl ): δ 4.46 (s, 2H), 4.11-4.00 (m, 2H), 1.64-1.55 (m, 2H), 1.26-1.24 (m,
8H), 0.85-0.81 (m, 3H).
Step 3: Reaction to produce heptyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-
diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (13).
(1R,2S,5R)Hydroxyoxo-1,6-diazabicyclo[3.2.1]octanecarboxamide (1) (673 mg) was
dissolved in THF (35 mL) and 1,3-dimethyltetrahydropyrimidin-2(1H)-one (5 mL) and the resulting
solution was cooled to -78 °C under an atmosphere of Ar. A 1.0 M solution of NaHMDS in THF (4.0
mL, 4.0 mmol) was added dropwise to the cooled solution and stirred for 20 min. Neat heptyl 3-
((chlorosulfonyl)oxy)-2,2-dimethylpropanoate (13b) (1.3 g, 4.0 mmol) was added quickly to the
reaction mixture. The syringe was rinsed with THF (3 × 3 mL) and the rinse was also added to the
mixture. After 10 min, the reaction mixture was warmed to 23 °C and stirred until complete as
determined by TLC and LC-MS. EtOAc (50 mL) and saturated aqueous NaHCO (50 mL) were
added to the mixture. The aqueous and organic layers were partitioned, and the organic layer was
washed with saturated aqueous NaHCO (50 mL), water (3 × 50 mL), brine (50 mL), then dried
(Na SO ), filtered and concentrated under vacuum to leave a crude residue. The residue was purified
by column chromatography on silica gel using EtOAc/hexanes (1:9 to 1:0) as eluent, followed by
purification using high-performance liquid chromatography to give the product (13) (65 mg, 4%) as a
solid. LC-MS: 464.3 [M+H] . H-NMR (300 MHz, CDCl ): δ 6.48 (s, 1H), 5.71 (s, 1H), 4.71 (d, J =
9.6 Hz, 1H), 4.60 (d, J = 9.3 Hz, 1H), 4.18-4.04 (m, 4H), 3.34-3.29 (m, 1H), 3.02 (d, J = 11.7 Hz,
1H), 2.47-2.40 (m, 1H), 2.19-2.11 (m, 1H), 2.01-1.79 (m, 2H), 1.66-1.59 (m, 2H), 1.37-1.26 (m,
14H), 0.90-0.86 (m, 3H). C-NMR (75 MHz, CDCl ): δ 174.3, 171.1, 167.0, 80.5, 65.6, 62.0, 60.2,
47.2, 43.0, 31.8, 29.0, 28.6, 25.9, 22.7, 22.2, 21.8, 20.9, 17.6, 14.2.
Example 14
Synthesis of tert-butyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (14)
Step 1 and Step 2: Reaction to produce tert-butyl 3-hydroxy-2,2-dimethylpropanoate (14a).
The compound was synthesized in accordance with PCT International Application Publication
No. WO 2007116922. Sodium hydride (60% in mineral oil; 2.0 g) was added to a cooled solution of
tert-butyl methyl malonate (4 g) in THF (100 mL) at 0 °C under an atmosphere of Ar. The mixture
was stirred at 0 °C for 10 min. MeI (3.2 mL) was added to the mixture and the stirring was continued
for 3 h (by this time the mixture was at room temperature). Brine and EtOAc were added to the
mixture, and the organic layer was separated, dried (Na SO ), filtered and concentrated under vacuum
to give the product (ca. 4.5 g), which was used directly in the next step.
Solid lithium tri-tert-butoxy-aluminohydride (7.1 g, 28 mmol) was added portion-wise over
min to a solution of tert-butyl methyl 2,2-dimethyl-malonate (2.2 g) in THF (100 mL) under an
atmosphere of Ar. The mixture was then heated to reflux and stirred overnight. After cooling to
room temperature, a saturated solution of NH Cl and EtOAc were added, and the aqueous and organic
layers were separated. The organic layer was washed with H O and brine, then dried (Na SO ),
2 2 4
filtered and concentrated under vacuum to provide a crude residue. The residue was purified by
column chromatography on silica gel using EtOAc / hexanes (0:1 to 3:7) as eluent to give the product
(14a) (900 mg) as an oil. H-NMR (300 MHz, CDCl ): δ 3.50 (d, J = 5.1 Hz, 2H), 2.53 (t, J = 6.5 Hz,
1H), 1.45 (s, 9 H), 1.14 (s, 6H)
Step 3: Reaction to produce tert-butyl 3-((chlorosulfonyl)oxy)-2,2-dimethylpropanoate (14b).
A solution of sulfuryl chloride (0.31 mL, 4.2 mmol) in Et O (6 mL) was cooled to -78 °C
under an atmosphere of Ar. A solution of tert-butyl 3-hydroxy-2,2-dimethylpropanoate (14a) (0.49 g,
2.8 mmol) and pyridine (0.25 ml, 3.1 mmol) in Et O (6 mL) was added dropwise to the sulfuryl
chloride solution over the course of 10 min. The mixture was stirred at -78 °C for 90 min and allowed
to warm to 23 °C after TLC revealed that the reaction had not proceeded to completion (10%
EtOAc/hexanes). The mixture was re-cooled to -78 °C and an additional 1 equivalent of sulfuryl
chloride was added, stirred for 10 min, and the mixture allowed to warm to 23°C (note: the mixture
was allowed to stir for a total of 1 h after the addition and during the warming period). The
precipitate was filtered, and the filtrate was concentrated under vacuum to give tert-butyl 3-
((chlorosulfonyl)oxy)-2,2-dimethylpropanoate (14b) (961 mg, yield assumed quantitative) as a clear,
oil. H-NMR (300 MHz, CDCl ): δ 4.46 (fd, J = 1.5 Hz, 2H), 1.47 (fd, J = 1.2 Hz, 9H), 1.27 (s, 6H).
Step 4: Reaction to produce tert-butyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-
diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (14).
(1R,2S,5R)Hydroxyoxo-1,6-diazabicyclo[3.2.1]octanecarboxamide (1) (463 mg, 2.5
mmol) was dissolved in THF (25 mL) and 1,3-dimethyltetrahydropyrimidin-2(1H)-one (1.5 mL), and
the resulting solution was cooled to -78 °C under an atmosphere of Ar. A 1.0 M NaHMDS solution in
THF (2.8 mL, 2.8 mmol) was added dropwise to the cooled solution, and the mixture stirred for 10
min. Neat tert-butyl 3-((chlorosulfonyl)oxy)-2,2-dimethylpropanoate (14b) (0.75 g, 2.8 mmol) was
added quickly to the reaction mixture. The syringe was rinsed with THF (3 × 3 mL) and these rinses
were also added to the mixture quickly. After 20 min, the reaction mixture was allowed to warm to
23°C. After stirring for 70 min, the reaction was complete as determined by TLC (70% EA/hexanes).
The mixture was cooled to 0 °C, diluted with EtOAc (50 mL), and quenched with saturated aqueous
NaHCO (50 mL). The aqueous and organic layers were partitioned, and the organic layer was
washed with saturated aqueous NaHCO (50 mL), water (3 × 50 mL), and brine (50 mL), then dried
(Na SO ), and concentrated under vacuum to provide a crude residue. The residue was purified by
column chromatography on silica gel using EtOAc/hexanes (1:9 to 1:0) as eluent to give the product
(14) (368 mg, 35% yield) as a solid. LC-MS: 422.1 [M+H] . H-NMR (300 MHz, CDCl ): δ 6.50 (s,
1H), 5.85 (s, 1H), 4.66 (d, J = 9 Hz, 1H), 4.56 (d, J = 8.7 Hz, 1H), 4.17 (s, 1H), 4.04 (d, J = 6.9 Hz,
1H), 3.33-3.29 (m, 1H), 3.02 (d, J = 12 Hz, 1H), 2.46-2.39 (m, 1H), 2.17-2.12 (m, 1H), 2.00-1.79 (m,
2H), 1.45 (s, 9H), 1.23 (s, 3H), 1.21 (s, 3H). C-NMR (75 MHz, CDCl ): δ 173.3, 171.1, 167.0, 81.6,
80.9, 62.0, 60.2, 47.2, 43.4, 28.0, 22.2, 21.6, 20.8, 17.6.
Example 15
Synthesis of 2-methoxyethyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (15)
Step 1: Reaction to produce 2-methoxyethyl 3-hydroxy-2,2-dimethylpropanoate (15a).
3-Hydroxy-2,2-dimethylpropanoic acid (1.2 g, 10.3 mmol) and Cs CO (3.4 g, 10.4 mmol)
were suspended in DMF (25 mL) at 23 °C, then 2-bromoethyl methyl ether (1.0 mL, 10.4 mmol) was
added. The resulting mixture was stirred at 70 °C overnight. After cooling, the mixture was filtered
through a pad of Celite®. The filtrate was diluted with EtOAc (150 mL), and the mixture washed
with water (3 × 100 mL) and brine, then dried (Na SO ), filtered and concentrated to leave a crude
residue. The residue was purified by column chromatography on silica gel using EtOAc/hexanes (1:4
to 4:1) as eluent to provide the product (15a) (1.3 g, crude weight) as an oil. H-NMR (300 MHz,
CDCl ): δ 4.28 (t, J = 4.8 Hz, 2H), 3.62 - 3.55 (m, 4H), 3.38 (s, 3H), 2.65 (t, J = 6.0 Hz, 1H), 1.21 (s,
6H).
Step 2: Reaction to produce 2-methoxyethyl 3-((chlorosulfonyl)oxy)-2,2-dimethylpropanoate
(15b).
A solution of freshly distilled sulfuryl chloride (0.2 mL, 2.8 mmol) in Et O (7.0 mL) was
cooled to -78 °C under an atmosphere of Ar. A solution of 2-methoxyethyl 3-hydroxy-2,2-
dimethylpropanoate (15a) (0.48 g, 2.7 mmol) and pyridine (0.24 mL, 3.0 mmol) in Et O (1 mL) was
added dropwise to the sulfuryl chloride solution over the course of 11 min. The flask was rinsed with
Et O (3 × 1 mL) which was also added to the reaction mixture. The mixture was stirred at -78 °C
until completion (monitored by TLC, 30% EtOAc/hex, 30 min). The precipitate was filtered, and the
filtrate was concentrated under vacuum to afford the product (15b) (0.5 g, 67%) as an oil, which was
used directly in the next step without further purification [Note: HNMR indicated desired product
with residue of pyridine and along with starting material].
Step 3: Reaction to produce 2-methoxyethyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-
diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (15).
(1R,2S,5R)Hydroxyoxo-1,6-diazabicyclo[3.2.1]octanecarboxamide (1) (162 mg, 0.9
mmol) was dissolved in THF (2.5 mL) and 1,3-dimethyltetrahydropyrimidin-2(1H)-one (0.3 mL), and
the resulting solution was cooled to -78 °C under an atmosphere of Ar. A 1.0 M solution of NaHMDS
in THF (1.0 mL, 1.0 mmol) was added dropwise to the cooled solution and the mixture stirred for 10
min. 2-Methoxyethyl 3-((chlorosulfonyl)oxy)-2,2-dimethylpropanoate (15b) (0.3 g, 1.1 mmol) in
THF (2 mL) was added quickly to the reaction mixture. After 10 min at -78 °C, the mixture was
allowed to warm to 23 °C and stirred for 30 min. The mixture was diluted with EtOAc (40 mL) and
water. The aqueous and organic layers were partitioned, and the organic layer was washed with water
(3 × 20 mL), and brine (50 mL), then dried (Na SO ), filtered and concentrated under vacuum to leave
a crude residue. The crude residue was purified by column chromatography on silica gel (4 g column)
using EtOAc / hexanes (3:7 to 1:0) as eluent to give an impure solid. The product was dissolved in
Et O (20 mL) with the aid of sonication, and precipitated with hexanes. The resulting solid was
filtered, and dried under vacuum to provide the product (15) (72 mg, 19.4%) as a solid. LCMS: m/z =
424.3 [M+H] . H-NMR (300 MHz, CDCl ): δ 6.48 (br. s, 1H), 5.56 (br. s, 1H), 4.62 (dd, J = 28.8,
8.7 Hz, 2H), 4.33-4.22 (m, 2H), 4.17 (br. s, 1H), 4.05 (d, J = 6.9 Hz, 1H), 3.60 (t, J = 4.6 Hz, 2H),
3.38 (s, 3H), 3.33 (d, J = 11.1 Hz, 1H), 3.02 (d, J = 12.0 Hz, 1H), 2.46-2.41 (m, 1H), 2.18-2.13 (m,
1H), 1.98-1.84 (m, 2H), 1.31 (s, 3H), 1.29 (s, 3H). C-NMR (75 MHz, CDCl ), δ 174.1, 170.8,
166.9, 80.2, 70.2, 64.1, 61.8, 60.0, 59.0, 47.1, 42.9, 22.1, 21.6, 20.7, 17.4.
Example 16
Synthesis of oxetanyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (16)
Step 1: Reaction to produce oxetanyl 3-hydroxy-2,2-dimethylpropanoate (16a).
3-Hydroxy-2,2-dimethylpropanoic acid (4.7 g, 40 mmol) and Cs CO (13.0 g, 40 mmol) were
suspended in DMF (100 mL) at 23 °C, then 3-iodooxetane (7.4 g, 40 mmol) was added. The resulting
mixture was stirred at 70 °C overnight. After cooling, the mixture was diluted with EtOAc (150 mL),
and the mixture washed with water (3 × 100 mL) and brine, then dried (Na SO ), filtered and
concentrated to provide a crude residue. The residue was purified by column chromatography on
silica gel using EtOAc/hexanes as eluent to give the product (16a) (3.6 g, 51%) as an oil.
Step 2: Reaction to produce oxetanyl 3-((chlorosulfonyl)oxy)-2,2-dimethylpropanoate
(16b).
A solution of freshly distilled sulfuryl chloride (0.2 mL, 2.7 mmol) in Et O (3 mL) was
cooled to -78 °C under an atmosphere of Ar. A solution of oxetanyl 3-hydroxy-2,2-
dimethylpropanoate (16a) (0.46 g, 2.6 mmol) and pyridine (0.2 mL, 2.7 mmol) in Et O (2 mL) was
added dropwise to the sulfuryl chloride solution over the course of 11 min. The flask was rinsed with
Et O (3 × 1 mL) which was also added to the reaction mixture. The mixture was stirred at -78 °C
until completion (monitored by TLC, 30% EtOAc/hex, 30 min). The precipitate was filtered, and the
filtrate was concentrated under vacuum to afford the product (16b) (0.5 g, 69%) as an oil, which was
used directly in the next step without further purification. H-NMR (300 MHz, CDCl ): δ 5.50-5.46
(m, 1H), 4.94-4.89 (m, 2H), 4.65-4.60 (m, 2H), 4.52 (s, 2H), 1.72 (br. s, 1H), 1.36 (s, 6H).
Step 3: Reaction to produce oxetanyl 3-(((((1R,2S,5R)carbamoyloxo-1,6-
diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoate (16).
(1R,2S,5R)Hydroxyoxo-1,6-diazabicyclo[3.2.1]octanecarboxamide (1) (200 mg, 1.1
mmol) was dissolved in THF (3 mL) and 1,3-dimethyltetrahydropyrimidin-2(1H)-one (2 mL), DMPU
was added, and the resulting solution was cooled to -78 °C under an atmosphere of Ar. A 1.0 M
solution of NaHMDS in THF (1.2 mL, 1.2 mmol) was added dropwise to the cooled solution, and the
mixture stirred for 10 min. A solution of oxetanyl 3-((chlorosulfonyl)oxy)-2,2-dimethylpropanoate
(16b) (0.37 g, 1.4 mmol) in THF (2 mL) was added quickly to the reaction mixture. After stirring at -
78 C for 10 min, the mixture was allowed to warm to 23 °C and stirred for a total of 1 h. The mixture
was diluted with EtOAc (40 mL) and H O. The aqueous and organic layers were partitioned, and the
organic layer washed with H O (3 × 20 mL), brine (50 mL), then dried (Na SO ), filtered and
2 2 4
concentrated under vacuum to give a crude residue. The crude residue was purified by column
chromatography on silica gel (4 g column) using EtOAc / hexanes (3:7 to 1:0) as eluent to give an oil.
The oil was triturated with Et O with the aid of sonication, and the filter cake was washed with Et O
to provide the product (16) (170 mg, 37%) as a solid. LCMS: m/z = 422.3 [M+H] . H-NMR (300
MHz, CDCl ): δ 6.48 (br. s, 1H), 5.54 (br. s, 1H), 5.48-5.44 (m, 1H), 4.89 (t, J = 7.4 Hz, 2H), 4.79 (d,
J = 8.7 Hz, 1H), 4.66- 4.58 (m, 3H), 4.18 (br. s, 1H), 4.05 (d, J = 6.9 Hz, 1H), 3.33 (d, J = 12.3 Hz,
1H), 2.44-2.42 (m, 1H), 2.20-2.16 (m, 1H), 2.00-1.80 (m, 2H), 1.32 (s, 3H), 1.31 (s, 3H). 13C-NMR
(75 MHz, CDCl ): δ 173.4, 170.8, 167.0, 80.0, 68.6, 76.6, 61.9, 60.2, 47.1, 42.7, 21.9, 21.6, 20.7,
17.4.
Example 17
Synthesis of ethyl 1-((((((1R,2S,5R)carbamoyloxo-1,6-diazabicyclo[3.2.1]octan
yl)oxy)sulfonyl)oxy)methyl)cyclohexanecarboxylate (17)
Step 1: Reaction to produce ethyl 1-(((chlorosulfonyl)oxy)methyl)cyclohexanecarboxylate
(17a).
A solution of freshly distilled sulfuryl chloride (77 µL, 1.1 mmol) in Et O (3 mL) was cooled
to -78 °C under an atmosphere of Ar. A solution of ethyl 1-(hydroxymethyl)cyclohexanecarboxylate
(0.2 g, 1.0 mmol) and pyridine (85 µL, 1.1 mmol) in Et O (2 mL) was added dropwise to the sulfuryl
chloride solution over 11 min. The flask was rinsed with Et O (3 × 1 mL) and the rinse added to the
reaction. The mixture was stirred at -78 °C until completion (ca. 30 min; monitored by TLC, 30%
EtOAc/hex). The precipitate was filtered, and the filtrate was concentrated under vacuum to afford
the title compound as an oil, which was used directly in the next step without purification. A second
batch using 476 mg of the starting alcohol, afforded 600 mg of the product (17a) (approximately, 85%
purity by H-NMR).
Step 2: Reaction to produce ethyl 1-((((((1R,2S,5R)carbamoyloxo-1,6-
diazabicyclo[3.2.1]octanyl)oxy)sulfonyl)oxy)methyl)cyclohexanecarboxylate (17).
(1R,2S,5R)Hydroxyoxo-1,6-diazabicyclo[3.2.1]octanecarboxamide (1) (0.33 g, 1.8
mmol) was dissolved in THF (7 mL) and 1,3-dimethyltetrahydropyrimidin-2(1H)-one (3.5 mL), and
the resulting solution was cooled to -78 °C under an atmosphere of Ar. A 1.0 M solution of NaHMDS
in THF (1.8 mL, 1.8 mmol) was added dropwise over 20 min, and the mixture stirred for 10 min.
Ethyl 1-(((chlorosulfonyl)oxy)methyl)cyclohexanecarboxylate (17a) (0.51 g, 1.8 mmol) in THF (2
mL) was added quickly to the reaction mixture. After 10 min stirring at -78 °C the mixture was
allowed to warm to 23 °C and stirred for a total of 1 h. The reaction mixture was diluted with EtOAc
(40 mL) and H O at -60 °C. The aqueous and organic layers were partitioned, and the organic layer
was washed with H O (3 × 20 mL), and brine (50 mL), then dried (Na SO ), filtered and concentrated
2 2 4
under vacuum to give the crude residue (330 mg). The oil was purified by column chromatography
on silica gel (4 g column) using EtOAc / hexanes (3:7 to 1:0) as eluent, followed by purification using
preparative HPLC (10-90% MeCN / H O over 20 min using UV detection at
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762505027P | 2017-05-11 | 2017-05-11 | |
US62/505,027 | 2017-05-11 | ||
PCT/US2018/032017 WO2018209051A1 (en) | 2017-05-11 | 2018-05-10 | Atropine pharmaceutical compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ758555A NZ758555A (en) | 2021-10-29 |
NZ758795B2 true NZ758795B2 (en) | 2022-02-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10722521B2 (en) | Beta-lactamase inhibitors and uses thereof | |
AU2018345321B2 (en) | Aztreonam derivatives and uses thereof | |
AU2020237440B2 (en) | Crystalline form of an avibactam derivative | |
NZ758795B2 (en) | Atropine pharmaceutical compositions | |
US11180500B2 (en) | Derivatives of relebactam and uses thereof | |
NZ758795A (en) | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor | |
RU2815314C2 (en) | Beta-lactamase inhibitors and their use | |
KR20220114629A (en) | Oral Administration Combination of Amoxicillin and Abibactam Derivatives to Treat Mycobacterial Infections |